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Introduction
The intensive care unit (ICU) of the Erasmus MC - Sophia Children’s Hospital yearly admits 
some 1100 children aged 0 to 18 years. Many of these are so severely ill that mechanical 
ventilation or vasoactive therapy is necessary to support organ dysfunction. Pediatric 
intensive care nurses provide care for critically ill children on a daily basis. Children 
in this setting inevitably are exposed to a series of painful and stressful events. These 
include not only invasive procedures like insertion of intravenous lines, catheters and 
tubes, mechanical ventilation, endotracheal suctioning, but also separation from parents, 
unfamiliar environment and disruption of the usual day-night cycle in a busy ICU.
Admission to an ICU has a great impact on both child and parents. As adult ICU 
patients have indicated, and which is now increasingly recognized, the distress and pain 
experienced during admission are very unpleasant.1,2 We can only speculate how children 
who cannot communicate their feelings experience all these things happening to them - 
often even without understanding where they are. And then, parents have to cope with 
a miserable and ill child, and will be concerned and insecure about their child’s health 
status.3-6  Nurses are confronted with the grief of both child and parents. An important 
part of nursing activities involves providing comfort and minimizing anxiety for both 
child and parents. Apart from discomfort and pain, stress is a well-recognized negative 
factor in determining the speed of recovery in children.7,8 The child will therefore often 
be given sedative and/or analgesic drugs to diminish anxiety or pain. Ideally, prescription 
is based on nurses’ observations and as such nurses hold a key position and have an 
advocacy role between child, parents and physician. The sedative of choice in our ICU 
is midazolam, which is the most commonly used sedative in other European pediatric 
ICUs as well.9,10 This drug reduces anxiety and agitation, retrograde amnesia, improves 
tolerance of ventilator support and facilitates nursing care. It usually given continuously 
by the intravenous route. Retrograde amnesia for ICU experiences is one of the aims of 
sedation and is especially reached by midazolam. Many adult and also pediatric patients 
have a memory of being uncomfortable while in the ICU.11-16 Opioids such as morphine 
and fentanyl are most commonly prescribed to relief severe pain in these children.10
Optimal sedation has been described as a state in which the patient is somnolent, 
responsive to the environment but untroubled by it, and with no excessive movements.17 
In ICU practice, this means that a child is conscious, breathes in synergy with the 
ventilator, and is tolerant or compliant with other therapeutic procedures. Still it can be 
difficult to reach this stage, because of the variability in drug plasma levels. On the other 
hand, the available arsenal of sedative drugs is limited in the pediatric ICU. Propofol, 
for example, drug with a good sedation qualification, is contra-indicated as a sedative in 
children below 16 years for long term administration.18,19 Optimal level of sedation varies 
for each patient and careful consideration should be given to the underlying diagnosis 
and severity of illness such as pulmonary hypertension.20 Meanwhile, strong evidence has 
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emerged that adult patients who are oversedated may need mechanical ventilation for a 
longer period. A daily drug holiday has a proven beneficial effect on duration of artificial 
ventilation in adult patients.21 On the other hand, undersedation is undesirable as it can 
lead to increased distress, auto-extubation, accidental displacements of catheter, tubes 
and vital lines, fighting the ventilator and hemodynamic instability. 
In clinical practice, it can be difficult to find a balance between under- or oversedation 
in children. About 65% of these children in the ICU are below 3 year of age.22  It can be 
especially hard to distinguish between pain, anxiety and distress in children who cannot 
communicate verbally. 
In the past decade a line of research was concerned with optimal assessment and therapy 
of pain in children in our ICU or on general ward. Within this context the COMFORT 
behavior scale as a postoperative pain instrument and the Checklist Pain Behavior in 
cognitive impaired children were developed.23-25 In the past years this line of research was 
extended to sedation in critically ill children. Recently, delirium in pediatric ICU patients 
has been studied in 877 children over a 4-year period and cumulative incidence of delirium 
in their patients was 5%.26 
Pain is closely intertwined with anxiety, fear and other unpleasant emotions and they 
may reinforce each other. Pain and other forms of discomfort are expressed in change of 
behavior or changing vital signs. In clinical practice this means that it is very difficult to 
know if an infant is in pain or distressed, or both. The gold standard of ensuring patient 
comfort is self-report. This is impossible, however, in pre-verbal children and in critically 
ill patients who have tracheal tubes in place and are often under effects of sedation. In 
these cases we have to fall back on the observations of nurses and physicians, but this 
gives wide range of variable descriptions. The variability in nurses’ and physicians’ 
observations arise from different ideas or attitudes toward discomfort, pain, best drugs 
and treatment, and knowledge of the latest scientific findings. Given this fact, the use 
of a validated assessment tool that contains behavioral and physiological components 
reduces this variability. In practice, nursing staff with varying degrees of expertise will 
change three times over the working day. This means that patients’ individual sedation 
requirements will be assessed by different nurses, and that patients therefore may receive 
variable dosages of sedatives.20 A standard tool will counteract this effect and promote 
continuity of care.
The disadvantage of assessment tools is the fact that it provides a snapshot 
impression in contrast with continuous monitoring with the Bispectral index (BIS) 
monitor. The BIS monitor was originally developed for assessing consciousness in 
adults. It is also used, however, to evaluate depth of sedation in pediatric and adult 
ICU patients.27-31
This brings us to the first important question of this thesis. How should the 
optimal level of sedation be assessed in critically ill children? 
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A second question concerns prolonged administration of benzodiazepines and/or 
opioids in children in an ICU environment. It has been documented that prolonged 
administration may induce physiological dependency and withdrawal symptoms. 
Withdrawal symptoms may develop when a drug that causes physical dependence is 
suddenly stopped, reduced too quickly or antagonized. Prevention and treatment of 
withdrawal symptoms is another aspect of optimal comfort.32,33 
Most of our knowledge on tolerance and withdrawal symptoms has been derived 
from research in newborns of drug-addicted mothers and from literature on adult 
opium-addicted patients.34,35 Withdrawal symptoms can also be observed in critically 
ill children. Physicians recently seem to have greater awareness of the need to prevent 
withdrawal symptoms in children.9 On the other hand, there are scarce data about the 
nature and incidence of benzodiazepines and opioids withdrawal symptoms in children. 
Incidences of benzodiazepines withdrawal symptoms in critically ill children have been 
only described in two studies so far, and varied from 17 to 35 %.36,37 Katz et al.38 evaluated 
the occurrence of opioids withdrawal symptoms in children after prolonged continuous 
fentanyl administration. In this study 57% of the children developed withdrawal 
symptoms.38 
The intensive care nurse has a key role in providing optimal comfort and especially 
in ensuring adequate sedation and prevention of withdrawal symptoms. The task of 
assessing seriously ill children for signs of tolerance, dependence or withdrawal notably 
falls into the professional domain of the pediatric intensive care nurse. Using a validated 
and reliable assessment tool could facilitate this task.
The second question therefore is: how do withdrawal symptoms present in pediatric 
ICU patients and what is the best way to assess withdrawal syndrome? 
Objectives of the thesis 
The overall aims of the studies presented in this thesis are: 
To study strategies for assessing level of sedation in pediatric intensive care patients by 
nurses (Chapters 2 and 3).  
To evaluate the value of the BIS monitor for objective assessment of level of sedation 
(Chapter 4).
To obtain insight in withdrawal symptoms in critically ill children after long-term 
administration of benzodiazepines and opioids, and to construct a validated scoring 
system for assessing these symptoms (Chapters 5-8).
•
•
•
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Outline of the thesis
Sedation in critically ill children
Chapter 2 describes the reliability and validity of the COMFORT behavior scale as a scoring 
system for level of sedation in pediatric intensive care patients aged from 0 to 16 years. 
Furthermore, new cutoff points are determined for assessing over- and under sedation. 
Chapter 3 describes the implementation of a sedation treatment protocol in the ICU and 
analyses nurses’ compliance with the protocol. Nurses in this protocol titrated sedatives 
based on COMFORT behavior assessments. The investigation in chapter 4 focuses on 
analyses of the usefulness of the BIS monitor for measuring sedation in infants aged up 
to 12 months. BIS values are compared with COMFORT behavior scores in non-sedated 
infants and postoperatively sedated infants.
Withdrawal symptoms 
Chapter 5 reviews the literature on withdrawal symptoms in critically ill children after 
long-term sedation. Next, chapter 6 evaluates the frequencies of benzodiazepines and 
opioids withdrawal symptoms described in the review. Also, possible correlations are 
determined between withdrawal symptoms and total doses of benzodiazepines or opioids 
and duration of use. Chapter 7 describes the construction of the ‘Sophia Observation 
withdrawal Symptoms-scale’ (SOS). This instrument is based on expert opinions and 
on the underlying clinical-empirical structure of withdrawal symptoms revealed by 
multidimensional scaling. Chapter 8 describes the feasibility of weaning at home of 
sedatives and analgesics in infants with congenital diaphragmatic hernia after extra 
corporeal membrane oxygenation therapy. 
Discussion and perspectives
Chapter 9 contains a general discussion of the results of the investigations presented in 
this thesis as well as directives for future research. 
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Chapter 2
Assessment of sedation levels in 
pediatric intensive care patients can 
be improved by using the COMFORT 
‘behavior’ scale
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Abstract
Objectives: The original COMFORT scale, including both observational and physiologic items, 
has been validated for measuring distress in children admitted to a pediatric intensive care unit. 
However, physiologic variables are influenced by drugs given in the pediatric intensive care 
unit setting. The objectives of this study were to assess the usefulness of physiologic variables 
in judgment of sedation and to determine new cutoff points for the COMFORT ‘behavior’ scale 
(COMFORT‑B), using only observational items.
Design: Prospective observational study.
Setting: Pediatric intensive care unit in a university hospital.
Patients: Seventy‑eight patients admitted to the pediatric intensive care unit.
Interventions: None.
Measurements and Results: COMFORT scores were obtained in this patient group. Similar to the 
original COMFORT scale validation, the expert opinion of nurses (Nurse Interpretation Score of 
Sedation) served to determine optimal cutoff scores for the COMFORT-B scale. A total of 843 
combined COMFORT and Nurse Interpretation Score of Sedation scores were obtained in 78 patients. 
Cronbach’s alpha for the COMFORT scale was 0.78, increasing to 0.84 when the physiologic items, 
blood pressure and heart rate, were excluded. COMFORT scores were significantly different for the 
three Nurse Interpretation Score of Sedation categories (Kruskal‑Wallis, p < 0.001). According to 
the pediatric intensive care unit nurses, undersedation was present in 11% and oversedation in 3% 
of all observations. Cutoff points for the COMFORT-B scale were < 10 for oversedation and > 23 for 
undersedation. The area in the COMFORT‑B score between 11 and 22 does not adequately predict 
under‑ or oversedation, pointing to a need for supplemental observation.
Conclusion: The COMFORT‑B scale is a reliable alternative to the original COMFORT scale. The 
cutoff points of the COMFORT-B scale in conjunction with the Nurse Interpretation Score of 
Sedation facilitate the use of sedation algorithms on the pediatric intensive care unit.
COMFORT behavior scale for the assessment of sedation in the PICU
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Introduction
Critically ill children admitted to a pediatric intensive care unit (PICU) will experience 
physical and psychological discomfort.1,2 Apart from discomfort, stress is a well‑recognized 
negative factor in determining the speed of recovery in children.3 Both factors warrant 
adequate sedation and pain relief in this vulnerable patient group.4,5
Although clinical judgment of trained PICU nurses and physicians is important, the 
development of an optimal scoring system for sedation is needed to both determine 
the efficacy of sedatives and related interventions and facilitate interinstitutional 
comparisons.
The Ramsay scale is the sedation scoring system most used in the adult intensive care 
setting.6 Several categories in this scale are based on judgment of level of consciousness. 
Other Ramsay scale categories, such as response to commands, are not relevant for young 
infants. This calls for other, more specific observations in the PICU setting. Contrary 
to adult intensive care, no gold standard for sedation is available for PICU use.7 Several 
sedation scoring scales have been described for children (Table 1): the Hartwig Sedation 
Scale,8 the COMFORT Scale,1 the University of Michigan Sedation Scale,9 and recently one 
for neonates (Neonatal Pain, Agitation, and Sedation Scale).10 All these scales have been 
validated by comparison with the ‘expert opinion’ of attending physicians and/or nurses, and 
each has its specific strengths and weaknesses (Table 1). At present, the COMFORT scale 
seems to be the most practical scoring system for PICU use. In contrast to the Hartwig 
scale, the COMFORT scale does not use reaction to suctioning as an item. This implies 
that the COMFORT scale can be used in both ventilated and nonventilated pediatric 
patients.7,11 
The University of Michigan Sedation Scale is restricted to level of consciousness and 
has only been validated for short, procedure related observations.9 Because comfort in 
children has many more aspects than consciousness alone, and preverbal infants are not 
able to clearly communicate discomfort, it is necessary to include other behavioral and 
physiologic variables. An additional advantage of the COMFORT scale is that it takes 
these variables into account.
Although the COMFORT scale was originally described in and validated for measuring 
discomfort in ventilated pediatric patients, the use of this instrument in the clinical PICU 
setting is disputed.1,12 The correct use of the physiologic variables of the COMFORT scale 
implies that reference values for heart rate and arterial blood pressure are adjusted each 
day. Because these physiologic variables are titrated by inotropic and other drugs often 
used in pediatric intensive care, we questioned whether their use contributes to the overall 
assessment of sedation in the individual patient. It has already been demonstrated that 
these two variables have a low interrater agreement.1 Two other studies have demonstrated 
insufficient correlation between physiologic and behavioral COMFORT items.13,14
We set up a study with a two-fold objective. The first objective was to assess whether 
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physiologic variables are really useful in the judgment of sedation with the COMFORT 
scale, and second, we aimed at determining cutoff points for an abbreviated COMFORT 
scale restricted to behavioral COMFORT items (the COMFORT‑B scale).
Table 1 Items in sedation scales used for children
Materials and Methods
Design
Prospective observational study.
Patients
Children aged 0 - 18 years admitted to the PICU of the Erasmus MC - Sophia Children’s 
Hospital between March 2002 and November 2002 were eligible for this study. Children 
with severe mental retardation, severe hypotonia, and neuromuscular blockade were 
excluded because the COMFORT scale has not been validated for these patients. Patients 
were included when at least one of five study nurses was on call to coordinate data 
sampling. Because of the strictly observational and noninvasive nature of the study, the 
institutional review board waived the need for informed consent.
Name of 
instrument 
Conditions measured Validated 
for (age)
Consciousness Agitation Ventilation Pain Psychological 
variables
Other
COMFORT 
Scale1
X X X X X Muscle tone Pediatric
Hartwig 
Sedation Scale8
X X X X Reaction 
to tracheal 
suction
Pediatric
Ramsay Scale6 X X Adult
Children’s 
Hospital of 
Wisconsin 
Sedation Scale19,20 
(modified 
Ramsay  scale)
X X Pediatric 
Neonatal‑PASS10 X X X X Neonate
University 
of Michigan 
Sedation Scale 
(UMSS)9
X X Pediatric
The Vancouver 
Sedative 
Recovery Scale21
X Pediatric
COMFORT behavior scale for the assessment of sedation in the PICU
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Measurements
COMFORT Scale
The COMFORT scale was originally developed to assess distress in pediatric patients in 
a PICU environment and has also been validated to assess postoperative pain in children 
< 3 years of age.1,13 The behavioral items are alertness, calmness, respiratory response 
(in ventilated patients) or crying (in nonventilated patients), muscle tone, physical 
movement, and facial tension. It contains two physiologic items, heart rate and mean 
arterial pressure, the latter requiring an indwelling arterial catheter.
All response categories range from 1, ‘no distress’, to 5, ‘severe distress’. The COMFORT 
scale has been officially translated into Dutch and adapted to the extent that the item 
‘crying’ was added for nonventilated patients.13 
Nurse Interpretation of Sedation Score
To facilitate a comparison between the COMFORT scale and the clinical judgment of 
the attending nurse, we used a reference score, similar to the one used in the original 
validation by Marx et al.12 The Nurse Interpretation of Sedation Score (NISS) is the nurse’s 
expert opinion of the level of sedation, reflected by one of these categories:
Insufficient sedation
Adequate sedation 
Oversedation
Using the expert opinion of a professional is common practice for validation of scales like 
the COMFORT Scale. Expert opinion can be viewed as the ‘silver standard’ when a ‘gold 
standard’ is not available.15 
Procedure/Measurement
The care-giving nurse assessed the patient every 8-hr shift at set times (2, 10, and 18 hrs) 
determining the NISS score before COMFORT score. Paired scores were obtained when 
the patient was uncomfortable (NISS = 1) or when sedation medication was administered 
or changed. Individual baseline values for heart rate (HR) and mean arterial blood pressure 
(MAP) were calculated each day. Severity of illness was scored using the Pediatric Index 
of Mortality score.16
Interobserver Reliability
All nurses at the PICU were trained to use the COMFORT scale by using both videotaped 
material and bedside instructions. Newly trained nurses performed ten COMFORT 
assessments together with a trained nurse. When the obtained linearly weighted 
Cohen’s kappa was satisfactory (> 0.65),17 nurses could participate in the study. The 
median interobserver‑reliability linearly weighted Cohen’s kappa in our PICU was 
0.84 (range 0.67 to 0.96) for 52 nurses.
In a random sample of this study, a second nurse performed a COMFORT score at the 
1.
2.
3.
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same time as the attending nurse. This test served to check whether the COMFORT score 
was influenced by the fact that the attending nurse had already performed a NISS score.
Sedation Medication
Administration of sedative drugs was at the discretion of the attending physician. The 
drug of first choice for sedation purposes in our PICU is midazolam (0.05 - 0.3 mg/kg/hr). 
When sedation is considered insufficient, morphine, ketamine, or fentanyl is given in 
addition to midazolam. Other drugs are used very infrequently.
Statistical Analysis
Interrater reliability was tested by using the linearly weighted Cohen’s kappa and the 
intraclass correlation coefficient.
The internal consistency was calculated by using Cronbach’s alpha, a reliability index 
that estimates the internal consistency of several items within a scale. Items were removed 
when item total correlation was < 0.40. Cutoff scores for the COMFORT-B scale were 
determined by using the NISS as the silver standard. COMFORT scores were compared 
for the three NISS categories by using the nonparametric Kruskal‑Wallis H test.
Results
Patient Characteristics
A total of 843 paired observations in 78 patients were obtained. Background characteristics 
of the patients are listed in Table 2. Median age was 17 months (range 0 to 223).
The age distribution of patients in this study and their Pediatric Index of Mortality 
scores are representative for the total population of our PICU.
Use of analgesics and sedatives is summarized in Table 3. Sixty-five of 78 (83.3%) 
patients received midazolam, with a median of 100 mcg/kg/hr (50 - 900 mcg/kg/hr).
Interobserver Reliability
In 40 observations, COMFORT scores were simultaneously assessed by two independent 
nurses, the caregiving nurse and a colleague. The intraclass correlation coefficient of 
40 paired observations was 0.99 for the COMFORT scale.18 The interobserver reliability 
(linearly weighted Cohen’s kappa) for the COMFORT items ranged from 0.77 to 1.00.
Internal Consistency
Cronbach’s alpha was 0.78, including all items for 596 observations. Missing data could be 
attributed to a lack of an arterial catheter. MAP and HR observations were below or equal 
to the obtained baseline values of the patients in 86.6% and 88.6% of cases, respectively. 
Table 4 shows the corrected item-total correlation of all comfort items. The internal 
COMFORT behavior scale for the assessment of sedation in the PICU
23
consistency, presented by the alpha if item deleted, increased to 0.80 (if MAP deleted) or 
0.79 (if HR deleted).
The Spearman’s rank order correlation coefficient of HR with the behavioral items 
ranged from 0.18 to 0.30 and for the MAP items with the other items ranged from 
0.05 to 0.20. Cronbach’s alpha increased to 0.84 when both MAP and HR were excluded. 
In this analysis, all corrected item total correlations were ≥ 0.50.
Table 2 Background characteristics of the patient group (N = 78)
Table 3 Sedatives and analgesics use for patient group (N = 78) 
a Number of patients
Variable N %
Gender
Male 49 63
Female 29 27
Age group
Neonate 12 15
1 ‑ 6 months 14 18
6 ‑ 12 months 11 14
1 - 3 years 17 22
> 3 years 24 31
Diagnosis
Cardiac ‑ congenital 15 19
Cardiac ‑ others 3 4
Respiratory failure 26 33
Sepsis, septic shock 14 18
Other diagnosis 20 26
PIM score
Mean 0.13
Median 0.07
Range (min, max) 0.002 ‑ 0.96
Number of ventilated patients 66 85
Medication Na % Doses, median (range)
Sedatives
Midazolam 65 83.3 100 mcg/kg/hr (50 - 900)
Ketamine 11 14.1 1 mg/kg/hr (1 - 4)
Analgesics
Morphine 31 39.7 15 mcg/kg/hr (5 - 40)
Fentanyl 4 5.1 1 mcg/kg/hr (1 ‑ 2)
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Concurrent Validity
COMFORT scores were significantly different for the three NISS categories (Kruskal-Wallis, 
Chi-square = 237, df = 2, p < 0.001). The median COMFORT scores were 7 (range 6 to 14) in 
the oversedated NISS category, 11 (range 6 to 26) in the adequately sedated category, and 
19 (range 11 to 29) in the undersedated category.
Table 4 Corrected Item-Total correlation (N = 596 observations)
Cutoff Points for the COMFORT-B Scale
Cutoff points were determined with emphasis on the importance of preventing 
undersedation in individual patients. Table 5 shows the frequency of different 
COMFORT‑B scores and the relative frequencies of COMFORT‑B scores between 6 and 
10, 11 and 22, and 23 and 30 within the three NISS categories. In 93 of 843 observations 
(11%), the impression of nurses was undersedation (NISS = 1), with most COMFORT 
scores between  11 and 22.
In 85.5% of all observations, nurses considered sedation as adequate, with COMFORT 
scores ranging between 6 and 22. In 29 of 843 (3.4%) of all observations, nurses considered 
infants oversedated, with most COMFORT scores between 6 and 10.
The risk of over- or undersedation with a COMFORT score ≥ 23 was 0% and 95%, 
respectively. The risk of over- or undersedation with a COMFORT score ≤ 10 was 7.8% and 
0%, respectively. With COMFORT scores between 11 and 22, patients were under‑ and 
oversedated in 15.4% (75 of 488) and 0.4% (2 of 488) of observations, respectively.
COMFORT and NISS Scores
Patients were considered adequately sedated (NISS = 2) in 721 (86%) of all observations. In 
57% of these observations, the COMFORT score pointed at adequate sedation.
Patients were considered oversedated (NISS = 3) in 29 observations in 18 patients. 
In 93% of these observations, the COMFORT score also implied oversedation. Patients 
were considered undersedated (NISS = 1) in a total of 93 (11%) observations in 35 patients. 
In 19.4% of these observations, the COMFORT scale also implied undersedation. These 35 
COMFORT Scale item Corrected Item-Total 
Correlation
Alpha if Item Deleted
MAP 0.27 0.80
HR 0.31 0.79
Alertness 0.60 0.74
Calmness 0.65 0.74
Respiratory response or crying 0.48 0.76
Physical movement 0.71 0.72
Muscle tone 0.43 0.77
Facial tension 0.54 0.76
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(NISS = 1) and 18 (NISS = 3) patients did not differ significantly from the total study group 
with regard to age, diagnosis, gender, or Pediatric Index of Mortality score.
Some differences between daytime observations (6 a.m. until 10 p.m., n = 546) and 
nighttime (n = 297) observations were observed. Oversedation (NISS = 3) occurred in 4.4% 
of daytime and 1.7% of nighttime observations. Undersedation (NISS = 1) was seen in 11.7% 
of observations during the day and 9.8% of observations during the night. The median 
COMFORT-B scores of 78 patients were significantly higher during daytime than during 
nighttime (Wilcoxon test, Z = -2.86, p = 0.004).
Table 5 COMFORT‑B scores, distinguished by level of sedation according to NISS
a low: favorable, high: unfavorable, b column percentages, NISS Nurse’s Interpretation of Sedation Score
COMFORT 
scorea
Frequency 
of 
observations
%
Cumulative 
%
NISS b = 1
Undersedated
93 observations 
(%)
NISS b = 2
Adequately 
sedated
721 observations 
(%)
NISS b = 3
Oversedated
29 observations 
(%)
6 11 1.3 1.3
7 38 4.5 5.8
8 60 7.1 12.9 0 (0) 309 (42.9) 27 (93.1)
9 128 15.2 28.1
10 99 11.7 39.8
11 104 12.3 52.1
12 96 11.4 63.5
13 71 8.4 71.9
14 57 6.8 78.7
15 49 5.8 84.5
16 40 4.7 89.2
17 17 2.0 91.2 75 (80.6) 411 (57.0) 2 (6.9)
18 16 1.9 93.1
19 13 1.5 94.6
20 12 1.4 96.0
21 9 1.1 97.1
22 4 0.5 97.6
23 5 0.6 98.2
24 5 0.6 98.8
25 3 0.4 99.2
26 2 0.2 99.4
27 3 0.3 99.7 18 (19.3) 1 (0.1) 0 (0)
28 0 0.0
29 1 0.1 99.8
30 0 0.0
Total 843 100.0 100.0 100 100 100
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Discussion
The main findings of this study are two-fold. First, physiologic variables do not correlate 
well with the behavioral items of the COMFORT scale. Second, there is a definite gray 
area, with COMFORT-B scores of ≥ 11 and ≤ 22, where adequate sedation cannot be based 
on COMFORT‑B scores alone.
Our results show a low variance of the MAP and HR items, because these variables 
are by nature artificially controlled in the PICU. Another explanation for the low variance 
in the HR and MAP items may be due to the construction of these two items within the 
COMFORT scale. The HR and MAP scores are compared with baseline values. HR and 
MAP are scored > 1 when these items are 15% above baseline. First, this may result in low 
values when baseline values were increased due to stress, and second, the 15% increase has 
to our knowledge never been tested for adequacy. Additionally, only low correlations of 
HR and MAP with the other items of the COMFORT scale were seen.
Exclusion of these physiologic items in the present study increased the reliability of 
the total COMFORT score. These findings are in line with those from two other studies.13,14 
The study by Carnevale and Razack14 in 18 pediatric patients indicated that physiologic 
variables have a very limited validity as determinants of the total COMFORT score. In 
a former study in postoperative patients (0 - 3 years), we demonstrated insufficient 
correlation between physiologic and behavioral COMFORT items, indicating that inclu‑
sion of physiologic variables was not useful.13 The surplus value of this study compared with 
the study of Carnevale and Razack lies in the greater sample size and the determination of 
cutoff points for the COMFORT-B scale.
This finding has implications for the clinical judgment of sedation. A COMFORT 
scale restricted to behavioral items needs new cutoff points. In the present study, as in 
the original study by Marx et al.,12 we used the expert opinion of experienced medical 
personnel, translated to a 3-point scale, to validate the COMFORT-B scale.1 Marx et  al.12 
originally used a 5-point scale, later also reduced to 3 points. Since the COMFORT 
score obtained by the attending nurse might be biased, a second COMFORT score was 
performed in a subset of observations. As shown in the results, no bias was detected. We 
realize the fallibility of using the nurse’s opinion (NISS) as the gold standard. There is no 
true gold standard to compare the COMFORT against. Self‑report is either not possible 
or not reliable in young children. We are, however, confident that the NISS is useful as a 
silver criterion.15 Nurses were not only experienced but also trained in comfort and pain 
assessment. The NISS integrates personal knowledge of the attending nurse on previous 
hours, illness, medication, idiosyncratic behavior, ventilation, and other PICU aspects of 
the child. The NISS expert opinion is therefore only valid when applied by the caregiving 
nurse and is not useful when scored by an observer unfamiliar with the context of the 
child.
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New cutoff points for the COMFORT-B scale were determined with an emphasis on 
preventing undersedation. In clinical practice, undersedation is a major concern from 
the viewpoint of patients, parents, doctors, and nursing staff. Regulation of sedative 
medication based on COMFORT-B scores should reflect this concern. In our population, 
cutoff points of 10 and 23 reached this goal. Patients with COMFORT-B scores ≤ 10 were 
never undersedated. Patients with COMFORT-B scores ≥ 23 were undersedated in 95% 
of cases. This means that in these ranges of the COMFORT‑B score, changes in sedative 
medication can be based on the COMFORT‑B score alone. With COMFORT‑B scores 
ranging from 11 to 22, patients had a 15.4% chance of being undersedated. The poor 
relationship between the COMFORT‑B score and the clinical judgment of the nurse in 
this middle COMFORT‑B score range can be explained by several factors. COMFORT‑B 
scores are obtained at fixed time points and do not always reflect the overall sedation of 
the patient over time. This sometimes leads to tapering of sedation medication on the 
basis of low COMFORT‑B scores, where the overall impression of the attending nurse is 
different. Factors such as day-night rhythm and procedure-related discomfort have to be 
taken in to account as well.
Daytime COMFORT-B scores in the present study were significantly higher than 
nighttime scores. This finding might be explained by other factors than day-night rhythm 
alone. At nighttime there are fewer nursing and medical staff present. Light and noise are 
reduced, and the children receive only necessary care and interventions.
Overall, COMFORT‑B scores are relatively low in this PICU sample, considering the 
median score of 11 and bearing in mind that, theoretically, the COMFORT‑B score may 
range from 6 to 30. These low scores may be attributed to increased use of sedatives 
in pediatric intensive care patients. The attention for optimal sedation is perhaps also 
reflected in the exceptionally low percentage of observations with oversedation (3.4%) 
by the PICU nurses. This low percentage might be related to the fact that in a PICU 
environment, care givers do not mind that infants and children are heavily sedated with 
concomitant retrograde amnesia for the period on the PICU.
A second explanation for the discrepancy between an adequate NISS and low 
COMFORT‑B score in this study is the fact that all children in whom this discrepancy was 
noted were critically ill, with circulatory and respiratory instability. In these cases, the 
attending nurse might include a previous negative influence of distress on hemodynamics 
and respiration in the judgment of the desired level of sedation. An example of this phe‑
nomenon was seen in patients with pulmonary hypertension in whom undersedation 
is a risk factor for recurrent bouts of increased pulmonary resistance. Undersedation 
according to the caregiving nurses occurred in 11% of all observations. This coincided 
with COMFORT-B scores > 10.
A limitation of this study is that the data were derived in one PICU with one set of PICU 
attending physicians and one set of PICU nurses. There is no international consensus 
about adequate or optimal sedation. Regional and cultural attitudes may influence the 
Ch
ap
te
r 
2
28
opinion about optimal sedation.
This study shows the feasibility of using the COMFORT‑B scale in judging sedation 
levels in critically ill children. The question remains how this sedation scale can be 
used in daily practice. Can an adequate sedation algorithm be developed solely on the 
basis of the COMFORT‑B scale? Is there room for the clinical judgment of the attending 
physician and nurse in such a protocol? The use of sedation observation scales, such as 
the COMFORT‑B scale, as a single measure of patient sedation has drawbacks. It limits 
observation of sedation to a single point in time, without including prior knowledge of 
the patient. However, as long as there are no methods to assess sedation as a continuous 
variable, the use of a score like the COMFORT‑B scale in the PICU remains necessary.
The clinical impression of the caregiving nurses (represented by the NISS) showed 
a relationship with the paired COMFORT‑B scale, albeit not a perfect one. Although it 
is tempting to focus on the statistical significance of these findings, it is more rational 
to admit that the COMFORT score is fallible. We cannot rely solely on an observational 
tool without prior knowledge or expertise. Even for experienced PICU nurses, though, it 
remains difficult to determine the emotional state of their patients. Are they in pain or 
distressed? Is it possible to distract the child or to apply non‑pharmacologic interventions? 
Our findings suggest that assessment of sedation in pediatric intensive care patients could 
benefit from adding a second score such as the NISS in the middle range (11-22) of the 
COMFORT-B score. We believe this would better reflect the inherent difficulties and 
pitfalls of assessing discomfort in critically ill children.
Conclusion
Our results indicate that the assessment of sedation levels in children admitted to a PICU 
can be improved by using a COMFORT‑B scale, leaving out physiologic variables. The 
place of a second subjective measure, for instance the NISS, in a sedation protocol based 
on sedation scores is currently under investigation in our PICU.
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Chapter 3
Implementation of standard sedation 
management in pediatric intensive 
care: effective and feasible?
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Abstract
Objectives: To study effects of the introduction of a sedation treatment protocol for children in 
intensive care, and to analyze PICU nurses’ compliance with this protocol. 
Methods: Administered sedatives and analgesics over the first seven days of admission was 
documented for convenience samples before and after implementation of standard sedation 
assessments and a sedation protocol. Pre- and posttest sedation scores were collected for three 
months with the use of the COMFORT behavior scale, Nurse Interpretation of Sedation Score 
and the Visual Analogue Scale. Nurses’ compliance with the sedation protocol, as well as amounts 
of sedatives and analgesics administered were evaluated  21 months after the posttest during 12 
months.  
Results: Sedatives for 27 patients were recorded pretest; and for 29 other patients after the 
implementation of the sedation protocol. Both median midazolam and median morphine 
administration was significantly higher in the posttest period. The proportion of patients with 
COMFORT scores between 11 and 22, indicating adequate sedation, had increased from 63% pretest 
to 72% posttest and to 75% in the long run. According to the cutoff points of the sedation protocol 
patients were adequately sedated in 71% of the assessments. In 45% of assessments indicating 
undersedation the infusion rate was increased according to the protocol. The majority of staff 
surveyed considered the sedation protocol comprehensible and useful for clinical practice. 
Conclusion: This study showed that regular sedation assessment in critically ill children was 
feasible and was found to be standard practice two years after the first posttest. There is insufficient 
evidence to conclude whether implementation of a sedation treatment protocol indeed improves 
sedation treatment. 
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Introduction
With a view on optimizing sedation and pain treatment in critically ill children, several 
authors and societies have recommended to assess levels of sedation and pain, and to 
titrate sedatives and analgesics on the guidance of guidelines, protocols or algorithms.1-4 
Clinical practice guidelines (CPGs) are widely advocated in the evidence-based health 
care literature, especially by the medical profession, as a method of improving practice, 
standardization of care and research utilization.5 Clinical practice, however, seems to 
lag behind in implementing pain management plans, mainly for lack of resources and 
motivation.6,7
Young children receiving intensive care should be given optimal pain, anxiety and 
discomfort  treatment. Apart from discomfort, they may suffer pain from procedures such 
as intubation, thoracic drain insertion, or from severe trauma or disease. Being disoriented 
in a perceived hostile environment and unable to comprehend the situation, they may also 
be prone to anxiety.8 It follows that implementation of a standard sedation management 
strategy might be of benefit. 
Several studies evaluated effects of sedation guidelines and/or pain management in 
adult9-15 or pediatric intensive care.16,17 Findings of the studies in the adult setting varied 
from a significant reduction (33 to 57%) in duration of mechanical ventilation9-12 to no 
effect.13,14 Chanques et al.11 reported also a significantly decrease of pain and agitation after 
implementation of systematic evaluation of pain and agitation. There is little evidence 
on use of sedation protocols in the pediatric intensive care (PICU). One study evaluated 
a sedation and analgesic protocol in 10 PICU patients.16 Patients received more sedation 
while on the protocol and the nurses found the protocol easy to use. A recent COMFORT 
scale study in PICU patients showed significant decreases of duration of mechanical 
ventilation and doses of sedatives in 21 patients managed with the use of a sedation 
protocol as compared with controls.17  
To date no studies of standard pain and sedation management in PICU patients have 
been reported in the European context for neonates and infants up to 3 years of age. Here 
we reported a study in a PICU in the Netherlands. The aim of this study was twofold. 
The main objective was to study effects of a sedation treatment protocol on doses of 
administered sedatives. The second aim was to investigate nurses’ compliance with the 
sedation protocol. 
Methods
Design and Setting
This pretest - posttest intervention study (see Figure 1) was conducted in a 15 beds ICU of 
the Erasmus MC - Sophia Children’s Hospital, Rotterdam, the Netherlands. In view of the 
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strictly observational and non-invasive nature of the study the institutional review board 
waived the need for informed consent.
Figure 1 Time scheme
Sedation measures
The COMFORT behavior scale
The COMFORT scale was originally developed to assess children’s distress in a PICU 
environment.18 An adapted version, the COMFORT behavior (COMFORT-B) scale, was 
validated to assess distress and postoperative pain in young children under the age 
of 3 years.19-21 Measurement of its internal consistency had yielded a Cronbach’s alpha 
of 0.92. Nurses rate alertness, calmness, respiratory response (in ventilated patients) or 
crying (in non-ventilated patients), muscle tone, physical movement and facial tension. 
With response categories ranging from 1 ‘no distress’ to 5 ’severe distress’, total scores 
range from 6 to 30. 
Nurses learned to use the COMFORT-B scale through a two-hour training using 
both videotaped material and bedside training. Inter-observer reliability was ensured by 
having nurses perform ten assessments together with an experienced nurse, after which 
linearly weighted Cohen’s kappa was calculated.22 Values > 0.65 are taken to indicate good 
inter‑observer reliability. All nurses met this criterion in the first instance.
Visual Analogue Scale
Pain research frequently uses a Visual Analogue Scale (VAS) as an observational 
instrument for pain intensity. The VAS is a horizontal continuous 10-cm line with word 
anchors ‘no-pain’ at the left end and ‘extreme pain’ at the right end.23 A mark on this 
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line representing pain intensity is converted to distance to give a pain score ranging from 
0 - 10 centimeter. Nurses assigned VAS ratings after completing the COMFORT-B scoring 
form. VAS ratings ≥ 4 were considered to reflect moderate to severe pain.24 
Nurse Interpretation of Sedation Score
To facilitate a comparison between the COMFORT-B scale and the clinical judgment of 
the attending nurse, we used a reference score, resembling the one used in the original 
validation study of the COMFORT scale by Marx et al.25 The Nurse Interpretation of 
Sedation Score (NISS) is the nurse’s expert opinion of the level of sedation, reflected by 
one of these categories:21
Insufficient sedation
Adequate sedation
Oversedation 
Procedure
Pretest
COMFORT‑B, VAS and/or NISS scores for patients  up to three years age admitted to the 
PICU in the second half of the year 2002 served as baseline assessment. Use of sedatives 
and analgesics over the first 7 days of admission was documented for a convenience 
sample of patients ventilated for > 48 hours and/or receiving midazolam or morphine. 
Pediatric Index of Mortality (PIM)26 was used to determine severity of illness. The primary 
investigator (MvD) acted as a focal point and supervised the study.  
Intervention 
The intervention consisted of implementation of standard sedation assessment scales; 
COMFORT-B scale, VAS and NISS, and a sedation treatment protocol developed by 
a pediatric intensivist and nursing scientist. It provides medication decision trees for 
hemodynamic stable and unstable patients (increasing medication) as well as weaning of 
medication (see Appendix). Within the boundaries of the protocol, nurses were allowed 
to titrate medication (midazolam and/or morphine) on the guidance of assessments. 
The cutoff points for sedation scores were established in a previous prospective study.21 
Undersedation: COMFORT-B scores of 23 or higher; or  COMFORT-B scores of 11 to 22 (also 
called grey area) in combination with NISS of 1. Adequate sedation: COMFORT-B scores 
of 11 to 22 (grey area) in combination with NISS of 2. And oversedation: COMFORT-B 
scores of 6 to 10; or COMFORT-B scores 11 to 22 in combination with NISS of 3.
Posttest
From December 2003 until March 2004 types and doses of sedatives and analgesics over 
the first 7 days of admission to the ICU were documented in a convenience sample of 
patients ventilated for > 48 hours and/or receiving midazolam or morphine. COMFORT‑B, 
1.
2.
3.
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VAS and/or NISS scores were collected during three months. 
Long run evaluation
Long run compliance with the sedation treatment protocol was assessed in 2006 (Figure 2). 
All eligible scores over this year were compared with the cutoff points of the sedation 
protocol. If the score indicated undersedation or oversedation, assessment and treatment 
doses of administered midazolam and morphine were compared to the protocol. 
Survey
A closed-ended survey was carried out to determine nurses’ and physicians’ attitude 
and satisfaction regarding the utility and feasibility of the treatment protocol.27 The 
respondents were asked to rate their opinion on statements of use of the sedation protocol, 
titration of medication, as well as comprehensibility and feasibility. 
Statistical analyses
Background characteristics of pretest and posttest groups were compared using Chi-square 
analysis for dichotomous variables and Mann-Whitney tests for continuous variables 
(e.g. medication, scores). We considered p < 0.05 to be statistically significant. Data were 
analyzed using Statistical Package for Social Sciences (SPSS), version 14.0.
Results
Study population
We recorded sedative and analgesic treatment of altogether 27 patients admitted (at least 
seven days) in the period August 2002 - November 2002 (pretest); and of 29 other patients 
admitted in the period December 2003 - March 2004, after the intervention.
Background characteristics of these patients are listed in Table 1. Sex, median age, 
diagnoses and median PIM score did not significantly differ between the pretest and 
posttest groups. 
In the long run group, in total 246 patients below the age of 3 years were admitted 
during 2006. Evaluation of the sedation protocol was performed in 131 patients (see 
Figure 2).
Sedation treatment
Table 2 gives an overview of administered sedatives and analgesics in pretest, posttest 
and long run groups. Morphine and midazolam were the most frequently administered 
drugs. Both median morphine and median midazolam doses were significantly higher 
in the posttest period. Morphine administration rose from 6.9 mcg/kg/hr to 11.2 mcg/kg/hr 
(Mann-Whitney, Z= -2.9, p = 0.004) for 63% versus 55% of patients, midazolam from 
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54.0 mcg/kg/hr to 112.8 mcg/kg/hr (Mann‑Whitney, Z= ‑3.34, p = 0.001) for 59% versus 
79% of patients (Table 2). Several patients received additional drugs such as esketamine, 
clonidine, paracetamol or alimemazine  to relieve distress and/or pain. 
Table 1 Background characteristics of pretest and posttest patients 0 - 3 years
 
Table 2 Frequency and doses of analgesics and sedatives
Mann-Whitney test for pre-posttest morphine (p = 0.004)* and midazolam (p = 0.001)**, IQR interquartile range, 
N number of patients, Additional medication administered in pretest / posttest / long run groups: Esketamine, 
2 / 3  / 28 patients; Alimemazine, 4 / 7 / 54 patients. 
Pretest (N = 27) Posttest (N = 29) p value*
Sex
Female / Male 6 / 21 13 / 16 0.08
Age
Neonate (< 28 days) 8 4
 1 – 6 months 8 18
 6 – 12 months 4 2
 1 – 3 years 7 5
Median age (months) 4.1 3.1 0.81
Ventilation (yes) 17 21 0.79
Diagnosis 0.89
Congenital heart disease 15 10
Sepsis 1 2
Respiratory failure 4 9
Other 7 8
PIM score
Median 0.04 0.05 0.80
min-max 0.002-0.97 0.002-0.78
PIM score Pediatric Index of Mortality score, * Mann-Whitney test used 
Pretest 2002
(N = 27)
Posttest 2003-2004
(N = 29)
Long run 2006 
(N = 131)
Analgesics
Morphine 
Median (mcg/kg/hr)*
Minimum – maximum 
N(% of group)
6.9
3.4-30.2
17 (63%)
11.2
7.4-31.5
16 (55%)
10.0
4.5-80.0
80 (61%)
Sedatives
Midazolam 
Median (mcg/kg/hr)**
Minimum – maximum 
N(% of group)
54.0
32.3-125.7
16 (59%)
112.8
39.9-246.0
23 (79%)
118.2
31.3-400.0
95 (73%)
COMFORT-B scale 
Number of assessments
Median score (IQR)
Number of patients
214
12 (11-13)
22
832
12 (11-13)
24
4067
12 (11-15)
131
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For the long run group, median doses for midazolam and morphine equaled those of 
the posttest group. COMFORT-B, VAS and NISS score distributions are shown in Table 3. 
The proportion of COMFORT-B scale scores between 11 and 22, indicating adequate 
sedation, increased from 63% during pretest period to 72% posttest and to 75% in 2006. 
Proportions of NISS scores indicating adequate sedation were nearly equal for the three 
stages. Proportions of VAS scores ≥ 4, indicating pain, were 4.6% and 5.5% for respectively 
the posttest group and the long run group.
Table 3 Sedation and pain assessments, COMFORT-B scale scores
 
NISS Nurse Interpretation of Sedation Score, VAS visual analogue scale, IQR interquartile range, N number, 
* During the pretest period the VAS was not assessed on the PICU; nurses instead scored level of sedation
Feasibility
All nurses (n = 44) involved reached the inter-observer reliability required for use of the 
COMFORT‑B scale in the first instance. The mean number of assessments increased 
slightly from 11 (440 assessment in 48 patients) pretest to 12 (1256/60) posttest. 
Long run - utilization and compliance of sedation protocol
In the long run, the sedation protocol was still being used and sedation assessments were 
analyzed. Sedatives were prescribed in 131 patients according to the sedation protocol. 
For these patients nurses’ compliance with interventions dictated by the protocol and 
with control assessments was evaluated. In total 3573 paired COMFORT-B and NISS 
Pretest 2002 Posttest 2003 - 2004 Long run 2006
COMFORT-B scale
Median (IQR) 11 (10 - 13) 12 (10 - 14) 12 (11 - 15)
Score ≤ 10 35.7% 26.3% 22.5%
Score 11 - 22 63.2% 72.0% 74.5%
Score ≥ 23 1.1% 1.8% 3.0%
Number of assessments 440 1256 4067
VAS*
Median (IQR) - 0 (0 - 1) 1 (0 - 1)
Score ≥ 4 - 4.6% 5.5%
Number of assessments - 675 3541
NISS
Under sedated 9.4% 8.8% 13.8%
Adequate sedation 87.5% 88.8% 83.7%
Over sedated 3.1% 2.4% 2.5%
Number of assessments 425 784 3573
Patients 
N 48 60 131
Median age (months) 6.5 3.1 4.0
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assessments were performed. Patients were adequately sedated in 64% (2273/3573) of 
the assessments correspondingly to cutoff point for sedation protocol, which implied no 
medical intervention was necessary according the sedation protocol. In 45% (209/461) 
of assessments indicating undersedation the infusion rate was increased according to 
decision tree (Table 4). A medical treatment intervention outside of the protocol was 
performed in 26% of the assessments indicating undersedation. Control assessments were 
performed in 197/330 (60%) of cases in which the infusion rate or other medical treatment 
was increased by protocol. Sedation was weaned by protocol in 85/704 of the assessments 
indicating oversedation. Only in 12 of 85 cases of weaning a control assessment was 
performed. Forty-six percent of these assessments were performed during the night. 
Figure 2 Inclusion patients long run evaluation
Table 4 Adherence of sedation protocol in long run evaluation (2006)
Survey
The posttest survey on the use of the sedation protocol was completed by 26 nurses and 4 
physicians (response rate of 60%). The results are summarized in Table 5. Twenty‑five of 
Condition Treatment according to protocol n (%) Number of control 
assessments 
Under sedated 461 (100)
No treatment 131 (28) 19
Infusion rate increased 209 (45) 137
Other medication increased (outside of protocol) 121 (26) 60
Over sedated 704 (100)
No treatment 619 (88) 1
Infusion decreased/ stopped 85 (12) 12
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the nurses (96.2%) considered the sedation protocol comprehensible and 88.5% of them 
considered it was useful for clinical practice. 76.9% of nurses titrated medication within 
the bounds of the protocol and based on the guidance of assessments.
Table 5 Results posttest survey of pain and sedation protocol (n = 30)
* nurse specific statements
Discussion
After the introduction of a sedation protocol, administered amounts of midazolam and 
morphine increased significantly. The implementation proved relatively successful in the 
long run in PICU. 
Effect of the implementation? 
Proportions of patients receiving morphine or midazolam did not significantly change. 
However, higher doses did not lead to significantly lower sedation scores. In contrast, 
the proportion of COMFORT-B scores 11 - 22 (‘adequately sedated’) increased slightly 
for the posttest group. The variety of sedatives (propofol, ketamine and alimemazine) 
administered in addition shows that optimal sedation and quality of sleep remain 
challenging for this patient group. Alexander et al.16 found also significantly higher 
doses of midazolam and fentanyl after implementation of a sedation protocol. The study 
population was small, however, and the authors did not provide a reason for the increase. 
In the long run evaluation, we found that median doses of midazolam and morphine 
were equal to those in the posttest group. These results, however, pertained to a larger 
Items of posttest survey Answer (%)
Statements Yes/yes! No/no! ?
1. Nurses independently titrated medication within the bounds 
of the protocol and based on the guidance of COMFORT-B 
assessments.*
76.9 19.2 3.8
2. The sedation protocol in combination with the COMFORT-B 
scale is comprehensible, joined with.*
96.2 3.8
3. The sedation protocol is useful for clinical practice.* 88.5 3.8 7.7
4. Independent administering of medicines within the bounds of 
the sedation protocol is a too large a responsibility.*
19.2 80.8
5. Independent administering of medicines within the bounds of 
the protocol is a challenge.*
61.5 34.6 3.8
6. The sedation protocol is only useful for postoperative patients. 10.3 82.8 6.9
7. Implementation of the sedation protocol on the ward has little 
impact. 
44.8 51.7 3.4
8. The protocol increases quality of care. 62.1 27.6 10.3
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population. Furthermore, doses recorded for the long run evaluation concerned patients’ 
total ICU stay, in contrast to the posttest group for which doses over the first 7 days were 
recorded. 
Most of the studies of nurse implemented pain and/or sedation protocols were 
performed in  adult‑ICU care. The effects of implementation were different, however, and 
therefore these cannot be generalized to our practice.10,11,14 
Several questions may be raised how we can explain the effect on the implementation 
in this study. Does higher dosing of sedatives and analgesics indeed reflect improved 
sedation treatment? Does higher number of COMFORT scores ≥ 23 point at undersedation, 
or at caregivers’ increased awareness of the necessity of adequate sedation? We selected 
midazolam and morphine to be used in our protocol for sedation treatment, but 
administered other additional sedatives and analgesics as well. Given the lack of solid 
data these preferences are not evidence-based.4,28 Seeing that pediatric drug studies are 
still scarce, physicians may tend to draw on personal experiences. 
Compliance  
Sedation assessment is the first step in multidisciplinary sedation management. In general, 
we may conclude that regular sedation assessment was feasible for the study period. 
What’s more, it was found to be standard practice two years after the first posttest, with 
acceptable compliance. We would like to propose three explanations. One, the research 
nurse’s continuous involvement in sedation issues was conducive to regular sedation 
assessment. Two, a patient data management system was in place, which is valuable when 
set to alert caregiving nurses to assess their patient(s) comfort and pain each shift. Also, 
it is essential to have the commitment of at least one physician on the PICU, not only 
to develop an protocol but also to supervise its use. Further, we may conclude that staff 
was satisfied with implementation of the sedation protocol. Regrettably, this proved no 
assurance for strict adherence to guidelines of sedation management and application of 
the protocol. We have seen this also in the long run evaluation. There were several reasons 
for violation of the treatment protocol. First, nurses were reluctant to decrease sedatives 
during nighttime. COMFORT‑B scores were significantly lower during nighttime than 
daytime.21 This might be explained by physiological sleep pattern, less noise and light and 
children receiving only necessary care and interventions.  Sedatives were mostly decreased 
after daily rounds and based on  nighttime and daytime sedation scores. This would be 
discussed with nurse and physician during rounds. Reluctance and anxiety may be other 
factors why nurses did not titrate sedatives or analgesics as prescribed in the protocol. 
Relatively few control assessments for evaluating medical treatment were performed, 
especially in oversedated patients. We speculated nurses were occasionally not focused 
on reduction of length of stay but more engaged with comfort of the patient. 
Cabana et al.6 have identified several barriers that refrain physicians and nurses 
from following guidelines, such as lack of awareness, familiarity and agreement. Such 
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factors may well have played a role in our study as well. On the other hand we agree with 
Alexander  et al.16 that the use of a sedation and pain protocol, which transfers some of the 
decision-making process from physicians to nurses, requires a change in culture.
In our opinion it is important to incorporate standard sedation assessment in a 
treatment protocol. The nurses can thus be given the authority to act on the basis of 
sedation assessment, albeit within the borders of the treatment protocol. Correcting 
inadequate sedation is inefficient in the absence of a protocol since it requires the nurse to 
first communicate her/his assessment, obtain a prescription, adjust the sedation and wait 
for the drug to take effect. This is a time‑consuming process which can lead to conflicts. 
The use of a protocol enables efficient interventions and avoids the need to negotiate with 
physicians. The success of nurse-directed protocols can be achieved, at least partly, by 
allowing more rapid clinical decision making to occur at the patient’s bedside.10 
The general purpose of the study was implementation of a sedation assessment tool 
and a related treatment protocol. Our study had some limitations. The time frame from 
start to finish was relatively long. This was needed, we felt, because of the well‑known 
problem of introducing new protocols on a ward. However, during this period a number 
of unknown influences might have led to the increased use of midazolam and morphine. 
The chosen design in this study had some weaknesses in contrast with a RCT. Other 
potential outcomes such as morbidity or duration of mechanical ventilation require much 
larger sample sizes. It proved difficult to find optimal outcome parameters for this study. 
Patient satisfaction cannot be tested in very young children, as they lack the ability for 
self‑report. Caregivers may be satisfied with their sedation treatment but their view may 
be biased. Finally, it proved difficult to check whether nurses worked according to the 
protocol. Sedation assessment scores could be retrieved from PDMS but determining if 
nurses indeed increased midazolam or morphine dosing themselves when scores were 
high proved very complex.
We conclude that the implementation of sedation assessment  was successful in our PICU. 
Satisfactory implementation of the protocol - i.e. treatment based on sedation assessment 
itself - remains questionable, however. We hypothesize that compliance was moderate, 
like with many other treatment protocols.1,29 Nurses may find it easier to ask an attending 
doctor to adjust dosing of sedatives rather than to consult a treatment protocol. Physicians, 
in turn, like to follow their clinical impression instead of providing treatment on the 
guidance of sedation scores. The higher dosages of midazolam and morphine noted in 
this study might well result from greater awareness of pain or anxiety invoked by the very 
study. Unfortunately, the relatively low level of evidence for these specific populations 
does not yet provide for solid based guidelines.4,28  
Implementation of standard sedation management in pedatric intensive care
43
References 
1. Gordon DB, Dahl JL, Miaskowski C, McCarberg B, Todd KH, Paice JA, Lipman AG, Bookbinder 
M, Sanders SH, Turk DC, Carr DB. American pain society recommendations for improving the 
quality of acute and cancer pain management: American Pain Society Quality of Care Task 
Force. Arch Intern Med 2005;165:1574-80.
2. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica 
MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA, 
Jr., Murray MJ, Peruzzi WT, Lumb PD. Clinical practice guidelines for the sustained use of 
sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41.
3. Jenkins IA, Playfor SD, Bevan C, Davies G, Wolf AR. Current United Kingdom sedation practice 
in pediatric intensive care. Paediatr Anaesth 2007;17:675-83.
4. Playfor S, Jenkins I, Boyles C, Choonara I, Davies G, Haywood T, Hinson G, Mayer A, Morton 
N, Ralph T, Wolf A. Consensus guidelines on sedation and analgesia in critically ill children. 
Intensive Care Med 2006;32:1125-36.
5. Hammond JJ. Protocols and guidelines in critical care: development and implementation. 
Curr Opin Crit Care 2001;7:464-8.
6. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don’t 
physicians follow clinical practice guidelines? A framework for improvement. Jama 
1999;282:1458-65.
7. Turk DC. Management of pain: best of times, worst of times? Clin J Pain 2001;17:107‑9.
8. Chambliss CR, Anand KJ. Pain management in the pediatric intensive care unit. Curr Opin 
Pediatr 1997;9:246-53.
9. Brattebo G, Hofoss D, Flaatten H, Muri AK, Gjerde S, Plsek PE. Effect of a scoring system and 
protocol for sedation on duration of patients’ need for ventilator support in a surgical intensive 
care unit. Bmj 2002;324:1386-9.
10. Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, Kollef MH. Effect of a 
nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care 
Med 1999;27:2609-15.
11. Chanques G, Jaber S, Barbotte E, Violet S, Sebbane M, Perrigault PF, Mann C, Lefrant JY, 
Eledjam JJ. Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit 
Care Med 2006;34:1691-9.
12. De Jonghe B, Bastuji-Garin S, Fangio P, Lacherade JC, Jabot J, Appere-De-Vecchi C, Rocha N, 
Outin H. Sedation algorithm in critically ill patients without acute brain injury. Crit Care Med 
2005;33:120-7.
13. Devlin JW, Holbrook AM, Fuller HD. The effect of ICU sedation guidelines and pharmacist 
interventions on clinical outcomes and drug cost. Ann Pharmacother 1997;31:689-95.
14. Elliott R, McKinley S, Aitken LM, Hendrikz J. The effect of an algorithm‑based sedation 
guideline on the duration of mechanical ventilation in an Australian intensive care unit. 
Intensive Care Med 2006;32:1506-14.
15. Erdek MA, Pronovost PJ. Improving assessment and treatment of pain in the critically ill. Int J 
Qual Health Care 2004;16:59-64.
16. Alexander E, Carnevale FA, Razack S. Evaluation of a sedation protocol for intubated critically 
ill children. Intensive Crit Care Nurs 2002;18:292-301.
17. Jin HS, Yum MS, Kim SL, Shin HY, Lee EH, Ha EJ, Hong SJ, Park SJ. The Efficacy of the 
COMFORT Scale in Assessing Optimal Sedation in Critically Ill Children Requiring Mechanical 
Ventilation. J Korean Med Sci 2007;22:693-7.
Ch
ap
te
r 
3
44
18. Ambuel B, Hamlett KW, Marx CM, Blumer JL. Assessing distress in pediatric intensive care 
environments: the COMFORT scale. J Pediatr Psychol 1992;17:95-109.
19. van Dijk M, de Boer JB, Koot HM, Tibboel D, Passchier J, Duivenvoorden HJ. The reliability and 
validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-old infants. 
Pain 2000;84:367-77.
20. Carnevale FA, Razack S. An item analysis of the COMFORT scale in a pediatric intensive care 
unit. Pediatr Crit Care Med 2002;3:177-80.
21. Ista E, van Dijk M, Tibboel D, de Hoog M. Assessment of sedation levels in pediatric intensive 
care patients can be improved by using the COMFORT “behavior” scale. Pediatr Crit Care Med 
2005;6:58-63.
22. Fleiss J. Statistical methods for rates and proportions. New York: Wiley; 1981.
23. Huskisson EC. Measurement of pain. Lancet 1974;2:1127-31.
24. Buchholz M, Karl HW, Pomietto M, Lynn A. Pain scores in infants: a modified infant pain scale 
versus visual analogue. J Pain Symptom Manage 1998;15:117-24.
25. Marx CM, Smith PG, Lowrie LH, Hamlett KW, Ambuel B, Yamashita TS, Blumer JL. Optimal 
sedation of mechanically ventilated pediatric critical care patients. Crit Care Med 1994;22:163-70.
26. Shann F, Pearson G, Slater A, Wilkinson K. Paediatric index of mortality (PIM): a mortality 
prediction model for children in intensive care. Intensive Care Med 1997;23:201-7.
27. Ista E, de Hoog M, van Dijk M. Usefulness of a sedation algorithm for critically ill children. 
Pediatr Crit Care Med 2005;6:242.
28. Prins S, van Dijk M, Tibboel D. Sedation and analgesia in the PICU: many questions remain. 
Intensive Care Med 2006;32:1103-5.
29. American.Pain.Society. Quality improvement guidelines for the treatment of acute pain and 
cancer pain. American Pain Society Quality of Care Committee. JAMA 1995;274:1874-80.
Implementation of standard sedation management in pedatric intensive care
45
Appendix A Basic scheme sedation protocol
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Appendix B Decision tree for hemodynamic stable
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Appendix C Decision tree for hemodynamic unstable
Ch
ap
te
r 
3
48
Appendix D Decision tree weaning midazolam
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Appendix E Decision tree weaning midazolam and ketamine
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Appendix F Decision tree weaning midazolam and morphine
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Chapter 4
Is the Bispectral Index monitor useful 
for measuring sedation depth in 
critically ill infants up to 12 months of 
age?
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Abstract
Background: The BIS monitor has been validated for assessment of sedation levels in adults and 
children above one year of age. Normal BIS values are available for adults, but not yet for infants. 
Aim: We aimed to examine the correlation between the BIS monitor and COMFORT behavior 
scale in infants up to 12 months and to evaluate the usefulness of the BIS for the assessment of 
consciousness in infants.
Methods: We created two groups. Infants in the ‘natural sleep’ group were drug free and free 
from intra-cerebral pathology, and were monitored with BIS and COMFORT behavior scale 
(COMFORT-B) for 24 hours. Infants in the ‘postoperative sedation’ group were monitored likewise 
during the first 48 hours postoperatively. The correlations and prediction coefficient (Pk) for BIS 
and the COMFORT-B item alertness were calculated. 
Results: 264 paired observations were collected for 32 hospitalized infants (median age 58 days; 
range 1 to 363) without any opioids and sedatives. The Spearman correlation coefficient between 
the BIS and COMFORT-B was rs = 0.62 and rs = 0.72 for the age groups 0 - 6 months and 6-12 months, 
respectively. The Pk for the BIS compared with alertness scores was slightly higher for the older age 
group. 
Thirty-nine infants were enrolled in the postoperative sedation group (median age 39 days; range 
4 to 97 days). In total 203 paired observations were obtained with a median BIS value of 67 (range 
12 to 98) and a median COMFORT-B score of 12 (range 6 to 30). The overall Spearman’s correlation 
coefficient was 0.50 (p < 0.0001). BIS values were significantly different for the five COMFORT-B 
alertness categories (Kruskal-Wallis, p < 0.0001). 
Conclusion: BIS values obtained using the present algorithm software during natural and 
pharmacological sleep (sedation or anaesthesia) should be interpreted with caution in infants up 
to 12 months of age. A new algorithm, derived from BIS values for this age group during ‘natural 
sleep’ and awake state needs to be developed.
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Introduction 
Critically ill children requiring mechanical ventilation almost always receive sedative 
and analgesic drugs. These will reduce possible distress, anxiety, pain, and facilitate 
intensive care therapy and nursing care. While undersedation fails to produce the desired 
effects, oversedation will lead to prolonged intensive care, longer duration of mechanical 
ventilation, and drug tolerance possibly with withdrawal syndrome.1,2 Optimal level of 
sedation will vary with age and severity of illness, among other things. Titrating optimal 
doses for each child is a difficult task therefore. In order to achieve this, a number of 
sedation scoring systems have been devised for use in the critically ill.3 Only three validated 
sedation scales assess distress in ventilated critically ill children; the COMFORT behavior 
scale, the Hartwig sedation scale and the State Behavioral Scale.4-8 The COMFORT-B scale 
has been recommended for regular sedation assessment.9 Concerns have been raised about 
the subjectivity of clinical sedation scales and their inability to differentiate between deep 
and moderate sedation. Furthermore, they assess sedation at single points in time, so that 
information about sedation levels in the intervening periods is lacking. 
As an alternative, brain monitors such as Bispectral Index (BIS) monitor  have 
been developed and validated for assessing depth of sedation (consciousness) - mostly 
during anaesthesia in adults and children over one year of age.10-15 Experience with the 
BIS monitor has been gained meanwhile in pediatric intensive care.16,17 Several BIS 
monitoring validation studies have been performed in critically ill infants and children 
in the intensive care setting (see Table 1).18-24 All studies showed from moderate to good 
correlation (0.54 to 0.89) between BIS values and clinical sedation scores. However, the 
BIS monitor has a major limitation when applied in young children. It makes use of an 
algorithm derived from adult electroencephalograms (EEG), which are known to differ 
from those in young children. Furthermore, in clinical practice it seems to be a moderate 
predictor of sedation level in the individual infant. 
Steriade25 reported that characteristic changes in EEG signals during general anaesthesia 
also occur to some degree during naturally occurring sleep; it would seem logical, therefore, 
to determine BIS values during ‘natural sleep’. Only for children undergoing surgery a 
correlation was established between BIS values based on the ‘adult algorithm’ and 
sevoflurane concentration with the.26 It seems likely, however, that BIS values for young 
children differ from adult ones and will change during the first years of life.27
The aim of this study was to examine the correlation between the BIS monitor and 
COMFORT behavior ratings in infants up to 12 months of age, and to evaluate the usefulness 
of the BIS assessment of consciousness level in infants. To this aim we compared BIS 
values and COMFORT behavior scores in ‘natural sleep’ infants without sedatives and 
postoperative (sedation) infants. 
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Methods
To examine the correlation between the BIS monitor and the COMFORT behavior scale we 
performed an observational prospective study in two different study groups. All patients 
were infants aged 0 up to 12 months and included in this study after written parental 
informed consent. The Erasmus MC institutional review board approved the research of 
the BIS monitor. 
Natural sleep group
Infants, free of opioids and midazolam and free from intra-cerebral pathology, were 
included in this study group between March 2003 and April 2004. BIS electrodes were 
applied at the forehead of the infants as instructed by the manufacturer during 24 hours 
at a medium care unit of the tertiary Erasmus MC - Sophia Children’s hospital. The BIS 
monitor was connected to a laptop, which collected all BIS data. During these 24 hours, 
hourly COMFORT behavior observations were planned. Simultaneously, BIS values were 
collected continuously,  read afterwards and paired with the COMFORT observations. 
Postoperative sedation group
Infants were included for this study between March 2002 and April 2003 if they were 
expected to undergo postoperative sedation for more than 48 hours after surgery. We 
evaluated the BIS monitor during sedation of infants admitted to the surgical pediatric 
intensive care unit of the Erasmus MC - Sophia Children’s Hospital using the COMFORT 
behavior scale. An independent observer (SP) randomly scored the COMFORT behavior 
scale together with BIS values during the first 48 hours postoperatively.
The COMFORT behavior scale
The COMFORT behavior scale is an adapted version of the scale that was originally 
developed by Ambuel and colleagues8 in 1992 and consisted of six behavioral items and 
two physiological parameters, heart rate and blood pressure. Marx and colleagues5  showed 
that this scale was useful to assess sedation. We showed that, leaving out the physiological 
items, the scale was still valid for both postoperative pain and sedation in children aged 
0 - 3 years.28 Six patterns of behavior are assessed: Alertness, Calmness/Agitation, Muscle 
tone, Physical movement, Facial tension, Crying (non-ventilated children) or Respiratory 
response (ventilated children). Each item is scored from 1 to 5; the total score thus ranges 
from 6 to 30: the higher the score, the more uncomfortable the child is thought to be. 
All nurses were trained to use the  scale, as reported in our earlier analgesia study.28 
Inter-observer reliability, represented by linearly weighted kappa, was satisfactory, with 
kappa > 0.65 for all nurses and the principal investigator.28 Scores < 9 are thought to 
represent over-sedation, scores between 9 and 16 no distress, scores  ≥ 17 distress.
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BIS monitor 
The BIS monitor uses a frontal, two channel electroencephalogram (EEG) to quantify 
hypnotic effects of anaesthetic and sedative drugs on the brain. First mainly used during 
surgery, over the years it has found its way to the pediatric intensive care unit as well.10,19 
Fourier transformation of the information and bispectral analysis are used to compute 
a number between 100 (fully awake) and zero (absence of brain electrical activity).11 BIS 
values above 60 are considered to be indicative of inadequate sedation and even risk 
of awareness in adults.12,13 A Bispectral A 2000 version 3.12 monitor (Aspect Medical 
Systems, Natick, MA, USA) with commercially available BIS sensor strips designed for 
children was used. A BIS sensor was placed on the patient’s forehead in accordance with 
the manufacturer’s instructions. The algorithm within the BIS monitor sets limits for 
electrode impedance and signal quality. Consequently, no value is displayed if the signal 
has too much noise or artefacts. We used the limits set in the monitor; if the BIS value was 
displayed, meaning a Signal Quality Index (SQI) > 50, it was recorded. BIS values of < 40 
were defined as very deep sedation, 41 - 60 as deep sedation, 60 - 79 as moderate sedation, 
80 - 89 as light sedation, and > 89 as awake. 
Statistical analyses
The data were analyzed using SPSS for Windows (version 14.0; SPSS, Chicago, IL). 
Correlations between BIS values and COMFORT scores were expressed by the Spearman 
rank correlation coefficient (rs). In this study scores on the COMFORT behavior item 
alertness represented the level of consciousness. These scores were compared with BIS 
values using the Kruskal-Wallis H test. Furthermore, to detect any age related differences, 
we created two age groups: 0 to 6 months of age and 6 months to 12 months of age. In 
anaesthesia the prediction probability coefficient (Pk) is commonly used as a measure 
of association between a clinical monitor such as the BIS monitor and consciousness 
(anaesthetic depth) reflected by observation.16,29 Pk gives the probability that the index 
values of two randomly selected data points predict correctly which of the data points 
correspond to the deeper or lighter level of anaesthesia. A Pk of 1 means that the values of 
the predicting index (BIS) will always correctly predict the level of consciousness.  A Pk 
value of 0.5 means that the values of the predicting index will predict level of anaesthesia 
no better than a 50 - 50 chance. Pk values depend on the number of levels of the observation 
scale.30 Statistical differences were considered significant if p < 0.05. 
Results
Natural sleep group
Thirty-two infants (22 boys and 10 girls) were included in the ‘natural sleep’ group. Their 
median age was 58 days (range 1 to 363 days). Twenty-five were 0 to 6 months of age and 
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seven infants were 6 months to 12 months of age. All patients were free of opioids and 
benzodiazepines. Nine (28%) were on acetaminophen (paracetamol) at the time of the 
observations. 
In total 264 COMFORT behavior scale observations were done, with a median of 
8 observations (range 2 to 17) per patient. The median BIS value for these observation 
moments was 73 (range 32 to 98); the median COMFORT behavior score was 13 
(range 6 to 23). The BIS-COMFORT behavior correlation was rs= 0.62 for the age group 
0 -  6 months and rs = 0.72 for the age group 6 - 12 months. The overall correlation for all 
observations was rs = 0.67 (p < 0.0001). Correlations between separate COMFORT behavior 
scale items and BIS ranged from 0.58 for facial tension to 0.79 for body movement. BIS 
values corresponding with the various response categories of the item alertness are shown 
in Figure 1. In spite of large overlaps, BIS values were significantly different for these 
categories (Kruskal-Wallis test, Chi-square 64.85, df = 4, p < 0.0001). The association 
between BIS values and the item alertness reflected by the prediction coefficient (Pk) 
was 0.86 (SE 0.02) for the overall group. The Pk was slightly better in the age group 6 - 12 
months (Table 2). 
Figure 1 BIS values for infants in the ‘natural sleep’ group in relation to the various response categories for the 
COMFORT item alertness
The response category Hyper-alert did not contain data. 
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Table 2 Correlation and prediction probability coefficients 
Pk prediction coefficient (SE), N  number of patients
Postoperative sedation group
Thirty-nine infants (32 boys and 7 girls) were enrolled in the postoperative sedation group. 
Their median age was 39 days (range 4 to 97 days). Two of them were > 6 months. These 
infants received analgesics and sedatives in the PICU after major abdominal (n = 30), 
craniofacial (n = 4) urological (n = 2), or other surgery (n = 3). 
Fifteen infants received only morphine, 2 infants only midazolam and 16 a 
combination of the two. Median dosages of morphine and midazolam were 10 mcg/kg/hr 
and 100 mcg/kg/hr respectively. Six infants received only acetaminophen during the 
observations. 
In total 203 COMFORT behavior observations were done with a median of 4 observations 
(range 2 to 14) per patient. The median COMFORT behavior score was 12 (range 6 to 
30) and the median BIS value for the observation moments was 67 (range 12 to 98). The 
overall Spearman correlation coefficient for all observations was rs = 0.50 (p < 0.0001). 
Correlations between separate COMFORT behavior items and BIS ranged from 0.20 for 
crying to 0.60 for alertness. 
Figure 2 shows BIS values corresponding with the various response categories of the 
item alertness. BIS values were significantly different for these categories (Kruskal-Wallis, 
Chi-square 64.8, df = 4, p < 0.0001). The association between BIS values and the item 
alertness reflected by the prediction coefficient (Pk) was 0.76 (SE 0.02) (see Table 2)
In 56.7% of the observations the infants were considered appropriately sedated on the 
basis of the BIS score (BIS 41 - 79 (deep and moderate)); in 10.8% they were considered 
oversedated (BIS < 40). On the other hand, in 69.0% of the observations the infants were 
adequately sedated on the basis of the COMFORT behavior score (9 - 16) and in 11.8% 
oversedated (< 9). 
Postoperative sedation group Natural sleep group
Total 
(N = 39)
0 - 6 
months
(N = 37)
6 - 12 
months 
(N = 2)
Total 
(N = 32)
0 - 6 months 
(N = 25)
6 - 12 months
(N = 7)
Spearman 
Correlation
0.50 - - 0.67 0.62 0.72
Pk (BIS-alertness) 0.76 (0.02) 0.76 (0.02) - 0.86 (0.02) 0.84 (0.020) 0.89 (0.037)
Pk (BIS-COMFORT-behavior) 0.69 (0.02) 0.69 (0.02) - 0.75 (0.016) 0.73 (0.019) 0.78 (0.039)
Number of 
assessment
203 198 5 264 210 54
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Figure 2 BIS values for infants in the postoperative group in relation to the various response categories for the 
COMFORT behavior scale item alertness.
Discussion 
To our knowledge this is the first study describing effects of sedation and physiological 
sleep on BIS values in infants up to 12 months of age. Our main finding is a moderate 
overall correlation between BIS monitor and COMFORT behavior scale for infants less 
than 12 months. For infants 6 to 12 months in the ‘natural sleep’ group, however, the 
correlation (rs= 0.72) was better than that in younger infants, and the prediction coefficient 
(Pk = 0.89) was good.
Maintaining adequate sedation in children in intensive care is a great challenge 
and often a difficult task. Appropriate RCTs in this field have not been performed yet.31 
A disadvantage of the use of sedation scales is that completion takes much time, with 
inherent risk of low compliance. What’s more, these ‘objective’ scales still carry the risk 
of some subjectivity in assessing sedation depth, such that sedation requirements may be 
set differently by different practitioners caring for a patient.32 A really objective method 
such as BIS monitoring could therefore be a helpful instrument to guide administration 
of sedatives and analgesics.17
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To date, relevant studies performed have primarily focused on validating BIS 
measurements by correlating BIS with existing clinical sedation scales (Table 1).18-24 
Except for Aneja et al.18 all authors included infants less 12 months of age. However, only 
two studies distinguished between young infants (< 6 - 12 months) and older children 
(> 6 months).23,24 While Twite et al.24 found a similar correlation as in our study, Triltsch et 
al.23 found a higher correlation in infants less than 6 months compared with the older 
children. Surprisingly, they could not explain the higher correlation in the younger 
children. Also, other authors have noted BIS scores in infants < 6 months of age to be 
unreliable during general anaesthesia.14,15,26 Like Twite et al.24 we conclude that the BIS 
monitor and the COMFORT behavior scale do not measure the same variables. The 
former measures level of consciousness (sedation), whereas the latter was designed for 
assessing overall distress. Although different, these variables yet are related and affect 
each other. For example, an infant may be awake and alert as shown from a high BIS value 
and comfortable on account of a moderately low COMFORT behavior score. Alternatively, 
a stimulus may awaken a sedated infant, increasing the BIS value but not changing the 
COMFORT behavior score to a great extent. BIS and COMFORT behavior scale detected the 
same proportion of undersedation, however, there was a discrepancy for the proportions 
of adequate sedation detected.
In this study the Pk measure was used to examine the association of BIS measures 
and ‘alertness’ in infants.16,29 We hold the view that level of consciousness is best reflected 
by the item ‘alertness’ of the COMFORT behavior scale. The results of this study indeed 
underpin this view (Table 2). Patients in the ‘natural sleep’ group showed a higher Pk 
association and Spearman correlation coefficient than those in the postoperative group. 
This suggests that assessing pharmacological sedation with the BIS monitor may be less 
reliable in infants less than 1 year old.  
Age-related differences in EEG patterns also are thought to affect the validity of BIS 
monitoring in children. The algorithm used in the BIS monitor is derived from adult EEG 
patterns, which differ from those of children and especially infants. The ‘normal awake’ 
EEG changes with brain maturation. With increasing age the frequency of the awake 
dominant background activity increases; at 6 months of age the dominant frequency is 
5  Hz, from 6 - 18 months 6 - 7 Hz, at 2 years 7 - 8 Hz, by 7 years it is 9 Hz and by 15 years 
of age reaches adult levels at 10 Hz. Under 5 year olds also have specific EEG patterns 
associated with the transition to, and from, sleep and drowsiness. Children aged 6 months 
to 4 years have short bursts of 4 - 8 Hz activity lasting 1 - 5 seconds. Also, longer periods 
of 1-Hz to 3-Hz activity may be seen in 3 months to 5 year old children, predominantly at 
12 months. Therefore the difference in EEG pattern is the most important limitation in the 
use of BIS monitor in infants.16,33,34  
The BIS monitor does not distinguish between various stages of natural sleep and 
pharmacologically induced sleep20,35. BIS values during REM sleep in adults and children 
have been found to range from 16 to 45. This range is equivalent to that used to define deep 
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sedation. In our study we found BIS values as low as 32 in infants without any medication. 
In contrast, in both study groups high BIS values were observed in infants supposedly 
‘deeply asleep’ according to the COMFORT score. The BIS is sensitive in reflecting changes 
in the EEG pattern that accompany the various stages of natural sleep. More specifically, 
BIS values decrease progressively as sleep becomes deeper. On the other hand, BIS 
values may surge to 88 on reawaking.35 The COMFORT behavior scale, however, does not 
differentiate between the different stages of REM sleep.
This study has several limitations. Firstly, it was hardly feasible to create two age groups 
for the postoperative group into, because we included only two patients aged 6 to 12 
months. Secondly, number of observations per patient widely ranged in the ‘natural sleep’ 
group. In addition, the observations gave us only snapshot views. Video recordings would 
be a means to get continuous data. 
A particular strength of this study is the clinical relevance. Because the results of this 
study give insight in the usefulness of the BIS monitor for assessing sedation in infants up 
to 12 months. 
Conclusion
The BIS monitor was not designed as a monitor for assessing the depth of sedation in 
children. BIS values obtained during pharmacological sleep (sedation or anaesthesia) 
with the standard algorithm should therefore be interpreted with caution in infants up to 
12 months of age. A new algorithm, derived from prospective raw EEG data of infants of 
this age during ‘natural sleep’ and wake, needs to be developed.
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Chapter 5
Withdrawal symptoms in children 
after long-term administration 
of sedatives and/or analgesics: a 
literature review. ‘Assessment remains 
troublesome’
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Abstract
Background: Prolonged administration of benzodiazepines and/or opioids to children in a pediatric 
intensive care unit (PICU) may induce physiological dependence and withdrawal symptoms. 
Objective: We reviewed the literature for relevant contributions on the nature of these withdrawal 
symptoms and on availability of valid scoring systems to assess the extent of symptoms. 
Methods: The databases PubMed, CINAHL, and Psychinfo (1980-June 2006) were searched using 
relevant key terms. 
Results: Symptoms of benzodi­azepi­ne and opi­oi­d wi­thdrawal can be classi­fied i­n two groups: central 
nervous system effects and autonomi­c dysfuncti­on. However, symptoms of the two types show a 
large overlap for benzodiazepine and opioid withdrawal. Symptoms of gastrointestinal dysfunction 
in the PICU population have been described for opioid withdrawal only. Six assessment tools for 
withdrawal symptoms are used in children. Four of these have been validated for neonates only. Two 
i­nstruments are avai­lable to speci­fically determi­ne wi­thdrawal symptoms i­n the PICU: the Sedati­on 
Withdrawal Score (SWS) and the Opioid Benzodiazepine Withdrawal Scale (OBWS). The OBWS is 
the only available assessment tool with prospective validation; however, the sensitivity is low. 
Conclusion: Wi­thdrawal symptoms for benzodi­azepi­nes and opi­oi­ds largely overlap. A suffici­ently 
sensitive instrument for assessing withdrawal symptoms in PICU patients needs to be developed.
Withdrawal symptoms in critically ill children, a review
67
Introduction
Ventilated, critically ill children commonly receive sedative and analgesic drugs to ease 
their mental burden, anxiety and pain, induced by frightening or painful interventions 
and environmental factors in the pediatric intensive care unit (PICU). Intravenous opioids 
(such as morphine and fentanyl) and benzodiazepines (such as midazolam) are the most 
commonly used drugs for this purpose.1,2 Tolerance and physiological dependence may 
develop during long-term administration of opioids and/or benzodiazepines and are 
risk factors contributing to withdrawal symptoms precipitated by too rapid tapering or 
cessation of these medications.3 Tolerance i­s defined as a decrease i­n a drug’s effect or the 
need to i­ncrease the dose to achi­eve the same effect.3,4 Physiological dependence is the 
requirement for continued administration of a sedative or analgesic to prevent signs of 
withdrawal.4 Psychological dependence is the need for a substance because of its euphoric 
effects and i­s encountered i­n the care and treatment of drug addi­cts.5 Discontinuation of 
medication in dependent patients leads to symptoms of withdrawal.5
Most of our knowledge on tolerance and withdrawal symptoms has been derived from research 
in newborns of drug-addicted mothers6,7 and from the literature on adult opium-addicted 
patients. Benzodiazepine withdrawal is also reported in adult psychiatric and drug-addicted 
populations.8-10 Two retrospective and one prospective randomized controlled trial have 
been reported on opioid and/or benzodiazepine withdrawal after long-term administration 
of analgesics or sedatives in the adult ICU setting.11-13 The reported incidence of withdrawal 
syndrome in adult ICU patients ranges from 32.1% (9/28) to 100%.11,12 Each of these studies used 
a di­fferent assessment tool, however, whi­ch makes i­t di­fficult to descri­be symptoms i­n a 
uniform manner. Symptoms in these patients are mostly agitation, irritability, anxiety, 
insomnia, tachycardia, hypertension, and sweating. High total doses and exposure to 
medication for longer than 7 days are risk factors for developing withdrawal symptoms 
in the adult ICU. This knowledge may serve to gain a better insight into problems of 
tolerance, dependence, and wi­thdrawal i­n pedi­atri­c i­ntensi­ve care, whi­ch are sti­ll i­nsuffici­ently 
recognized.14 Recogni­ti­on of wi­thdrawal i­n PICU pati­ents i­s di­fficult because the symptoms 
may strongly overlap clinical signs of inadequate sedation, such as agitation, anxiety, 
and movement disorder. An objective instrument to establish withdrawal symptoms of 
critically ill children in clinical practice is necessary to establish severity and course of the 
symptoms and to evaluate efficacy of wi­thdrawal treatment.
This review of the literature addresses two questions. First, what withdrawal symptoms 
resulting from long-term use of sedatives (opioids and/or benzodiazepines) in critically 
ill children in a PICU have been described and might be useful in an assessment tool? 
Second, are there any validated, reliable tools to assess withdrawal symptoms in children 
in a PICU in clinical practice?
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Methods
The databases PubMed, CINAHL, and Psychinfo were searched for relevant literature on (a) 
benzodiazepine and opioid withdrawal symptoms or (b) assessment tools for withdrawal 
symptoms. Time limits were set at January 1980 and May 2006. Only articles published 
in English or Dutch were included in the study. The following exploded MeSH terms were used: 
‘withdrawal symptoms’, ‘abstinence syndrome’, ‘tolerance’ with ‘opioid’, ‘benzodiazepine’, 
and with ‘PICU’, ‘critically ill children’, or with ‘assessment tool’, ‘scoring system’. The age limits 
were set at 0 and 16 years. Preterm neonates (< 37 weeks gestation) and neonates of addicted 
mothers were excluded because generally they are not admi­tted to a PICU. A first search 
for reviews retrieved seven relevant articles which were used to delineate the domain of 
withdrawal symptoms.3-5,15-17 Two of these reviews relate to patients in a neonatal ICU.7,15 They 
were nevertheless included because PICUs admit surgical neonates as well. Also, these two 
reviews did not focus on neonates of addicted mothers.
In total, abstracts of 53 articles were evaluated. Articles on withdrawal symptoms had 
to meet two criteria for inclusion in this review: describing a study of benzodiazepine and/or 
opioid withdrawal symptoms and relating to the age restriction. In total 20 articles, either case 
studies, retrospective or prospective studies, met these criteria.18-37 Table 1 lists the studies from 
which the withdrawal symptoms were derived, grouped by type of medication, study design, and 
methodological quality. Studies on assessment tools for identifying withdrawal symptoms 
had to meet the following criteria: (a) the tool should be aimed at identifying symptoms of 
benzodiazepine and/or opioid withdrawal; (b) the tool should be appropriate for children. Two 
articles met these criteria.17,29
Results
Withdrawal symptoms
Opioid withdrawal symptoms
Clinical signs of opioid withdrawal in newborns include those of the neurological 
system (high-pitched crying, irritability, increased wakefulness, hyperactive deep 
tendon reflexes, i­ncreased muscle tone, tremors, exaggerated Moro-reflex, sei­zures, 
intraventricular hemorrhage), those of the gastrointestinal tract (poor feeding, 
uncoordinated and/or constant sucking, vomiting, diarrhea, dehydration), autonomic signs 
(i­ncreased sweati­ng, nasal stuffiness, fever, mottli­ng), and others (poor wei­ght gai­n, 
increased rapid-eye movement sleep, skin excoriation).6,15 Symptoms of opioid withdrawal 
in newborns of drug addicted mothers are generally divided into three main groups: 
overstimulation of the central nervous system (CNS), gastrointestinal dysfunction, and 
autonomic dysregulation or sympathetic hyperactivity.4,15,38 Table 2 lists the described signs 
and symptoms of withdrawal in children relating to either opioids or benzodiazepines, 
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or combined use, broken down for these three groups. (a) Common manifestations 
of CNS overstimulation are: tremors, increased muscle tension, anxiety, restlessness, 
irritability, and insomnia.21,23-27,29,30,32,33 In addition, Lane et al.26 and French and Nocera30 
described the development of choreoathetoid movements as a withdrawal symptom of 
fentanyl admi­ni­strati­on i­n five chi­ldren and one chi­ld, respecti­vely, as well as i­ntermi­ttent 
muscle contractions and uncontrolled movements after long-term use of fentanyl. (b) The 
most frequent gastrointestinal symptoms of opioid withdrawal are vomiting and 
diarrhea.23-25,27,29,32 Carnevale and Ducharme32 in addition reported reduced oral intake. 
(c) Autonomic phenomena are: fever, perspiration, sneezing, yawning, increased heart rate, 
and blood pressure.23-25,29,30 Note that increases in heart rate and blood pressure should be seen 
in relation to the normal values for the child’s age and disease. In summary, the clinical signs 
of opioid withdrawal in children (Table 2) are largely congruent with those in newborn babies 
of drug-addicted mothers.
Benzodiazepine withdrawal symptoms
Classical characteristics of benzodiazepine withdrawal described for the domains of adult 
psychiatry and drug addicts care are: severe anxiety, involuntary muscle tremors, confusion, 
insomnia, perception disorders, depression, and generalized convulsions.4,9 In contrast to 
opi­oi­ds, a systemati­c classi­ficati­on of benzodi­azepi­ne wi­thdrawal symptoms i­s not avai­lable i­n the 
literature. For the sake of uniformity, however, the grouping for opioid withdrawal symptoms will 
be used here as well. Table 2 lists the observed withdrawal symptoms for benzodiazepines. 
Strikingly, most symptoms have been described on the basis of single case-reports and case 
series with small numbers of patients. Only two articles describe larger patient groups 
of 40 and 53 patients, respectively.28,31 Symptoms observed i­n these two studi­es were di­fferent, 
however, and the used observati­on forms i­ncluded no more than five and seven symptoms, 
respectively. These qualitative and quantitative limitations, notably in the case studies, provide 
only limited insight into the symptoms of benzodiazepine withdrawal. The benzodiazepines 
studies were all of a descriptive nature, in contrast to the opioids studies. (a) Regarding CNS 
overstimulation, Sury et al.22 i­n a case-report first descri­bed wi­thdrawal symptoms resulti­ng 
from long-term use of midazolam in children. Three children aged 4, 11, and 12 years received 
midazolam as a sedative for 7, 14 and 17 days, respectively. Within 24 h after discontinuation 
they showed signs of (visual) hallucinations, irritability, confusion, restlessness/agitated 
behavior and generalized convulsions. These are all manifestations of CNS overstimulation. 
Other studies report tremors, anxiety, agitation, restlessness, inconsolable crying, muscle 
twitching, and myoclonic movements of the extremities.18,19,21,28,29,31-33 (b) Regarding 
sympathetic hyperactivity, a case study of two children observed tachycardia and fever as 
benzodiazepine withdrawal reactions.19 Others observed perspiration, insomnia and severe 
coughing.29,31 (c) Regarding gastrointestinal dysfunction, one case study of a 14-day-old 
newborn reported vomiting caused by a distended stomach resulting from swallowing 
air.19 Thi­s si­ngle case report provi­des i­nsuffici­ent evi­dence to i­nclude thi­s symptom as
Ch
ap
te
r 
5
70
Ta
bl
e 
1 O
ve
rv
ie
w
 o
f s
tu
di
es
 o
f b
en
zo
di
az
ep
in
e 
an
d/
or
 o
pi
oi
d 
w
ith
dr
aw
al
 sy
m
pt
om
s
R
ef
er
en
ce
St
ud
y 
de
si
gn
Po
pu
la
ti
on
 
(a
ge
)
N
at
ur
e 
of
 s
tu
dy
M
ed
ic
at
io
n
W
it
hd
ra
w
al
 s
ym
pt
om
s 
Ty
pe
D
ur
at
io
n
(d
ay
s)
To
ta
l d
os
es
(m
g/
kg
)
A
ss
es
sm
en
t 
to
ol
O
bs
er
ve
d 
sy
m
pt
om
s
Su
ry
 e
t a
l.2
2  
C
as
e 
se
ri
es
3 
ch
ild
re
n 
(4
, 1
1, 
12
 y
rs
)
D
es
cr
ip
tiv
e
BZ
D
s
7,
 14
, 1
7
37
.3
, 5
8.
8,
 2
30
-
Ir
ri
ta
bi
lit
y,
 h
al
lu
ci
na
ti
on
s,
 c
on
fu
si
on
, 
re
st
le
ss
ne
ss
, c
on
vu
ls
io
ns
Va
n 
En
ge
le
n 
et
 a
l.1
9
C
as
e 
se
ri
es
2 
ch
ild
re
n 
(1
4 d
ay
s,
 15
m
o)
D
es
cr
ip
tiv
e
BZ
D
s
12
, 2
9 
0.
14
, 0
.5
7 
pe
r h
 
(m
ea
n 
do
se
s)
-
Re
st
le
ss
ne
ss
, t
ac
hy
ca
rd
ia
, f
ev
er
, v
om
it
in
g 
(a
s 
re
su
lt 
of
 s
w
al
lo
w
in
g 
ai
r)
H
ug
he
s 
et
 a
l.2
8
Pr
os
pe
ct
iv
e 
53
 c
hi
ld
re
n 
(0
 - 1
1 y
rs
)
In
ci
de
nc
e,
 
D
es
cr
ip
tiv
e
BZ
D
s
4.
9 
(1
.2
 - 1
7.
9)
a 
In
f      
3.
5 
(1
 - 1
4.
8)
a 
 C
hi
ld
14
.6
 (1
.8
 - 4
6.
2)
a 
In
f     
 
9.
6 
(0
.9
 - 3
9.
0)
 a
 C
hi
ld
-
H
al
lu
ci
na
ti
on
s 
(v
is
ua
l a
nd
 a
ud
io
), 
di
so
ri
en
ta
ti
on
, n
ot
 re
co
gn
iz
in
g 
pa
re
nt
s,
 
ab
no
rm
al
 m
ov
em
en
ts
 (p
up
pe
t-
lik
e 
m
ov
em
en
ts
), 
in
ap
pr
op
ri
at
e 
la
ug
ht
er
Fo
ns
m
ar
k 
et
 a
l.3
1
Re
tr
os
pe
ct
iv
e
40
 c
hi
ld
re
n 
(6
 m
o 
- 1
4 
yr
s)
In
ci
de
nc
e,
 
de
sc
ri
pt
iv
e
BZ
D
s
4 
(1
 - 1
3)
a 
W
   
   
   
3 
(1
 - 1
1)
a 
N
W
30
.9
 (0
.0
1 -
 9
9.
2)
a 
W
     
4.
6 
(0
.3
 - 3
3.
3)
a 
N
W
O
C
A
gi
ta
ti
on
, a
nx
ie
ty
, m
us
cl
e 
tw
itc
hi
ng
, 
sw
ea
ti
ng
, t
re
m
or
Be
rg
m
an
 
et
 a
l.3
3  
C
as
e 
se
ri
es
3 
ch
ild
re
n 
(3
, 5
, 1
5 
m
o)
D
es
cr
ip
tiv
e
O
P/
BZ
D
s
1 -
 38
29
.8
 (1
.4
 - 2
86
)a 
M
id
a      
0.
18
 (0
 - 2
.9
)a 
Fe
nt
-
Ir
ri
ta
bi
lit
y,
 h
ig
h-
pi
tc
he
d 
cr
yi
ng
, a
bn
or
m
al
 
m
ov
em
en
ts
, c
ho
re
oa
th
et
ot
ic
 m
ov
em
en
ts
To
bi
as
21
 
C
as
e 
se
ri
es
3 
ch
ild
re
n 
(15
, 2
7 m
o,
 11
 y
rs
)D
es
cr
ip
tiv
e
O
P/
BZ
D
s
4 
- 2
8
N
D
-
C
ho
re
oa
th
et
oi
d 
m
ov
em
en
ts
, r
es
tle
ss
ne
ss
, 
ir
ri
ta
bi
lit
y,
 tr
em
or
s 
Ya
st
er
 
et
 a
l.1
8
C
as
e 
se
ri
es
2 
ch
ild
re
n 
(4
 m
o,
 8
 y
rs
)
D
es
cr
ip
tiv
e
O
P/
BZ
D
s
> 
5
N
D
-
A
gi
ta
ti
on
, r
es
tle
ss
ne
ss
C
ar
ne
va
le
 
et
 a
l.3
2
C
as
e 
se
ri
es
 
3 
ch
ild
re
n 
(1
5,
 2
7 
m
o,
 11
 yr
s)
D
es
cr
ip
tiv
e
O
P/
BZ
D
s
4 
- 5
7
N
D
O
C
Tr
em
or
s,
 tw
itc
hi
ng
, j
itt
er
in
es
s,
 in
co
ns
ol
ab
le
 
cr
yi
ng
, i
rr
it
ab
ili
ty
, a
gi
ta
ti
on
, g
ri
m
ac
in
g 
vo
m
it
in
g,
 p
oo
r f
ee
di
ng
To
bi
as
20
Re
tr
os
pe
ct
iv
e
9 
ch
ild
re
n 
(4
.4
 ±
 1.
8y
rs
)b
Ef
fic
ac
y o
f s
w
itc
hi
ng
 
to
 su
bc
ut
an
eo
us
 
fe
nt
an
yl
O
P/
BZ
D
s
16
 - 2
4
N
D
N
A
S
-
Fr
an
ck
 
et
 a
l.2
9
Pr
os
pe
ct
iv
e
15
 c
hi
ld
re
n 
(1
.5
 - 2
8 
m
o)
D
es
cr
ip
tiv
e,
 
va
lid
at
io
n 
in
st
ru
m
en
t
O
P/
BZ
D
s
9 
(4
 - 1
8)
a
7.
4 
(2
.5
 - 1
9.
2)
a 
O
P   
   
26
.4
 (0
 - 1
54
)a 
M
id
a
O
BW
S
C
ry
in
g/
ag
it
at
io
n,
 s
le
ep
le
ss
ne
ss
, h
yp
er
ac
tiv
e 
M
or
o 
R
efl
ex
, t
re
m
or
s,
 p
up
i­l 
di­
la
ti­
on
, 
m
ov
em
en
t d
is
or
de
r, 
ha
llu
ci
na
ti
on
s,
 fe
ve
r, 
ta
ch
yp
ne
a,
 fr
eq
ue
nt
 s
uc
ti
on
 re
qu
ir
ed
, 
sw
ea
ti­
n
g,
 y
aw
n
i­n
g 
sn
ee
zi­
n
g,
 n
as
al
 s
tu
ffi
n
es
s,
 
vo
m
it
in
g,
 d
ia
rr
he
a
D
uc
ha
rm
e 
et
 a
l.3
4
Pr
os
pe
ct
iv
e,
 
ca
se
 s
tu
dy
27
 c
hi
ld
re
n 
(0
 - 1
9 
yr
s)
E
xa
m
i­n
e 
eff
ec
ts
 
of
 O
/B
 w
ea
ni
ng
 
ra
te
s
O
P/
BZ
D
s
1-
 >
21
N
D
-
Tr
em
or
s/
tw
itc
hi
ng
/j
itt
er
in
es
s,
 In
co
ns
ol
ab
le
 
cr
yi
ng
, g
ri
m
ac
in
g,
 a
gi
ta
ti
on
/i
rr
it
ab
ili
ty
/
fu
ss
in
es
s,
 g
ag
gi
ng
/v
om
it
in
g,
 p
oo
r f
ee
di
ng
, 
di­
ffi
cu
lt
y 
sl
ee
pi­
n
g 
c
Withdrawal symptoms in critically ill children, a review
71
Ta
bl
e 
1 C
on
tin
ue
d
R
ef
er
en
ce
St
ud
y 
de
si
gn
Po
pu
la
ti
on
 
(a
ge
)
N
at
ur
e 
of
 s
tu
dy
M
ed
ic
at
io
n
W
it
hd
ra
w
al
 s
ym
pt
om
s 
Ty
pe
D
ur
at
io
n
(d
ay
s)
To
ta
l d
os
es
(m
g/
kg
)
A
ss
es
sm
en
t 
to
ol
O
bs
er
ve
d 
sy
m
pt
om
s
A
rn
ol
d 
et
 a
l.3
5
Re
tr
os
pe
ct
iv
e 
37
 n
eo
na
te
s
In
ci
de
nc
e 
of
 N
A
S,
 
i­d
en
ti­
fi
ed
 r
i­s
k 
fa
ct
or
s
O
P
N
D
3.
4 
± 
2.
5b
 F
en
t  
    
   
1.8
 ±
 1.
5b
 F
en
t
N
A
S
La
ne
 e
t a
l.2
6
Re
tr
os
pe
ct
iv
e
13
 c
hi
ld
re
n 
(5
.3
5 ±
 5.
1y
rs
)b
D
es
cr
ip
tiv
e
O
P
7.
8 
± 
4.
9b
0.
6 
± 
0.
5b
 F
en
t 
-
Tr
em
or
s,
 a
ta
xi
a,
 c
ho
re
ao
th
et
os
is
 (m
ov
em
en
t 
di
so
rd
er
), 
m
yo
cl
on
us
, i
rr
it
ab
ili
ty
, i
ns
om
ni
a 
Fr
en
ch
 e
t 
al
.30
Pr
os
pe
ct
iv
e 
12
 c
hi
ld
re
n 
(0
 - 2
5 
m
o)
D
es
cr
ip
tiv
e,
 
in
ci
de
nc
e
O
P
6.
7 
± 
5.
0b
0.
56
 ±
 0
.5
2b
 F
en
t 
N
A
S
A
gi
ta
ti
on
, i
rr
it
ab
ili
ty
, t
re
m
or
s,
 in
cr
ea
se
d 
m
us
cl
e 
to
ne
, c
ho
re
oa
th
et
oi
d 
m
ov
em
en
ts
, 
in
so
m
ni
a,
 in
cr
ea
se
d 
re
sp
ir
at
or
y 
ra
te
 a
nd
 
eff
or
t
K
at
z 
et
 a
l.2
7  
Pr
os
pe
ct
iv
e 
23
 c
hi
ld
re
n 
(0
 -2
2 
m
o)
D
es
cr
ip
tiv
e,
 
in
ci
de
nc
e
O
P
13
.1 
± 
11.
3b
 W
   
   
3.
8 
± 
1.5
b 
N
W
2.
96
 ±
 4
.1b
 W
, F
en
t  
   
0.
53
 ±
 0
.3
7b
 N
W
, F
en
t 
N
A
S
Ir
ri
ta
bi
lit
y,
 tr
em
or
s,
 d
ec
re
as
ed
 s
le
ep
in
g,
 
di
ar
rh
ea
, v
om
it
in
g 
Fr
an
ck
 
et
 a
l.3
7
Pr
os
pe
ct
iv
e/
    
 
re
tr
os
pe
ct
iv
e
34
 n
eo
na
te
s
D
es
cr
ip
tiv
e,
 
pr
ev
al
en
ce
 
w
it
hd
ra
w
al
 a
ft
er
 
EC
M
O
O
P
20
.7
 ±
 12
.0
b 
Fe
nt
 
13
.5
 ±
 8
.0
b 
M
or
p
1.3
 ±
 0
.9
b 
Fe
nt
   
   
   
 
3.
0 
± 
1.8
b 
M
or
p
N
A
S
Ro
be
rt
so
n 
et
 a
l.2
4
Pr
os
pe
ct
iv
e 
10
 c
hi
ld
re
n 
(6
 m
o 
- 1
8 
yr
s)
D
es
cr
ip
tiv
e,
 
ev
al
ua
ti
on
 o
pi
oi
d 
 
w
ea
ni
ng
 p
ro
to
co
lO
P
15
 (7
 - 5
3)
a
N
D
-
Tr
em
or
s,
 ir
ri
ta
bi
lit
y,
 d
ia
rr
he
a,
 s
w
ea
ti
ng
 
Lu
go
 e
t a
l.2
5  
Re
tr
os
pe
ct
iv
e 
22
 c
hi
ld
re
n 
(6
.1 
± 
5.
4y
rs
)b
D
es
cr
ip
tiv
e 
ev
al
ua
tio
n 
w
ith
-
dr
aw
al
 p
ro
to
co
l
O
P
17
.8
 ±
 8
.4
b
1.3
 (0
.3
5 -
 7.
54
)a 
Fe
nt
     N
A
S
A
gi
ta
ti
on
/i
rr
it
ab
ili
ty
, c
ry
in
g/
in
co
ns
ol
ab
ili
ty
, 
tr
em
or
s,
 ta
ch
yp
ne
a,
 d
is
or
ie
nt
at
io
n,
 
hy
pe
rt
en
si
on
, s
w
ea
ti
ng
, d
ia
rr
he
a
Si
dd
ap
pa
 
et
 a
l.2
3
Re
tr
os
pe
ct
iv
e
30
 c
hi
ld
re
n 
(0
 - 1
6 
yr
s)
D
es
cr
ip
tiv
e 
ev
al
ua
tio
n 
w
ith
-
dr
aw
al
 p
ro
to
co
l
O
P
12
.5
 (7
 - 2
6)
a 
W
 
10
 (7
 - 4
1)
a 
N
W
   
   
    
4.
2 
(1
 - 1
0.
5)
a 
W
, F
en
t 
1.3
 (0
.5
 - 5
.9
)a 
N
W
, F
en
t         O
C
Sl
ee
p 
di
st
ur
ba
nc
e,
 a
gi
ta
ti
on
, t
re
m
or
s,
 
se
iz
ur
es
, c
ho
re
oa
th
et
oi
d 
m
ov
em
en
ts
, 
vo
m
it
in
g,
 d
ia
rr
he
a,
 h
yp
er
te
ns
io
n,
 
ta
ch
yc
ar
di
a,
 ta
ch
yp
ne
a,
 fe
ve
r, 
sw
ea
ti
ng
, 
ya
w
ni
ng
, m
ot
tli
ng
 c
Be
re
ns
 
et
 a
l.3
6
Pr
os
pe
ct
iv
e
37
 c
hi
ld
re
n 
(9
.8
 ±
 26
.2
m
o)
b
D
es
cr
ip
tiv
e  
ev
al
ua
tio
n 
w
ea
ni
ng
 
w
ith
dr
aw
al
 p
ro
to
co
lO
P
15
.5
 ±
 10
.7
b
2.
2 
± 
1.7
b 
Fe
nt
N
A
S
Ty
pe
 o
f m
ed
ic
at
io
n 
BZ
D
s b
en
zo
di
az
ep
in
es
, O
P 
op
io
id
s, 
D
ur
at
io
n 
nu
m
be
r o
f d
ay
s a
dm
in
is
tr
at
in
g 
of
 se
da
tiv
es
/a
na
lg
es
ic
s, 
a  m
ed
ia
n 
(r
an
ge
), 
b  m
ea
n 
± 
SD
 (s
ta
nd
ar
d 
de
vi
at
io
n)
, 
c o
nl
y a
ss
es
si
ng
 it
em
s, 
N
D
 n
o 
da
ta
, W
 W
ith
dr
aw
al
, N
W
 N
o 
w
ith
dr
aw
al
, m
o 
m
on
th
s, 
yr
s y
ea
rs
, F
en
t F
en
ta
ny
l, 
M
or
p 
M
or
ph
in
e,
 M
id
a 
M
id
az
ol
am
, I
nf
 In
fa
nt
s, 
Ch
ild
 C
hi
ld
re
n,
 
N
A
S 
N
eo
na
ta
l A
bs
tin
en
ce
 S
co
re
, O
C 
O
w
n 
ch
ec
kl
is
t 
Ch
ap
te
r 
5
72
a benzodiazepine withdrawal symptom. Dysfunction of the gastrointestinal tract as a 
symptom of benzodiazepine withdrawal has not been described in adults.9,12 In summary, the 
major symptoms of benzodiazepine withdrawal in children are anxiety, tremors, and other 
involuntary muscle movements, irritability, perspiration and insomnia. These correspond to 
the classical manifestations of benzodiazepine withdrawal in adults.4,9
Table 2 Described signs and symptoms of benzodiazepine and opioid withdrawal in children
Combined benzodiazepine-opioid withdrawal symptoms
Di­fferences between opi­oi­d and benzodi­azepi­ne wi­thdrawal symptoms are margi­nal.4 
Symptoms associated with CNS overstimulation and sympathetic hyperactivity largely 
overlap after long-term use of benzodiazepines or opioids in children (see Table 2). However, 
benzodiazepine withdrawal is not associated with symptoms of the gastrointestinal tract.4,12 
The Moro-reflex i­s used as an opi­oi­d wi­thdrawal symptom i­n neonates.6,15 The Moro-reflex 
disappears between the ages of 1 and 3 months and is therefore never observed in children 
older than 3 months. The study by Franck et al.29 included 1.5- to 28 month-old children, 
and the Moro-reflex was one of the i­tems i­n thei­r assessment tool. In vi­ew of the age 
limitation we feel it is not feasible to use this symptom as a withdrawal symptom for PICU 
patients.3 Several studies found it hard to determine whether the withdrawal symptoms 
were speci­fically caused by benzodi­azepi­nes dependence because i­n these studi­es opi­oi­ds 
(morphine, fentanyl) were administered for sedation as well.18,21,28,29,33 This illustrates the 
Central Nervous System 
irritability
Gastrointestinal 
dysfunction
Autonomic dysfunction
Opioids Increased muscle tone Vomiting Tachypnea
Myoclonus Poor feeding Yawning 
Ataxia Diarrhea Sneezing 
Abnormal movements Hypertension 
Pupil dilation (> 4 mm) Mottling
High pitched crying
Benzodiazepines Muscle twitching Frequent suction required
Inconsolable crying
Grimacing
Jitteriness
Visual, auditory 
hallucinations
Disorientation
Seizures
Movement disorder
Opioids &  
Benzodiazepines
Tremor Fever 
Anxiety Sweating
Agitation/Crying Tachycardia
Irritability
Insomnia/sleep disturbance 
Choreoathetoid movements 
(of upper extremities) 
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practi­cal li­mi­tati­on for descri­bi­ng speci­fic benzodi­azepi­ne-related wi­thdrawal symptoms 
in the PICU. From clinical experience we know that benzodiazepines and opioids are 
usually administered in combination for sedation and analgesia, from several days to 
weeks as reflected i­n the li­terature.1,38 Given the overlap in symptoms, it is hard to ascribe 
withdrawal symptoms to either opioids or benzodiazepines.21,29,32 
Incidences and influencing factors of benzodiazepine and opioid withdrawal
Knowledge on the incidences of benzodiazepine and opioid withdrawal symptoms in general 
as well as the frequencies of the separate phenomena provide clues for the symptoms 
to be used in an assessment tool. Furthermore, knowledge of possible risk factors for the 
development of withdrawal symptoms enables physicians and nurses to identify patients at 
ri­sk. Only five arti­cles descri­be i­nci­dences and i­nfluenci­ng factors for the development of 
withdrawal symptoms after long-term use of benzodiazepines or opioids in children.27,28,31,35,37
Incidence
Fonsmark et al.31 in a retrospective study found that 14 of 40 (35%) of sedated children 
(6 months-14 years) developed withdrawal symptoms. A prospective study of abrupt 
discontinuation of midazolam in critically ill children (0 - 11 years) reports adverse side 
effects i­n 17% of the 53 pati­ents.28 Opioid withdrawal symptoms were seen in 13/23 (57%) 
children aged 0 - 22 months after prolonged continuous fentanyl administration.27 Methods 
differed between these three studies. Katz et al.27 used the Neonatal Abstinence Score 
(NAS) developed by Finnegan et al.6 which has only been validated for use in newborns. 
Hughes et al.28 and Fonsmark et al.31 did not use existing tools but recorded withdrawal 
symptoms through self-developed observation lists. These lists included a limited number 
(five) of behavi­oral i­tems.28,31 Fonsmark et al.31 included ‘sweating’ as a physiological item. 
The authors did not provide data on reliability and validity of their observation lists.28,31 
Patients who required extracorporeal membrane oxygenation (ECMO) therapy comprised 
a speci­fic PICU populati­on. In these populati­ons opi­oi­d wi­thdrawal (NAS > 8) was seen in 
9 - 57% of children.35,37
Influencing factors
Various authors have shown that dosing and duration of benzodiazepines or opioids 
i­nfluence development of wi­thdrawal symptoms.27,30,31 Fonsmark et al.31 found a total 
midazolam dose higher than 60 mg/kg to be associated with the occurrence of withdrawal 
symptoms. Katz et al.27 found a total fentanyl dose of 2.5 mg/kg or higher or a fentanyl 
infusion for at least 9 days to result in withdrawal symptoms in 100% of cases. Arnold et al.35 
found that neonates receiving ECMO therapy with total doses greater than 1.6 mg/kg 
fentanyl or an ECMO durati­on of longer than 5 days had a si­gni­ficantly greater i­nci­dence of 
wi­thdrawal symptoms reflected by the NAS. In another study i­n ECMO pati­ents the authors 
demonstrated that neonates who received total fentanyl doses higher than 1.2 mg/kg were 
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13 times more likely to experience opioid withdrawal after ECMO.37 Evaluation of the various 
studies reveals that children in a PICU receiving benzodiazepines and/or opioids for 
5 days or longer are at risk for developing withdrawal symptoms.17,23-25,27-31 Benzodiazepine 
and/or opioid withdrawal symptoms may occur if these medications are abruptly stopped 
or tapered off too rapi­dly i­n chi­ldren showi­ng physi­cal dependence.38 Manifestations 
typically occur 8 - 48 hr after discontinuation.
Systematic clinical assessment of withdrawal symptoms 
The task of assessing seriously ill children for signs of tolerance, dependence, or withdrawal 
notably falls to the pediatric critical care nurse.4 This requires particularly awareness, 
knowledge of and insight into these phenomena. For clinical purposes a validated and reliable 
assessment tool would be very helpful. Table 3 provides details of six assessment tools for 
withdrawal symptoms in children that are used in practice and in research. Four of these 
were developed and validated for application in neonates after long-term use of opioids or in 
newborn babies of drug-addicted mothers.6,39-41 The most widely used is the NAS.6 These four 
instruments have not been validated for use in older children. However, in the absence of a 
validated and reliable instrument for children, several authors have opted for the NAS.24,25,27,30 
Other authors designed observation checklists themselves, including 5 - 13 symptoms.25,28,31 These 
observation checklists have not been properly validated for use in children.25,31 Two recent 
articles describe assessment tools for observing withdrawal symptoms after long-term use 
of opioids and/or benzodiazepines in children in a PICU: the Sedation Withdrawal Score 
(SWS)17 and the Opioid Benzodiazepine Withdrawal Scale (OBWS).29
Sedation Withdrawal Score
The SWS includes 12 symptoms of withdrawal (see Table 3) and was developed in 2004 
by Cunli­ffe et al.17 Each symptom is scored on a three-point scale, ranging from absent 
(0), mild (1), to severe (2). Thus a maximum score of 24 is possible. The authors provide 
i­nstructi­ons for the regi­men for decreasi­ng sedati­ves based on cutoff poi­nts. However, a 
justi­ficati­on for these cutoff poi­nts i­s not gi­ven. The authors consi­der the SWS to be cli­ni­cally 
sensitive in detecting abstinence in a child of any age with signs of withdrawal from sedatives 
and/or opioids.17 However, data on sensi­ti­vi­ty, speci­fici­ty, vali­di­ty, and reli­abi­li­ty are lacki­ng.
Opioid Benzodiazepine Withdrawal Scale
The OBWS is a 21-item checklist with 16 withdrawal items for determining frequency and 
severity of withdrawal symptoms in children (see Table 3).29 Franck et al.29 tested the 
predictive validity of the OBWS by performing 693 assessments in 15 children aged 
6 weeks-28 months. Sensi­ti­vi­ty of the OBWS at scores 8 (cutoff) or hi­gher was 50%, whi­ch 
i­mpli­es that the scale i­s not better than chance predi­cti­on. Speci­fici­ty was 87%, whi­ch 
i­mpli­es that the scale ri­ghtly classi­fies 87% of the chi­ldren wi­thout wi­thdrawal symptoms. 
The predictive value expressed in terms of positive and negative likelihood ratio, 4.0 and 0.57, 
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respectively, is moderate for a diagnostic instrument. The interrater reliability was higher 
than 0.8; the agreement procedure, however, was not published. Neither age range nor 
diagnoses of the patients in this study are representative for a general PICU. Finally, including 
the Moro-reflex i­s questi­onable i­n vi­ew of the i­nherent age restri­cti­on, and reduces the 
scale’s content validity. In summary, although both instruments include relevant withdrawal 
symptoms associated with benzodiazepine and/or opioid withdrawal in children, we feel that 
psychometri­c i­ssues of the measurements have been gi­ven i­nsuffici­ent attenti­on.
Discussion and conclusion
Nurses and physicians could give more priority to the observation and treatment of 
withdrawal symptoms in children in a PICU. This literature study describes observable 
withdrawal symptoms related to benzodiazepines and opioids use in children in a PICU. 
It appears that vomiting cannot be included as a symptom of benzodiazepine withdrawal 
in this population.4 The same i­s true for the hyperacti­ve Moro-reflex as a symptom of 
opioid withdrawal, given the age limitation.27 Furthermore, withdrawal symptoms for 
benzodiazepines and opioids had a large overlap for symptoms such as agitation, anx-
iety, tremors, insomnia, fever, sweating, and tachycardia. Symptoms such as seizure and 
hallucinations have been described only as benzodiazepine withdrawal in PICU patients.
As clinical practice tends to combine medication from both groups, symptoms 
cannot easily be ascribed to either group. Several authors studied only either benzodiazepine 
or opioid withdrawal symptoms in patients who received both medications.25,27,28,31 Then it 
was not possi­ble to determi­ne whether the wi­thdrawal symptoms were speci­fically caused by 
benzodiazepine or opioids because in these studies additional benzodiazepine or opioids 
were administered for sedation as well. For treatment and management purposes we should 
preferably distinguish between withdrawal symptoms caused by weaning of benzodiazepines 
or opioids. Therefore assessment tools should be sensitive enough to discriminate between 
benzodiazepine and opioid related withdrawal symptoms.3,24,42 Generali­zati­on of the i­denti­fied 
withdrawal symptoms is hampered by the fact that most are based on case series and case 
reports and consequently on small numbers of patients. Furthermore, most studies considered 
only few withdrawal symptoms. Thus representative incidence numbers based on the full 
spectrum of withdrawal symptoms are lacking.
In this review high total doses, duration of opioid, and/or benzodiazepine infusion and 
ECMO therapy are described as risk factors in developing withdrawal symptoms in PICU 
patients. These factors are also described in adult studies.11,12 The diagnosis of withdrawal 
in patients must be made carefully. Withdrawal symptoms vary from patient to patient in 
number, severity and presentation. However many PICU patients show relatively subtle 
clinical symptoms that can easily be confused with responses to other factors in the PICU. 
Symptoms such as agitation, anxiety, insomnia, irritability, fever, tachycardia, hypertension, 
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and sweating are also an expression of inadequate sedation or pain management, ventilator 
distress, infection, noisy environment, paradoxical reactions, or delirium.43-47 These key 
confounders may mask withdrawal symptoms. With Tobias3, we maintain that the diagnosis of 
withdrawal symptoms remains one of exclusion. For example, fever or vomiting should never 
be attributed to withdrawal until other possible causes are excluded. Key confounders 
must be excluded as well. We feel that the occurrence of withdrawal symptoms must be 
time-related to a decrease or cessation of benzodiazepines and/or opioids.
Strategi­es to reduce the i­nci­dence of wi­thdrawal symptoms begi­n by maki­ng efforts 
to reduce the total doses of benzodiazepines and/or opioids administered. Based on a 
few prospective studies several authors recommend a daily tapering rate of 10 - 20% for 
children who receive benzodiazepines and/or opioids for more than 5 - 7 days.23-25,29 
This strategy did not result, however, in the absence of withdrawal symptoms. Adult 
sedative and analgesic guidelines recommend that daily dose decrements of opioids 
should not exceed 5 - 10% in high-risk patients.48 Playfor et al.49 support use of this 
practi­ce i­n the PICU i­n spi­te of the fact that there i­s li­ttle evi­dence for i­ts efficacy. 
Several studies evaluating withdrawal symptoms, incidence and risk factors in the 
PICU used an assessment tool (NAS) not validated for use in children in a PICU. The 
results of these studies therefore may not be reliable, and symptoms may have been 
overlooked. Most of these scoring systems (four of six, see Table 3) were developed to 
assess the severity of withdrawal in infants and drugs-addicted mothers. They have 
some limitations, however. First, they were developed to assess neonatal behavior and 
opioid withdrawal.3,49 Certai­n reflexes such as the Moro can only be judged i­n chi­ldren 
below 3 months, and this implies that they cannot be used in the total PICU age group. 
Second, cutoff poi­nts for other pati­ents than newborns of addi­cted mothers are not 
defined. For these reasons the NAS i­s less useful i­n PICU pati­ents because most recei­ve 
both opioids and benzodiazepines.
The available literature demonstrates that a good assessment tool for clinical use 
in children is lacking.49 A good assessment tool can be defined as a tool, whi­ch i­s vali­d 
reli­able, and cli­ni­cally useful. Thi­s means that a cutoff poi­nt i­s establi­shed, and that 
the tool shows sensitivity to change.50,51 Furthermore Franck et al.29 stated that clinical 
utility may be improved with fewer items and longer intervals between assessments. 
The OBWS displays moderate validity and includes an item that is not representative 
for the target populati­on. We agree wi­th Cunli­ffe et al.17 that the SWS includes clinically 
relevant items for the observation of withdrawal symptoms in children on the basis of 
the described withdrawal symptoms in our literature study. However, it lacks a good 
methodological foundation. The OBWS is the only available assessment tool with 
prospective validation; however, its sensitivity is low. In general, assessment tools 
must preferably be tested in a multicenter study with a larger patient population and an 
extensive patient mix. The criterion validity can be tested using an independent expert’s 
opinion because there is no gold standard for opioid and benzodiazepine withdrawal 
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i­n chi­ldren. Further assessments should be carri­ed out before and after taperi­ng off of 
opioids or benzodiazepines. At least key confounders that mask withdrawal must be 
excluded. In conclusion, the OBWS can be feasible for assessing benzodiazepine and/or 
opioid withdrawal symptoms in children in a PICU when additional validation has been 
completed.
Thi­s revi­ew clearly provi­des di­recti­ons for further research. Fi­rst, quanti­ficati­on of 
withdrawal symptoms in children based on the symptoms and signs listed in this review 
i­s needed to clearly define the spectrum of wi­thdrawal i­n PICU pati­ents. Second, an 
adapted wi­thdrawal assessment tool based on thi­s quanti­ficati­on needs to be developed 
and psychometric issues must be tested before application in the PICU population.
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Chapter 6
Withdrawal symptoms in critically 
ill children after long-term 
administration of sedatives and/or 
analgesics, a first evaluation
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Abstract
Objectives: To establish frequencies of benzodiazepines and opioids withdrawal symptoms as well as 
correlations with total doses and duration of administration. 
Design: A prospective, repeated measures design. 
Setting: Two pediatric intensive care units in a university children’s hospital. 
Patients: Seventy-nine children, aged 0 days to 16 years, who received intravenous midazolam and/or 
opioids for more than 5 days. 
Interventions: None.
Measurements and Main Results: PICU nurses assessed withdrawal symptoms using the Sophia 
Benzodiazepine & Opioid Withdrawal Checklist (SBOWC), which includes all withdrawal symptoms 
(n = 24) described  in the pediatric literature. Over six months, 2188 observations in 79 children 
were recorded. Forty-two percent of observations were performed within 24h after tapering off or 
discontinuation of medication. Symptoms representing overstimulation of the central nervous system, 
such as anxiety, agitation, grimacing, sleep disturbance, increased muscle tension and movement 
disorder, were observed in more than 10% of observations. Of symptoms reflecting gastrointestinal 
dysfunction, diarrhea and gastric retention were most frequently observed. Tachypnea, fever, 
sweating and hypertension as manifestations of autonomic dysfunction were observed in more than 
13% of observations. The Spearman rank correlation coefficient between total doses of midazolam 
and maximum sum score (of the SBOWC) was 0.51 (p < 0.001). The correlation between total doses of 
opioids and the maximum sum score was 0.39 (p < 0.01). A significant correlation (0.52; p < 0.001) was 
also found between duration of use and maximum sum score. 
Conclusions: This is the first study to report frequencies of all 24 withdrawal symptoms observed 
in children after decrease or discontinuation of benzodiazepines and/or opioids. Agitation, anxiety, 
muscle tension, sleeping less than 1 hour, diarrhea, fever, sweating and tachypnea were observed most 
frequently. Longer duration of use and high dosing are risk factors for development of withdrawal 
symptoms in children. 
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Introduction 
Ventilated, critically ill children commonly receive sedatives and analgesic drugs to 
ease their anxiety, pain and mental burden induced by the pediatric intensive care unit 
(PICU) setting. Usually these medications are intravenous opioids and benzodiazepines.1,2 
Long-term exposure to these drugs, however, carries the risk of physical dependence. 
Abrupt discontinuation or too rapid tapering down of sedatives and analgesics in physically 
dependent children may result in withdrawal syndrome.3 High total cumulative doses, 
long-term infusion (> 5 - 7 days) and too rapid tapering off or abrupt discontinuation of 
sedatives and/or analgesics have been found to increase the risk of withdrawal syndrome 
in children in a PICU.4-7 
Symptoms observed in withdrawal syndrome in children include: (1) central nervous 
system irritability (e.g. agitation, anxiety, tremors, increased muscle tension, sleep 
disturbance, abnormal movements); (2) gastrointestinal dysfunction (vomiting, diarrhea 
and poor feeding); and (3) autonomic dysfunction (e.g. sweating, fever, tachycardia, 
hypertension and tachypnea).4-18
The reported incidences of benzodiazepine withdrawal syndrome in critically ill 
children range from 17 to 35%.5,6 So far, only Katz and colleagues have documented opioid 
withdrawal in critically ill children; it was found in 13 of 23 PICU patients (57%) receiving 
fentanyl.7
Diagnosing withdrawal syndrome in PICU patients is a complex matter, because 
some symptoms may strongly overlap with clinical signs of inadequate pain or 
sedation  management, ventilator distress, delirium and stress induced by the noisy 
environment.19-23 Furthermore, symptoms of benzodiazepine withdrawal largely overlap 
with those of opioid withdrawal. Yet we should be able to distinguish between opioid and 
benzodiazepine related withdrawal as well as confounders, as each requires a different 
treatment approach. Therefore, a clinically validated and sensitive assessment tool is 
needed to determine the presence and nature of different withdrawal symptoms and their 
relative frequencies. Such a tool is still lacking,24,25 leaving aside the Neonatal Abstinence 
Score (NAS) developed for infants of drug-dependent mothers26 which has been used in 
several studies in critically ill children.7,11,13,27,28
Documenting the prevalences of relevant withdrawal symptoms is an essential first 
step in the development of an assessment tool. To our knowledge, prevalences of the 
whole spectrum of withdrawal symptoms have not yet been prospectively studied in 
PICU patients. We therefore conducted a study evaluating all withdrawal symptoms in 
critically ill children described in the literature and recently reviewed by us.24 A second 
aim was to establish possible correlations between withdrawal symptoms and total doses 
of benzodiazepines or opioids and duration of use.
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Materials and Methods
Design
A prospective, repeated-measures design was used to estimate occurrences of withdrawal 
symptoms using a self-designed observation form that included withdrawal symptoms 
described in the literature. 
Patients 
Children aged ≤ 16 years admitted to the pediatric and pediatric surgical intensive care 
units of our level three children’s hospital between September 2005 and February 2006 
were eligible for this study if they received midazolam (a benzodiazepine), morphine or 
fentanyl (opioids) by continuous infusion for at least 5 days. These units serve as a referral 
centre for all critical care patients (medical and surgical, 0 -  16 years) except postoperative 
open heart surgery. Exclusion criteria were: status epileptic treated with midazolam, use 
of neuromuscular blocking agents (NMBA), and severely disturbed behavior pattern on 
account of underlying neurological disease.
The Erasmus MC institutional review board reviewed and approved this study. 
Because of the strictly observational and noninvasive nature of this study, the need for 
informed consent was waived. The parents of enrolled subjects received an information 
sheet explaining the study. 
Severity of illness was scored using the Pediatric Index of Mortality (PIM) and the 
Pediatric Risk of Mortality (PRISM II).29,30
Weaning from midazolam and/or morphine was by protocol. This provides for 
midazolam administered by continuous infusion to be decreased by steps of 50 mcg/kg/hr 
per 8 hours, and for morphine by steps of 10 mcg/kg/hr per 24 hours. 
Measurement
For this study we composed a checklist which we named Sophia Benzodiazepine and 
Opioid Withdrawal Checklist (SBOWC). It contains all symptoms of benzodiazepine 
and opioids withdrawal described in the literature specific to critically ill children.24 The 
final checklist was approved by 10 experienced pediatric intensivists to guarantee content 
validity. The 24 items of the SBOWC are listed in Table 3.31 Tachycardia was defined as a 
heart rate of more than 15% above the baseline value.32,33 The latter criterion accordingly was 
applicable to the items tachypnea and hypertension. For heart rate, respiratory rate and 
arterial blood pressure, the highest values within the past four hours were automatically 
generated by the patient data management system (PDMS) when the nurse completed the 
SBOWC. The daily baseline values for the physiological items were also computed from 
PDMS data. 
All nurses of the two PICUs received verbal and written instruction on how to use the 
SBOWC. In addition, an instruction manual was available at each patient’s bedside. Items 
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were to be scored ‘yes’ if the symptom had been present during the past 4 hours. For the 
purpose of analysis, items assigned ‘yes’ were recoded in the numeric value ‘1’; all other 
items were recoded in ‘0’. The sum score for each assessment was computed by summating 
the numeric values. The SBOWC sum score thus can range from 0 to 24 (no symptoms 
versus all symptoms of withdrawal were observed).  
Procedure
The attending nurse completed the SBOWC every shift at set times (4 a.m., 2 and 8 p.m.). 
These set times had been determined on the basis of the daily nursing staff schedule, i.e. 
three 8 hours shifts, taking into account that a nurse must have been able to look after the 
child for a minimum of 4 hours before scoring. Scores were entered into the PDMS,  which 
system also ‘reminds’ the nurse when to complete the SBOWC. For logistical reasons data 
collection ceased after the child’s discharge from the PICU. 
Statistical analyses 
Descriptive statistics were used to present demographics, administered medication and 
withdrawal symptoms. The doses for fentanyl were converted to morphine equivalents by 
the formula 0.1 mg∙kg-1 of fentanyl = 10 mg∙kg-1 of morphine.
34
Spearman’s rank correlation coefficient (rs) was used to explore association between 
the variables total dose, duration of infusion and maximum SBOWC sum score. For every 
rs a 95% confidence interval (CI) was computed. The maximum sum score of the SBOWC 
was computed for each patient. 
The observations were divided into four groups. First, the total group, 2161 observations 
made in all 79 children. Second, a ‘weaning group’, 932 observations in 76 children obtained 
within 24 hours after decrease and/or discontinuation of midazolam and/or opioids. 
Third, a ‘high doses’ group as a subset of the second group, 496 observation in 19 children 
with the highest total doses of midazolam during admission (>  70 mg/kg). These are 
children at particular risk of developing withdrawal symptoms. Fourth, an ‘unsuccessful 
weaning’ group, 93 observations in 27 children. These observations were obtained before 
increasing midazolam and/or opioids during the weaning process in order to counteract 
possible withdrawal related symptoms. 
Interobserver reliability was tested for the dichotomous items by Cohen’s kappa 
and the intraclass correlation coefficient (ICC) for continuous data.35 A Cohen’s kappa 
below 0.65 was considered unsatisfactory.36 SBOWC assessments were excluded for 
analysis when three or more (> 10%) items were missing. A p value of < 0.05 indicated a 
statistical significance. 
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Results
Patients 
During the study period a total of 687 patients were admitted; 91 patients received 
prolonged midazolam and/or opioids, however, 12 patients were excluded. Of these, 
10/12 patients were admitted with status epilepticus and treated with midazolam, and 
two patients had severely disturbed behavior pattern (one patient with syndrome of West 
and another patient with infantile encephalopathy with choreoathetosis) on account of 
underlying neurological disease. Thus, 79 (11%) patients fulfilled the inclusion criteria 
and were enrolled in this study. Median age was 3.4 months (range 0 days to 15.5 years). 
Demographic data and background characteristics are listed in Table 1. 
Table 1 Patient characteristics (N = 79)
ECMO extracorporeal membrane oxygenation, * median (min-max), ‡ median (P25 - P75)
Variables N %
Sex
Male
Female
45
34
57
43
Age
Neonate (< 28 days)
1 – 6 months
6 – 12 months
1 – 3 year
3 – 10 year
> 10 year
19
26
12
11
9
2
24
33
15
14
11
3
Age in months, median (range) 3.4 (0-185)
Diagnosis
Respiratory insufficiency
Cardiac (pre- en postoperative (after ≥48 hours)
Postoperative 
Congenital defects
Sepsis
Other  
34
21
9
5
4
6
43
27
11
6
8
5
Surgery (yes) 56 71
ECMO therapy (yes) 11 14
Ventilation
Number of patients 76 96
Number of days* 8 (1 to 107)
Length of stay PICU‡ (days) 11 (7 to 21)
Pediatric Index Mortality score* (%) 3.2 (0.4 to 43.7)
Pediatric Risk of Mortality* (%) 13 (0 to 32)
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Medication 
Specifics of dosing and duration of medication are given in Table 2. All 79 patients were 
sedated with midazolam at a median dose of 176 mcg/kg/hr (range 25 to 397). Seventy-three 
(92%) also received opioids. Midazolam was administered for a median 10 days (range 3 to 
108 days). The median total dose of midazolam administered was 33 mg/kg (range 2 to 
595) and of opioids 4 mg/kg (range 0 - 682). Opioids were administered for a median of 8 
days (range 1 to 41 days). 
The first line drugs were midazolam, morphine and fentanyl. Several patients received 
additional drugs such as ketamine (n = 26), propofol (n = 14) and clonidine (n = 26) to 
relieve distress and/or pain. 
Table 2 Continuous midazolam and opioid iv infusion
* median (min-max), + median (min-max) and [P25 - P75], ‡ the doses for fentanyl were converted to morphine 
equivalents34
Interobserver reliability
Twenty-three observations were scored simultaneously by the attending nurse 
and the principal investigator (EI). The intraclass correlation coefficient was 0.85 
(95% CI 0.69 to 0.94). The interobserver reliability (Cohen’s kappa) of the individual 
items of the SBOWC ranged from 0.59 to 1.0. Interobserver reliability for the items high 
pitched crying (0.59), and  mottling (0.62) showed a kappa below 0.65. 
Withdrawal symptoms 
A total of 2188 assessments were performed in 79 children. Twenty-seven observations 
in 14 patients were excluded from analysis because more than 2 items were missing. 
The median number of assessments in individual patients was 14 (range 2 to 198) over a 
median of 6 days (range 1 to 67 days). In 3 patients there were no observations performed 
after weaning or cessation of midazolam and/or opioids because they were discharged. 
The frequencies of withdrawal symptoms for the groups defined above are summarized 
in Table 3. 
Midazolam Opioids 
(Morphine and fentanyl‡)
Number of patients 79 73
Number of days* 10 (3-108) 8 (1-41)
Mean continuous doses (mcg/kg/hr)* 176 (25-397) 14 (5-559)
Maximum doses (mcg/kg/hr)* 300 (25-700) 20 (2-1200)
Total doses during admission (mg/kg)+ 33 (2-595) 3.8 (0-682)
[20-70] [1-11]
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Central Nervous System irritability
Symptoms such as anxiety, agitation, grimacing, sleep disturbance, increased muscle 
tension and movement disorder were observed in more than 10% (10 to 22.1%) of all 
observations. Their frequencies differed little between the total, weaning and high doses 
groups. 
Symptoms such as seizures, tremors, high pitched crying, pupil dilatation and 
hallucinations were rarely seen (0 to 4%) in all groups. 
The group ‘unsuccessful weaning’ showed much higher frequencies of the symptoms 
agitation, anxiety, increased muscle tone, motor disturbance, grimacing and sleep < 1 
hour (20.4 to 46.2%) than observed in the two other ‘weaning’ groups. Figure 1 illustrates 
this finding. Administration of additional sedatives and analgesics, including ketamine, 
clonidine and propofol, was slightly higher (10.5%) in the unsuccessful weaning group 
as compared to the total group. On the other hand, in 45 (48%) of the 93 assessments 
in this group midazolam, morphine and fentanyl were tapered off before administering 
additional medication. Strikingly, in 13 of 45 observations the tapering rate was between 
10 - 20% per step. In 32 of 45 cases these medications were tapered off faster (> 20% of 
initial doses) indicating that tapering rate might be a factor of influence.
Gastrointestinal dysfunction
Diarrhea and increased gastric residuals after feeding were most frequently observed 
(respectively 14.5 to 21.5% and 12.4 to 25.5%) in all four groups. Vomiting was seen twice 
more frequently (11.8%) in the unsuccessful weaning group than in the three other groups. 
Frequency of increased gastric residuals after feeding was higher in this group as well. 
Autonomic dysfunction
Tachypnea, fever, sweating and hypertension were observed in more than 13% of 
assessments in all four groups. Sneezing and yawning were rarely observed in all the 
groups. The unsuccessful weaning group showed higher frequencies of notably the 
symptoms sweating and mottling with a relative increase of 10% or more (see Figure 1).
Correlation between SBOWC sum scores and doses medication
The maximum SBOWC sum scores per patient ranged from 1 to 12 with a median of 
6. The rs between total doses of midazolam and maximum SBOWC sum score in 76 
children was 0.51 (95% CI 0.32 to 0.66, p < 0.001). The rs between total doses of opioids 
and the maximum SBOWC sum score was 0.39 (95% CI 0.17 to 0.57, p < 0.01, n = 71). The 
correlation between duration of medication and maximum SBOWC sum score was 0.52 
(95% CI 0.34 to 0.67, p < 0.001, n = 76).
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Figure 1 Withdrawal symptoms with percentage of > 10%
Discussion  
This study in a large PICU population is the first that prospectively evaluates occurrences 
of all 24 benzodiazepine and opioids withdrawal symptoms described in the literature 
for PICU patients. Previous publications included fewer symptoms or focused on either 
opioid or benzodiazepine withdrawal symptoms.4,5,7,9
Only Franck et al.10 prospectively studied both benzodiazepine and opioid withdrawal 
symptoms. The number of symptoms was limited to 16, however, and the study group 
included only 15 patients with a complex congenital heart disease. Their findings 
demonstrate that symptoms like sleeplessness, temperature above 37.2°C, diarrhea, 
tremors and pupil dilation were most frequently observed, which coincides with findings 
in the present study, except for tremors. Based on the literature we did not expect GI 
symptoms such as diarrhea and vomiting as withdrawal symptoms in patients with 
midazolam37 However, two of six patients who received only midazolam showed GI 
symptoms not caused by viral infection or use of antibiotics. Still, this is no clear evidence 
to state that GI symptoms can be seen as benzodiazepine withdrawal symptoms.  
Several authors found correlations between withdrawal symptoms and total 
cumulative doses (mg/kg) of midazolam or opioids.4,5,7,10,11,38 In this study we found similar 
significant correlations. We also found correlations between duration of use and total 
dose of midazolam administration on the one hand, and maximum SBOWC sum score on 
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the other hand (respectively 0.52 and 0.51). The correlation between total doses of opioids 
and maximum sum score (rs = 0.39) is moderate.
We found that patients whose medication is tapered off (weaning group) and those 
with high cumulative total doses (high doses group) were at risk for developing withdrawal 
symptoms during weaning. Surprisingly, frequencies of withdrawal symptoms hardly 
differed between total group and these subsets of observations, in which higher frequencies 
would have seemed likely. Thus, the observed symptoms need not necessarily have been 
withdrawal symptoms, but may have been expressions of discomfort, pain or ventilator 
distress. Based on these findings and in line with other authors, we recommend awareness 
of possible over diagnosis of withdrawal symptoms.25 For example, fever or vomiting 
should never be attributed to withdrawal until other possible causes are excluded. With 
other authors we agree that the occurrence of withdrawal symptoms must be time-related 
to a decrease or discontinuation of sedatives and analgesics.5-7,10,13,14,27,39 Furthermore, the 
results of this study underscore that withdrawal symptoms are more likely to occur in 
patients receiving high (cumulative) doses of midazolam and/or morphine.
Strikingly, a particular set of symptoms stood out clearly in this ‘unsuccessful weaning’ 
group (agitation, increased muscle tension, anxiety, grimacing, sleeping less than 1 hour, 
poor feeding and tachypnea). These symptoms therefore need to be included in an 
assessment tool. Of symptoms occurring less frequently yawning and sneezing require 
constant observation and may therefore be difficult to assess in a reliable manner. 
Symptoms such as tremors, hallucinations and seizures may have a high positive predictive 
value, even if seen less frequently. 
Based on the findings of this study, we propose that the SBOWC could form the basis 
for an assessment tool for withdrawal symptoms in PICU patients. Still we believe it is 
questionable if all items in the SBOWC were clinically relevant. Therefore, it is necessary 
to prospectively study the co-occurrences of several symptoms. In a further study it 
would be advisable to have independent observers assess videotaped material, so as to 
increase the validity and reliability. Also, items of the checklist should be further clarified 
so as to ensure there is no misinterpretation possible for nurses. Item reduction would 
seem advisable to achieve easier clinical use. Particularly the two items for which low 
interobserver reliability was obtained should be investigated for their relevance. A way of 
dealing with these items is giving them more emphasis during training of nurses. On the 
other hand, it would be worthwhile to investigate if the items with a kappa below 0.65 are 
relevant for the final assessment tool. 
Some limitations of this study must be pointed out. First, there may have been observer 
bias arising from the fact that the observers were the ones who nursed the children. 
Second, when completing assessment forms in the PDMS, nurses were not blinded to 
earlier recorded assessments. This may have influenced objectivity. Third, the frequencies 
of benzodiazepine and opioid withdrawal symptoms may have been influenced by 
administration of additional sedatives. Long-term administration of these sedatives 
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is known to cause withdrawal symptoms as well.25,38,40 Fourth, The fact that weaning in 
this study might differ from weaning strategies in other centres might influence  the 
prevalences of withdrawal symptoms.
For treatment purposes, opioid withdrawal symptoms need to be distinguished 
from those of benzodiazepines  because each type of withdrawal syndrome is treated 
differently.24,25 This was not possible, however, in the present study, because 73 of 79 
children received both types of medication, as is common practice in PICU patients.41,42 
The subset of six patients receiving only midazolam is too small to allow conclusions on 
specific benzodiazepine withdrawal symptoms.
Conclusion
This is the first study which gives a complete overview of frequencies of all 24 known 
withdrawal symptoms after tapering off or cessation of benzodiazepines and/or opioids 
in PICU patients. Both longer duration of administration and higher total doses of 
midazolam and opioids were clearly related with the occurrence of withdrawal symptoms, 
and may therefore be considered risk factors. 
The checklist (SBOWC) used in this study now forms the basis for a psychometric 
validation study aimed at establishing a clinically useful assessment tool for PICU patients 
that could facilitate prevention of withdrawal syndrome and application of a treatment 
algorithm.  
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Abstract
Objectives: To construct a reliable and clinically practical instrument for monitoring opioid and 
benzodiazepine withdrawal symptoms in pediatric ICU patients. 
Design: Instrument development.
Setting: Intensive care unit in an academic children’s hospital.
Patients and participants: 79 patients up to age 16 years on intravenous midazolam and/or opioids 
for ≥ 5 days. An expert panel of 85 physicians and nurses rated clinical relevance of withdrawal 
symptoms. 
Intervention: During drug weaning repeated observations were performed with a checklist of 24 
withdrawal symptoms described in the literature. 
Measurements and results: For 76 children, 932 observations were obtained within 24 hours 
after decreasing and/or discontinuation of midazolam or opioids. Most frequent symptoms were 
tachypnea, agitation, motor disturbance, diarrhea, fever, anxiety, sleep disturbance and hypertension 
(14.6 to 29.6%). Multidimensional scaling (MDS) was performed to detect the underlying empirical 
structure of co-occurrences of symptoms. An expert panel judged clinical relevance of each withdrawal 
symptom using a four-point scale ranging from ‘definitively so’ to ‘definitively not’. Agitation, anxiety, 
inconsolable crying, increased muscle tension, tremors, tachycardia and sweating were considered 
relevant by 85% to 95% of the experts. On the basis of the MDS results and the expert opinions, 15 
symptoms were selected for inclusion in the final instrument. 
Conclusions: We are the first to develop an assessment tool for withdrawal symptoms in pediatric 
ICU patients on the basis of the underlying empirical structure of co‑occurrences of withdrawal 
symptoms that experts considered relevant. Future studies need to define cutoff points and clarify 
psychometric issues. 
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Introduction
Many critically ill children, admitted to a specialized intensive care unit (ICU), receive 
benzodiazepines and/or opioids to reduce pain and anxiety. Long-term exposure to these 
medications may result in physical dependency. These patients are at risk for withdrawal 
symptoms after abrupt discontinuation or too rapid tapering-off of these medications.1
Symptoms of withdrawal can be categorized into three main groups, i.e.: overstimulation 
of the central nervous system (CNS), gastrointestinal dysfunction, and autonomic 
dysregulation.1‑3
A reliable, validated and clinical useful assessment tool is indispensable for monitoring 
withdrawal syndrome. Two such tools are available, the Sedation Withdrawal Score (SWS) 
and the Opioid Benzodiazepine Withdrawal Scale (OBWS).4,5 Yet each has its limitations. 
The Sedation SWS was designed includes 12 symptoms. While all these symptoms seem 
clinically relevant for assessing withdrawal, data on validity and reliability are lacking. The 
OBWS was evaluated in a small sample of PICU children (n = 15) comparing OBWS scores 
and nurses’ clinical judgment. Sensitivity of the OBWS at scores 8 (cutoff) or higher 
was 50% and the specificity was 87%, which implies moderate validity of the scale.5 
Symptoms of the OBWS were indirectly adapted from the Neonatal Abstinence Score.6
Within our line of research we studied the (co‑)occurrences of withdrawal symptoms 
in critically ill children with the ultimate objective to develop a valid assessment tool. 
Specifically, we estimated the (co-)occurrences of the withdrawal symptoms, both 
bivariately and multivariately. The objective was to find out which symptoms were 
sufficient for developing of a reliable and valid instrument tailored to adequately assess 
withdrawal symptoms in critically ill children. 
Materials and methods
Methods
Several steps of scale development involved in the construction of the Sophia Observation 
withdrawal Symptoms‑scale (SOS) were taken. Figure 1 shows the outline of the study. The 
institutional review board approved the study and because of the strictly observational 
and non‑invasive nature of this study, they waived the need for informed consent. 
The first step was a review of the literature on withdrawal symptoms in critically children 
admitted to a PICU based on an extensive evaluation of the literature as recently published 
by our group.3 Based on this review, we selected 24 symptoms for in a preliminary scale, 
which we called the Sophia Benzodiazepine and Opioid Withdrawal Checklist (SBOWC). 
Twelve symptoms concerned the central nervous system, four the gastrointestinal tract, 
and eight the autonomic nervous system (see Table 1). 
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Figure 1 Outline of the steps taken to construct the Sophia Observation withdrawal Symptoms‑scale (SOS)
The second step was a prospective observational study in critically ill children admitted 
to the intensive care of the Erasmus MC ‑ Sophia Children’s Hospital between September 
2005 and February 2006. Eligible for inclusion were children aged ≤ 16 years who had 
received midazolam (benzodiazepine), morphine or fentanyl (opioids) by continuous 
infusion for at least 5 days. 
The SBOWC was assessed within 24 hours after tapering-off or cessation of 
midazolam and/or opioids (morphine or fentanyl). All nurses had received verbal and 
written instruction on the SBOWC. An instruction manual explaining the symptoms to 
be observed was available at each patient’s bedside. Details about reliability and validity 
of the SBOWC have been presented in earlier work.7 
The third step was twofold. In step 3a the underlying structure was identified by 
multidimensional scaling. Step 3b was to obtain expert opinion on the relevance’s of the 
SBOWC symptoms. To this end we mailed a questionnaire to all pediatric intensivists and 
their clinical fellows in pediatric intensive care of all eight PICUs in the Netherlands and 
to critical care nurses of our own PICU. 
Step 4 selected the relevant items; symptoms which had insufficient discriminative 
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value were eliminated.
Study population
The observations were stratified into two groups. First, a ‘weaning group’ (WEAN), in 
which 932 observations in 76 children were obtained within 24 hours after decrease 
and/or discontinuation of midazolam and/or opioids. Those children were at risk for 
developing withdrawal symptoms.  Second, an ‘unsuccessful weaning’ group (WEAN-), 
93 observations in 27 children. These observations were obtained before increasing 
midazolam and/or opioids during the weaning process in order to counteract possible 
withdrawal related symptoms. In this ‘unsuccessful weaning’ group we expect more 
withdrawal related symptoms compared to the ‘weaning group’. 
Statistical analyses 
As the frequency distribution of the symptoms of SBOWC was skewed, the response 
categories were dichotomized. Of clinical interest is to determine the interrelationship 
of the symptoms. Conventionally, one or another kind of correlation technique as an 
association measure is used. To our belief, in this study it is not of interest to estimate 
the association between symptoms, but preferably to estimate the co‑occurrences of 
these symptoms. To that end, Jaccard’s measure of similarity tailored to estimate these 
occurrences will be applied.
Expert opinions 
The experts were asked to rate the relevance of each withdrawal symptom in critically 
ill children using a four-point scale ranging from ‘definitively so’ to ‘definitively not’. 
In addition we asked them to state which symptoms were absolutely necessary for an 
assessment tool. Each symptom of the checklist was recoded. A symptom was coded 
relevant if the expert scored the first question as ‘that’s definitely so’ or ‘that’s true’ or 
the second question with ‘absolutely necessary’. We considered a symptom was deemed 
relevant if 50% or more of the respondents agreed on relevance.
Multidimensional scaling
The goal of multidimensional scaling (MDS) analysis technique in this study is to detect 
meaningful underlying dimensions of observed similarities and dissimilarities (distances) 
between withdrawal symptoms. 
The (dis)similarities between the withdrawal symptoms identified by MDS are based 
on the co‑occurrences of these symptoms. Then, MDS attempts to arrange ‘objects’ 
(withdrawal symptoms) in a space of as few dimensions as possible without substantial 
loss of information. This enables reproducing the observed distances adequately. 
Nevertheless, in general, the more dimensions we use in order to reproduce the distance 
matrix, the better the fit of the reproduced matrix to the observed matrix. We considered 
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the Jaccard measure as a similarity measure of co-occurrences. The fit of the models 
were represented by the normalized raw stress, a measure of model performance. This 
coefficient varies from 0 to 1 and should be < 0.05 as a good fit. The Tucker’s φ coefficient 
of congruence is a measure of correspondence between the distances of the empirical data 
and the distance derived from the model. Ideally, this coefficient should be > 0.95. To identify the 
clinical-empirical structure the computer algorithm PROXSCAL (Proximity Scaling) was used. 
Two symptoms were excluded from analysis. First, hypertension since it was not always 
possible to measure arterial blood pressure, i.e. when the child did not have an indwelling 
arterial catheter, in 386/932 (41%) observations. Second, high pitched crying, since this 
symptom could only be observed if patients did not have an endotracheal tube, which was 
not always the case (629/932, 67%). Furthermore, as the SBOWC asked for observation 
of either feeding retention or poor feeding, these items were taken together in the MDS 
procedure. Final item selection was based on the expert opinions and the results of MDS. 
Inclusion in the SOS required symptoms to have a substantial score (z-score) ≥ 0.30 on at 
least one dimension of the MDS solution. And, a symptom was deemed relevant if 50% or 
more of the respondents agreed on relevance. The robustness of the normalized raw stress 
and the Tucker’s φ coefficient of congruence of the MDS solution was tested with tenfold 
cross‑validation and presented by the mean (SD) value. 
Interobserver reliability was tested for the dichotomous items by Cohen’s kappa and 
the intraclass correlation coefficient (ICC) for continuous data.8 A Cohen’s kappa below 
0.65 was considered unsatisfactory.9 
Statistical analyses were performed with the Statistical Package for Social Sciences 
(SPSS), version 14.0. 
Results
Characteristics study sample
Seventy-nine children - 43% girls; 57% boys - met the inclusion criteria.  Their median age 
was 3.4 months (range 0 days to 15.5 years). All 79 received midazolam at a median dose 
of 176 mcg/kg/hr. Seventy‑three children (92% ) also received opioids at a median dose of 
14 mcg/kg/hr. Midazolam was administered for a median of 10 days (range 3 to 108 days); 
opioids were administered for a median of  8 days (range 1 to 41 days). The median  total 
dose of midazolam was 33 mg/kg (range 2 to 595 mg/kg), and of opioids 4 mg/kg (range 
0 to 682 mg/kg). 
For 76 children, 932 observations were obtained within 24 hours after decreasing and/
or discontinuation of midazolam and/or opioids (WEAN). In 3 patients there were no 
observations performed after weaning or cessation of midazolam and/or opioids because 
they were discharged. Ninety‑four ‘unsuccessful weaning’ observations were obtained for 
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27 children in the ‘unsuccessful weaning’ group (WEAN-). The latter observations were 
obtained before midazolam and/or opioids were increased during the weaning process in 
order to counteract possible withdrawal related symptoms. 
Interobserver reliability
Twenty‑three observations were scored simultaneously by the attending nurse and 
the principal investigator (EI). The intraclass correlation coefficient was 0.97 (95% CI 
0.92 to  0.98). The interobserver reliability (Cohen’s kappa) of the individual items of the 
SOS ranged from 0.73 to 1.0. 
Bivariate analysis of co-occurrences of withdrawal symptoms 
Table 1 presents (co)‑occurrences of symptoms for the two conditions, i.e. observations 
performed within 24 hours after weaning (WEAN, n = 932) of opioids/benzodiazepine
Table 2 Construction of the SOS based on two methods (MDS and Expert opinion)
SBOWC SBOWC - MDS SBOWC - Expert opinion SOS
Anxiety + + 95.3 +
Agitation + + 84.7 +
Increased muscle tension + + 85.9 +
Motor disturbance
Slight muscle jerks
Uncoordinated, robust movements
+
+
+
72.9
78.8
+
Tremors + + 92.9 +
Inconsolable crying + + 88.2 +
High pitched crying * + 68.2 ‑
Grimacing + + 76.5 +
Sleep disturbance
< 1 hour + + 71.8 +
Seizures ‑ ‑ 35.3 ‑
Pupil dilation ‑ + 56.6 ‑
Hallucinations + + 76.5 +
Vomiting + + 61.2 +
Diarrhoea + + 50.6 +
Feeding
Poor feeding 
Feeding retention
+
+
‑
55.3
43.5
‑
Tachycardia + + 89.4 +
Tachypnea + + 69.4 +
Hypertension * + 67.4 ‑
Fever + + 50.6 +
Sweating + + 90.6 +
Sneezing ‑ ‑ 24.7 ‑
Yawning ‑ ‑ 44.7 ‑
Mottling + ‑ 45.9 ‑
* not performed in the MDS analysis because of many missing observations, + meet criteria for inclusion, ‑ do 
not meet inclusion criteria
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(lower triangle) and observations performed before decreasing medication (WEAN-, 
n = 94) (upper triangle).
For WEAN, high prevalence’s were noted for tachypnea (29.6%), agitation (21.1%), 
diarrhea (17.8%), fever (17.6%) anxiety (14.8%), sleep pattern (14.6%) and hypertension 
(14.6%) showed. On the other hand, for WEAN- , symptoms such as agitation (46.2%), 
motor disturbance (37.6%), tachypnea (31.2%), increased muscle tension (28.0%) and 
feeding retention (25.5%) showed the highest prevalence’s. The symptoms tremors, 
hallucination, seizure, pupil dilatation, sneezing and yawning demonstrated very low 
prevalence’s (from 0.3 to 1.9). 
With regard to co‑occurrences (Table 1) the highest percentage was seen for agitation co‑
occurring with motor disturbance, both in the WEAN (9.5%) and WEAN- (25.8%). Groups 
substantially differed in frequencies of the following co-occurrences: agitation/anxiety, 
agitation/muscle tone, agitation/motor disturbance, agitation/grimacing, agitation/
sleeping, agitation/sweating, muscle tone/motor disturbance. The co‑occurrences with 
symptoms such as seizures, pupil dilatation, hallucinations, yawning and sneezing were 
very low. 
Table 3 Multidimensional scaling, dimensional quantifications (z-scores)
Z-scores > 0.30 were highlighted, these symptoms has substantial score on one of the three dimensions.
Withdrawal symptoms Dimension
 1 2 3
Agitation 0.909 0.274 -0.190
Anxiety -0.594 -0.591 0.223
Increased muscle tension -0.609 0.696 0.173
Motor disturbance -0.820 0.032 -0.280
Tremors 0.126 0.350 -0.417
Crying -0.090 0.168 0.678
Grimacing 0.232 -0.006 -0.668
Sleep disturbance (less 1 hour) 0.465 -0.605 -0.177
Pupil dilation 0.153 -0.052 -0.236
Seizures 0.102 -0.200 0.070
Hallucinations -0.144 0.167 0.326
Vomiting 0.014 0.523 -0.259
Diarrhea -0.050 -0.520 0.456
Feeding 0.523 -0.391 0.340
Tachycardia -0.437 -0.108 0.227
Tachypnea 0.064 0.719 0.273
Fever 0.632 0.198 0.296
Sweating -0.360 -0.178 -0.646
Yawning -0.174 0.121 -0.259
Sneezing 0.168 0.003 0.289
Mottling -0.110 -0.600 -0.218
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Expert opinions 
In total 85 experts, 22 physicians and 63 nurses responded to the questionnaire. Most 
of them (84.7%) were female. The median work experience was 8 years, for physicians 
(IQR 4 - 11.3) and nurses (IQR 4.5 - 15) alike. 
The following symptoms were considered most relevant: agitation, anxiety, 
inconsolable crying, increased muscle tension, tremors, tachycardia and sweating 
(84.7% to 95.3%) (see Table 2). For five symptoms less than 50% of the experts agreed on 
relevance, i.e. seizures, feeding retention, yawning, sneezing and mottling. 
Multidimensional analysis of co-occurrences
The PROXSCAL-procedure was applied with random starts was chosen as initial 
configuration. Twenty-one symptoms were entered and the solution of the MDS procedure 
turned out to be three-dimensional. The normalized raw stress was 0.0498, indicating 
a good fit. The Tucker’s φ coefficient of congruence equaled 0.97. Decompositions of 
normalized Raw Stress ranged from 0.02 to 0.06. The tenfold cross-validation of the 
MDS solution identified a mean normalized raw stress of 0.0501 (SD = 0.002) and a mean 
Tucker’s φ coefficient of congruence of 0.97 (SD = 0.0009). 
The symptoms seizures, pupil dilatation, sneezing and yawning had a z‑score below 
0.30 on either of the three dimensions (see Table 3). Finally, based on the MDS results as 
well as the expert opinions, 15 symptoms (Table 2) were selected for inclusion in the SOS 
(see also Appendix). 
Discussion
To our knowledge, this is the first study to identify the underlying empirical structure of 
co-occurrences of withdrawal symptoms that experts (physicians and nurses) considered 
to be of relevance in critically ill children. The co‑occurrences of these symptoms could be 
adequately represented in a three‑dimensional solution. Nevertheless, the heterogeneity 
suggested that the symptoms did not constitute homogeneous clusters within the 
three‑dimensional solution. In all probability, this should be attributed to the low levels 
of occurrences of withdrawal symptoms, and, consequently, low levels of co‑occurrences. 
This finding suggests that the nature of withdrawal symptoms varies between individuals 
which is supported. 
As withdrawal symptoms of children in the PICU are usually treated immediately, 
extreme reactions are seen for short times only. Ethically this is correct because we strive 
for comfortable patients. This, however, makes it difficult to determine co-occurrences 
of withdrawal symptoms. Although the underlying empirical structure of the symptoms 
was unraveled nicely, the question arises whether the composed SOS based on MDS 
and expert opinion adequately covers all phenomena of the withdrawal syndrome. The 
symptoms included in the SOS have been extensively described in the literature.3-5,10 Also, 
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the tenfold cross validation on children showed that the empirical solution was robust. 
Therefore, we could conclude the SOS covers true the withdrawal symptoms. 
Several items were excluded from MDS analysis. We do not preclude that assessment 
of arterial blood pressure (ABP) might be of additional value, particularly in children 
being ventilated for a long time. This item was excluded because not all children had an 
indwelling arterial catheter. High‑pitched crying can only be assessed when children are 
not ventilated. This item was excluded, therefore, even though experts identified it as 
relevant. The item feeding was eliminated. ‘Poor feeding’ was judged as relevant by 55% 
of the experts, but ‘Feeding retention’ was judged irrelevant. Both Feeding items were 
combined in the MDS analysis and it was impossible to distinguish which feeding item 
had a substantial z‑score. Therefore, we decided to eliminate the item Feeding and not 
incorporate it in the SOS. 
The OBWS and SWS largely overlap with our SOS scale, except for the symptoms 
hyperactive Moro-reflex, high pitched crying, sneezing, yawning, frequent suction 
required, seizures and pupil dilation.4,5 These symptoms were not included in the SOS. 
Given the inherent age restriction for the symptom Moro-reflex this item cannot be 
included in the scale for all ages. We included three other symptoms - anxiety, grimacing 
and tachycardia ‑ which the two other scales do not contain. On the basis of the literature, 
however, these symptoms were identified as withdrawal symptoms.3 
A particular strength of the SOS is that it incorporates the opinions of health care 
workers, so as to make it clinically relevant. Also, it does not ask the raters to assess 
severity of the symptoms, unlike the Sedation Withdrawal Score. Therefore we feel that 
it is not only more simple in use, but also  more reliable, seeing that the reliability of an 
assessment tool will increase as symptoms are unambiguous.11  
In future research, we will explore the sensitivity to change of the SOS in critically 
ill children. Furthermore, cut off scores, sensitivity and specificity must be defined for 
treatment purposes. 
In conclusion, the SOS is feasible for assessing benzodiazepine and/or opioid 
withdrawal symptoms in critically ill children in an ICU environment. 
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Appendix A - SOS'DWH7LPH2EVHUYHU PLQPLQ (QWHUKLJKHVWUDWHLQSDVWKRXUVLISUHVHQWRWKHUZLVHUHDGWKHPRQLWRUILUVWRUFRXQWEUHDWKLQJ%DVHOLQHYDOXHKHDUWUDWH PLQ 3OHDVHWXUQRYHUIRULQVWUXFWLRQRQGHWHUPLQLQJEDVHOLQHYDOXH3OHDVHWXUQRYHUIRULQVWUXFWLRQRQGHWHUPLQLQJEDVHOLQHYDOXH%DVHOLQHYDOXHEUHDWKLQJUDWH PLQ7LFNLI\HV$XWRQRPLFG\VIXQFWLRQ7DFK\FDUGLD <HVLIKHDUWUDWHH[FHHGVEDVHOLQHYDOXHE\7DFK\SQHD)HYHU <HVLIERG\WHPSHUDWXUHH[FHHGHG&LQSDVWKRXUV6ZHDWLQJ 1RWFDXVHGE\URRPWHPSHUDWXUHFORWKLQJVZDGGOLQJHJ&HQWUDOQHUYRXVV\VWHPLUULWDELOLW\$JLWDWLRQ$Q[LHW\6SRQWDQHRXV,QUHVSRQVHWRHQYLURQPHQWDOVWLPXOL 6OLJKWLQYROXQWDU\UK\WKPLFPRYHPHQWVRIKDQGDQGRUIHHW6SRQWDQHRXV,QUHVSRQVHWRHQYLURQPHQWDOVWLPXOL6SRQWDQHRXV,QUHVSRQVHWRHQYLURQPHQWDOVWLPXOL ,QYROXQWDU\RIIRUHDUPVORZHUOHJVPXVFOHWZLWFKLQJ 1RWHSOHDVHWXUQRYHUIRULQVWUXFWLRQV,QFUHDVHGPXVFOHWHQVLRQ &OHQFKHGILVWVRUWHQVHFOHQFKHGWRHV,QFRQVRODEOHFU\LQJ*ULPDFLQJ6OHHSOHVVQHVV 6OHHSVQRWPRUHWKDQKRXUDWDVWUHWFK+DOOXFLQDWLRQV9RPLWLQJ $WOHDVWRQFHLQSDVWKRXUVQRWUHODWHGWRIHHGLQJFKDQJHV'LDUUKHD &RXQWWLFNHGER[HV
(QWHUKLJKHVWUDWHLQSDVWKRXUVLISUHVHQWRWKHUZLVHUHDGWKHPRQLWRUILUVWRUIHHOSXOVH+HDUWUDWH%UHDWKLQJUDWHWDFK\SQRH <HVLIEUHDWKLQJUDWHH[FHHGVEDVHOLQHYDOXHE\<HVLIFKLOGVKRZVDWOHDVWRQHRIWKHVHVLJQVLUULWDEOHUHVWOHVVDJLWDWHGILGJHW\8QUHVWRUDQ[LRXVIDFHH\HVZLGHRSHQH\HEURZVWHQVHDQGUDLVHG%HKDYLRUFDQYDU\IURPSDQLFN\WRGUDZEDFN
([SODQDWLRQ6WHS6WHS
&KRUHRDWKHWRVLVRIDUPVOHJVDQGRUKHDG*DVWURLQWHVWLQDOG\VIXQFWLRQ <HVLIFKLOGFDQQRWEHFRQVROHGE\SDUHQWVRUE\RIIHULQJGLVWUDFWLRQHJSDFLILHUIRRGRUJDPHSOD\LQJIRUROGHUFKLOGUHQ6FRUHVLOHQWFU\LQJLQLQWXEDWHGFKLOGUHQ(\HEURZVFRQWUDFWHGDQGORZHUHGQDVRODELDOIROGYLVLEOH'XULQJWKHSDVWKRXUVFKLOGVHHPVWRVHHKHDURUIHHOWKLQJVWKDWDUHQRWWKHUH:DWHU\VWRROVQRWUHODWHGWRIHHGLQJFKDQJHVGRQRWVFRUHHJZKHQWKHUHVXOWRIEUHDVWIHHGLQJ
6WLFNHUZLWKSDWLHQW¶VQDPH6266RSKLD2EVHUYDWLRQZLWKGUDZDO6\PSWRPVVFDOH&KLOGUHQ±\HDUV
&RS\ULJKW'XWFKDQG(QJOLVKYHUVLRQ(,VWD0YDQ'LMN0GH+RRJDQG'7LEERHOYHUVLRQ2FWREHU'RQRWUHSURGXFHZLWKRXWSHUPLVVLRQ
7UHPRUV SLFNRQH0RWRUGLVWXUEDQFHSLFNRQHRIIRXU8QFRQWUROOHGUREXVWPRYHPHQWV6OLJKWPXVFOHMHUNV 0D[LPXPVFRUHLV
 3OHDVHWXUQRYHUIRUIXUWKHULQVWUXFWLRQV
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Appendix B - SOS Instructions
SOS - Sophia Observation withdrawal Symptoms-scale
Instructions
Target group:
Children, up to 16 years old, who have received benzodiazepines and/or opioids for more 
than 4 days, start from the 5th day. 
Excluded are children who:
- Receive neuromuscular blocking agents continuous;
- Have been admitted with status epilepticus (and therefore receive midazolam);
- Show severely disturbed behavioral pattern on account of underlying neurological disease.
For assessing abstinence in infants of drug-dependent mothers, we recommend the Neonatal Abstinence 
Score (NAS) of L.P. Finnegan (1975). 
Procedure:
- Observe the child:
  At 4 a.m., 2 p.m. and 8 p.m.
  At suspicion of withdrawal syndrome.
  2 hours after an intervention for treatment of withdrawal symptoms.
- Please fill in the form carefully after observation;
- Please score for each item the most extreme/ worst moment during the past 4 hours;
- Check the explanation if a particular item is not clear.
Step 1
Determining baseline values for heart rate and breathing rate:
The baseline value is the mean value over the past 24 hours. Dependent on type of ‘patient data 
management system’ it could be automatically generated, otherwise it must be computed by hand.  
For example:
The baseline value of heart rate is 100. Compute baseline “exceeded by 15 %” as follows: 
100 x 1.15 = 115. The highest rate observed in the past 4 hours is 124. This is higher than 115, so 
tick yes for tachycardia (step 2).
Step 2 Items 7 and 8
Instructions for tremors and motor disturbance:
Tremors and motor disturbance can present in two ways:
 1. spontaneous, not related to environmental stimuli or touching of the child;
 2. in response to environmental stimuli (caretaking, noise, etc.).
Please take this into account when completing the form. 
Example: a child show tremors when you attend to it. The tremors stop when you have finished. 
In this case, please tick yes for ‘tremors – in response to environmental stimuli’. 
For clarification and questions please send email to w.ista@erasmusmc.nl
Chapter 8
Weaning of opioids and 
benzodiazepines at home after critical 
illness in children, a guideline
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Abstract
Objectives: To evaluate the feasibility of weaning sedatives and opioids at home in children.
Design: Retrospective observational study.
Participants: 30 neonates treated for congenital diaphragmatic hernia (CDH) with extra corporeal 
membrane oxygenation (ECMO).
Setting: Intensive Care Unit of the Erasmus MC - Sophia Children’s Hospital
Results: Of the 30 neonates treated for CDH with ECMO from 2003 through 2005, 15 survived. Five 
children were weaned at home, though telephone contact once a week. The mean infusion rates of 
midazolam and morphine for the weaned at home children were significantly higher than those 
for other  children (Midazolam: Kruskal-Wallis, Chi-Square = 7.44, df = 2, p = 0.024; Morphine: 
Kruskal-Wallis, Chi-Square = 6.86, df = 2, p = 0.032). Weaning at home took respectively 11, 42, 107, 
173 and 180 days. Two parents reported inconsolable crying, agitation, sleeplessness and irritability 
especially on days when doses were tapered off. As a consequence, dosages for two patients had to be 
kept at the same level for two weeks because of serious withdrawal symptoms. 
Conclusions: Home weaning reduces length of hospital stay by a median of 107 days in the five infants 
presented in this study. Parents should be well informed about possible withdrawal symptoms and 
should consent in this strategy. The strategy of final weaning with the aid of weekly telephone 
consultations with a consultant pediatric intensivist was feasible and satisfying for these parents. 
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Introduction
To minimize patients discomfort in the pediatric intensive care unit (ICU), sedation and 
pain relief has become an integral part of critical care practice. After prolonged exposure of 
sedatives and opioids, physical dependence may develop, placing the critically ill children 
at risk for withdrawal symptoms after abrupt discontinuation or tapering too fast.1,2 This is 
a significant problem and too less recognized. Although the exact incidence of iatrogenic 
withdrawal is unknown. 
Neonates born with a congenital diaphragmatic hernia (CDH) often need life-saving 
Extra Corporeal Membrane Oxygenation (ECMO) treatment. In contrast to many other 
patient groups they treated with ECMO, CDH patients often remain hospitalized for 
prolonged artificial ventilation due to the high incidence of bronchopulmonary dysplasia 
and pulmonary hypertension. This subset group is especially at high risk for developing an 
iatrogenic withdrawal syndrome. They receive intravenous sedatives and opioids at high 
doses and for long periods of time, which requires cautious monitoring. For one thing, 
sudden discontinuation of this medication carries the risk of withdrawal syndrome.3,4 
Furthermore, animal studies have suggested that neurodegeneration, with possible 
cognitive sequela, is a potential long-term risk of sedatives and anesthetics in neonates 
and young children.5 
The gradual tapering of intravenous sedatives and opioids to prevent or limit the 
occurrence of withdrawal symptoms is a time consuming process and may result in even 
longer hospital stay. A possible alternative is a switch to oral agents such as methadone, 
lorazepam, clonidine and alimemazine. The switch to oral administration eliminates the 
need for intravenous sedatives. Patients then could be discharged earlier to complete final 
weaning at home. Stepwise weaning in the home environment might even facilitate the 
weaning process, and, for that matter, considerably shortens hospital stay. 
Physicians should nevertheless be well aware of the differences in potency, half-life and 
oral availability between the sedatives and opioids. Regrettably, guidelines for weaning of 
benzodiazepines and opioids are scarce. The few available reports all describe an ICU 
hospital setting.1,6-8
Home weaning of iatrogenic drug dependent infants has been evaluated in two 
studies.9,10 Tobias et al.9 evaluated this strategy for three children (15 months, 17 months 
and 11 years) and found that tapering of oral sedatives and opioids was feasible within 
4 to 6 weeks, without signs of withdrawal. Meyer et al.10 evaluated weaning of methadone 
in 29 children with a mean age of 26 months. Sixteen children had been discharged to 
complete their weaning schedule at home. In this study, however, withdrawal symptoms 
at home were not assessed.
The aim of the present study was to describe aspects of home weaning of 
benzodiazepines and opioids for five children with CDH after prolonged sedation. A 
second aim was to develop a guideline for this treatment mode. 
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Methods
We retrospectively reviewed data of patients with CDH who received ECMO treatment in 
the Intensive Care Unit of the Erasmus MC - Sophia Children’s Hospital from January 2003 
up to and including December 2005. 
During ECMO to our unit-specific protocol all patients received both opioids (such 
as morphine and fentanyl) and benzodiazepines (such as midazolam) to relieve pain 
and physical and psychological discomfort, respectively.11 These were administered 
intravenously by continuous infusion or as intermittent bolus. Doses and durations were 
retrieved from the patient data management system. 
Opioids and benzodiazepines were weaned stepwise by 10 to 20% per 24 hours.1,6 
If weaning procedures required a longer time or were unsuccessful and resulted in 
withdrawal symptoms, opioids were replaced by methadone and midazolam was replaced 
by clonidine according to our protocol. Methadone was administered orally; clonidine 
first by continuous intravenous infusion and later by mouth. 
As from 2003, selected patients with CDH who had undergone ECMO treatment 
were discharged home with the intention to complete drug weaning at home. Parents 
were recruited for weaning at home if they were sufficiently motivated and capable. 
They received support from one of the pediatric intensivist consultants (DT). In weekly 
telephone consultations parents described possible withdrawal symptoms after which 
the consultant advised on decreasing or maintaining doses. Furthermore, the child was 
regularly examined in the outpatient clinic for disease specific morbidity, on the guidance 
of the interdisciplinary and protocollized care plan for patients with CDH.
Once weaning was completed, a researcher (MvD) or nurse (MdL) interviewed the 
parents. Interviewing had a twofold aim. First, parents were asked to identify the withdrawal 
symptoms they had observed, both in hospital and at home, from a 24-item withdrawal 
symptom checklist (Sophia Benzodiazepine and Opioid Withdrawal Checklist).12 The 
second aim was to gain insight in parents’ views on the feasibility of weaning at home. 
Statistical analysis
The data were analyzed using SPSS for Windows (version 14.0.1; SPSS Inc., Chicago, IL, 
USA). With regard to drug administration we calculated total duration of administration 
(days), and mean doses (mcg/kg/hr). We distinguished three patient groups: weaned 
before discharge, transferred to other hospital and weaned at home (see Figure 1). Mean 
doses of midazolam and morphine for these groups were compared with the nonparametric 
Kruskal-Wallis test. 
Results
In the three-year study period, 30 neonates with CDH (20 boys, 10 girls) underwent 
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ECMO treatment (see Figure 1). Fifteen of them died during hospitalization due to 
therapy resistant pulmonary hypertension with a variable amount of pulmonary 
hypoplasia. Table 1 summarizes doses and durations of sedatives and analgesics 
administered to the 15 survivors. The mean infusion rates of midazolam and morphine for 
the weaned at home group were significantly higher than those for the two other groups 
(Midazolam: Kruskal-Wallis, Chi-Square = 7.44, df = 2, p = 0.024; Morphine: Kruskal-Wallis, 
Chi-Square = 6.86, df = 2, p = 0.032). Clonidine and methadone were almost exclusively 
administered to the patients who were weaned at home. 
Five survivors were transferred to other hospitals for additional treatment, of whom 
three required further weaning. One of these five had been judged eligible for home 
weaning, but the parents nevertheless could not face the responsibility. This child was 
weaned in the other hospital within 6 weeks after transfer. The other two patients were 
lost to follow-up. 
Five of the remaining ten infants were weaned in hospital before discharge home. The 
other five were weaned at home from various combinations of methadone, midazolam, 
clonidine and alimemazine (Table 2). Successful weaning at home took respectively 
11, 42, 107, 173 and 180 days (Table 2). Parents most commonly identified withdrawal 
symptoms such as agitation, inconsolable crying, increased muscle tension, sweating and 
mottling during hospital stay. At home, parents reported inconsolable crying, agitation, 
sleeplessness and irritability as occasional withdrawal symptoms, especially on days when 
doses were tapered off. This necessitated dosages for two patients to be kept at the same 
level for two weeks because of serious withdrawal symptoms. 
Parents of the five patients weaned at home quite appreciated the support from our 
quarters, including the weekly telephone consultations with a pediatric intensivist. 
Figure 1 Flowchart patients
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Table 1 Medication (sedatives and analgesics) during hospital stay of survivors (N = 15)
Table 2 Weaning medication at home (N=5)
Type of sedatives / analgesics PICU stay 
(days)
Duration of 
home weaning 
(days)Midazolam Methadone Clonidine Alimemazine
Patient 1 X X X 44 11
Patient 2 X 73 42
Patient 3 X X 167 107
Patient 4 X X X 136 173
Patient 5 X X X X 184 180
X  type of agent weaned at home
Transferred to other 
hospital 
(N=5)
Weaned before discharge 
(N=5)
Weaned at home 
(N=5)
Continuous
(mcg/kg/hr)
Bolus
(mg/kg/day)
Continuous
(mcg/kg/hr)
Bolus
(mg/kg/day)
Continuous
(mcg/kg/hr)
Bolus
(mg/kg/day)
Midazolam
Mean doses 105 (83 - 318) 2 (0.2 - 3.9) 110 (81 - 180) 0.3 (0.1 - 0.9) 285 (196 - 330) 5 (0.4 - 10)
Duration (days) 10 (9 - 37) 2 (1 - 46) 21 (6 - 29) 6 (3-13) 32 (29 - 88) 66 (4 - 128)
N 5 3 5 5 5 5
Clonidine
Mean doses 0.15 2.9 0.3 (0.3 - 0.5) 8.1 (5.4 - 14.3)
Duration (days) 25 37 27 (22 - 40) 74 (20 - 114)
N 1 1 3 4
Morphine
Mean doses 9.8 (7 - 23.9) 0.02 10.5 (4.9 - 17) 23.3(15.4 - 36.2) 0.1 (0.07 - 0.7)
Duration (days) 13 (7 - 55) 4 15 (10 - 25) 53 (30 - 64) 3 (1 - 13)
N 5 1 5 5 4
Fentanyl
Mean doses 2.6 10 (1.7 - 16.2)* 6.6 (5.7-16.2)* 2.3 (1.5 - 3) 8.3 (6.3 - 12.9)*
Duration (days) 11 4 (1 - 24) 6 (3 - 9) 19 (10 - 28) 18 (2 - 62)
N 1 5 5 2 5
Methadone
Mean doses 1.2 0.6 (0.3 - 3.9)
Duration (days) 43 78 (19 - 128)
N 1 4
* Mean doses fentanyl bolus in mcg/kg/day, mean doses and duration: median (min-max)
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Discussion 
Prolonged exposure to benzodiazepines, opioids and other sedatives has been associated 
with withdrawal syndrome after abrupt cessation or too rapid tapering off. Our study 
showed that parents can cope with weaning at home, provided they are given structural 
medical back up. This is in line with the findings demonstrated in three cases by Tobias 
et al.9  
Methadone is used increasingly for treatment of opioids withdrawal in infants and 
children because of its demonstrated efficacy in opioid-dependent adults and infants 
of drug-addicted mothers. Its enteral administration is easy and it has a long duration 
of action. Several methadone weaning strategies in PICU patients have been studied 
prospectively in the past years. These strategies largely vary, however, as they are determined 
by duration of exposure, type of opioid and practitioner bias and preference.7,10,13 Robertson 
et al.13 used a weaning strategy based on duration of exposure. This strategy involved a 
20% daily decrease of methadone dose for patients who had been exposed to opioids for 
7 - 14 days, and a 20% decrease every other day for patients exposed longer than 14 days. 
Successful weaning was achieved in 80% percent (16/20), i.e. with minimal withdrawal 
symptoms regardless of duration of weaning. Another study showed successful weaning 
from opioids without withdrawal symptoms in 25 of 29 patients over a 10-day period 
(NAS < 8).10 These patients had received fentanyl for 14.5 ± 9.2 days. Sixteen of them had 
been discharged to complete their weaning schedule at home, but withdrawal symptoms 
were not assessed at home. Berens et al.7 performed a RCT comparing two systematic 
opioid weaning protocols in critically ill children at high risk for opioid withdrawal. They 
found that opioid-tolerant children could be weaned with oral methadone as effectively 
in 5 days as in 10 days. Effects of benzodiazepines withdrawal were mostly not taken 
along in these studies. Moreover, patients in these studies had been exposed to opioids 
for much shorter times (mean 36 days) than the patients weaned at home in our study 
(median 53  days). Therefore, weaning strategies must be performed carefully in infants 
after ECMO therapy. 
The first step in preventing withdrawal syndrome is the identification of risk factors. For 
children in intensive care these factors include high cumulative doses of benzodiazepines 
and/or opioids,14,15 long exposure to these drugs, and long duration of ECMO therapy.3,16
The next step is careful monitoring of patients found to be at risk of withdrawal 
symptoms, preferably with the help of an assessment tool. The Neonatal Abstinence Score 
(NAS) is commonly used.17 This tool, however, is only applicable for opioid withdrawal. 
As pediatric patients are also given benzodiazepines, with risk of withdrawal symptoms 
as well, we have proposed an assessment tool sensitive enough to assess both opioids and 
benzodiazepines withdrawal symptoms.2 
A weaning strategy for gradual decreasing opioid and benzodiazepine dosages is 
essential to prevent withdrawal symptoms. Strategy options include slowly tapering 
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off the intravenous infusion rate over time or using an alternative route, like the 
subcutaneous or enteral routes. Subcutaneous administration of fentanyl and midazolam 
has been described in PICU patients.18 This may be helpful for children who are not yet 
tolerating enteral nutrition. In line with several other authors we prefer the enteral route 
for prevention of opioid and benzodiazepine withdrawal because it provides for reliable 
symptom control and allows for discharge home to complete weaning.1,10 
Based on our experience we proposed the following steps to wean children from 
long-term high-dose sedatives and opioids administered by continuous infusion: a) replace 
intravenous route by enteral route; b) gradually decrease doses by 15 to 20% of initial dose 
per 72 of 96 hours; c) wean one agent at a time; d) weaning sedatives first, then opioids 
(Figure 2). At each step in the weaning process, possible withdrawal symptoms should be 
carefully monitoring with the help of a validated assessment tool applied by nurses in the 
clinical setting and by parents in the home situation. 
Conclusion
Final weaning at home with the aid of weekly telephone consultations with a pediatric 
intensivist was satisfying for these parents. Nevertheless, they still observed withdrawal 
symptoms. Weaning of sedation is usually completed in hospital, but home weaning 
reduces length of hospital stay by a median of 107 days in the five infants presented in this 
study. This resulted in a € 156,220 reduction of health care related costs. Parents should 
be well informed about the nature of withdrawal symptoms and how to observe these. 
Parental use of an observation tool such as the SBOWC is highly recommended.
Weaning of opioids and benzodiazepines at home
119
Figure 2 Proposed weaning algorithm
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Prologue
The papers presented in this thesis basically concern the question how to provide optimal, 
consistent sedation and prevent withdrawal in critically ill children - with an important 
role for the intensive care (IC) nurse. 
The overall aims of this thesis were twofold. First, to study strategies by which nurses 
can accurately assess level of sedation in pediatric intensive care patients. Second, to 
develop a valid and reliable scoring system for possible withdrawal symptoms after 
long‑term administration of benzodiazepines and opioids. This final chapter evaluates 
the main findings in relation to other studies and gives suggestions for further research. 
What have we learned?
Sedation in critically ill children
In the past decades, several sedation scales have been developed for PICU patients. These 
are reviewed in Chapter 2. 
COMFORT scale
At the time when the studies in this thesis were planned, the COMFORT scale was the 
most used instrument for assessing pain and sedation level in ventilated children.1 
This observational scale consists of two physiological items - Heart rate and Arterial 
blood pressure - and six behavioral items - Alertness, Calmness/Agitation, Respiratory 
response, Physical movement, Muscle tension and Facial tension. The COMFORT scale 
was originally designed and validated for measuring discomfort in ventilated pediatric 
patients2,3 and later also validated for postoperative pain.4 The COMFORT scale - or the 
adapted version for postoperative use, COMFORT behavior scale, which does not include 
the two physiological items - has been applied in a number of randomized controlled 
trials comparing different types of analgesics or sedatives. Many psychometric properties 
of this scale have been tested,5 but some essential information, for instance on sensitivity 
to change, is still lacking. Validation of scales should therefore be an ongoing process. We 
chose to use the COMFORT behavior scale because assessment of mean arterial pressure 
and heart rate would require comparison with baseline values. In critically ill children, 
however, ‘true’ baseline values may be confounded by for instance medication such as 
inotropics, or other confounding variables. 
COMFORT behavior scale
In chapter 2 we studied the relationship between behavioral and physiological items of the 
COMFORT scale in a large sample of PICU patients (N = 78) and calculated cutoff scores 
General discussion
123
after having excluded the physiological items. Nurses’ interrater reliability proved to be 
good, and so was internal consistency, which increased to 0.84 when both physiological 
items were excluded. Furthermore, concurrent validity of the COMFORT behavior scale 
was tested by comparison with a ‘silver criterion’, the Nurse Interpretation of Sedation 
Score (NISS). COMFORT scores were significantly different for the three categories of the 
NISS, indicating good concurrent validity. 
Cutoff points that may guide treatment are essential to improve the clinical utility 
of the COMFORT behavior scale. Nevertheless, as well-sedated children do not always 
show unambiguous behavior, it seemed more realistic to define score ranges rather than 
cutoff points. Score range 6 ‑ 10 was defined to indicate oversedation; score range 23 ‑ 30 
was defined to indicate undersedation. Score range 11 ‑ 22 was defined as a grey area in 
which a second assessment, for example NISS, is recommended for clinical purposes. We 
concluded that the COMFORT behavior scale in the PICU setting is reliable and valid to 
assess children’s wellbeing on a sliding scale from comfort to distress or pain. 
New sedation tool; State Behavioral Scale versus COMFORT behavior scale
In 2006 Curley and colleagues developed a new sedation assessment tool for mechanically 
ventilated children, the State Behavioral Scale (SBS).6 The SBS appraises seven behavioral 
dimensions; ‘Respiratory drive/ response to ventilation’, ‘Coughing’, ‘Best response to 
stimulation’, ‘Attentiveness to care provider’, ‘Tolerance to care’, ‘Consolability’ and 
‘Movement after consoled’. 
The psychometric properties of the SBS are presented in Table 1 for comparison with 
the original COMFORT scale and the COMFORT behavior scale. Curley et al.6 tested its 
reliability and validity in 198 paired assessments in 91 children aged 6 weeks to 6 years old. 
The weighted kappa ranged from 0.44 (consolability) to 0.76 (respiratory drive) for the 
seven SBS dimensions, indicating low to moderate interrater agreement. Cluster analysis 
yielded five distinct state profiles, with mean numeric rating scale (NRS) ratings of 1.1, 
2.5, 4.0, 5.3 and 7.6. The five profiles of each dimensions were significant different with 
the mean scores on the NRS. With this, the authors supported the discriminant validity 
of the SBS.
One drawback of the SBS is the necessity of a progressive stimulus with an incremental 
level (from ‘say patient name aloud’ to endotracheal suctioning or nail bed pressure). It 
would seem unethical, for example, to apply nail bed pressure to obtain a reaction from 
a sleeping child. Furthermore, when the assessment is not performed during suctioning, 
the observer has to ask the bedside nurse to score this item based on the last suctioning 
procedure. This may lead to information bias. 
Some categories in the SBS and the COMFORT behavior scale share several items. The 
latter, however, has the advantage of being applicable in non-ventilated high care patients as 
well. In future research it may be interesting to study both scales simultaneously and compare 
their psychometric properties in situations such as weaning from mechanical ventilation.
Ch
ap
te
r 
9
124
Ta
bl
e 
1 C
ha
ra
ct
er
is
tic
s o
f t
he
 C
O
M
FO
RT
 (b
eh
av
io
r)
 sc
al
e 
an
d 
th
e 
St
at
e 
Be
ha
vi
or
 S
ca
le
In
st
ru
m
en
t
Pa
ra
m
et
er
 
m
ea
su
re
d
Po
pu
la
ti
on
(a
ge
)
Ex
cl
us
io
n 
cr
ite
ri
a
O
bs
er
va
ti
on
 it
em
s
Sc
or
e 
ra
ng
e
Ps
yc
ho
m
et
ri
c 
pr
op
er
ti
es
C
ut
off
 
po
in
ts
It
em
 /
 T
ot
al
Re
lia
bi
lit
y
Va
lid
it
y
CO
M
FO
RT
 
sc
al
e2
,3
D
is
tr
es
s
37 (n
ew
bo
rn
 to
 17
 y
rs
)
Se
ri
ou
sl
y 
co
m
pr
om
is
ed
 
ne
ur
ol
og
ic
al
 st
at
us
a , 
Pr
of
ou
nd
 m
en
ta
l 
re
ta
rd
at
io
n,
 
Re
ce
nt
 m
ul
ti
pl
e 
tr
au
m
a,
A
lte
re
d 
m
us
cl
e 
to
n 
or
 
co
nt
ra
ct
ur
es
,
Se
ve
re
 a
cu
te
 p
ai
n
H
ea
rt
 ra
te
,
M
ea
n 
ar
te
ri
al
 
pr
es
su
re
,
A
le
rt
ne
ss
,
C
al
m
ne
ss
/a
gi
ta
ti
on
,
Re
sp
ir
at
or
y 
re
sp
on
se
,
Ph
ys
ic
al
 m
ov
em
en
t,
M
us
cl
e 
to
ne
,
Fa
ci
al
 e
xp
re
ss
io
n
N
um
er
ic
al
It
em
: 1
 to
 5
To
ta
l: 
8 
to
 
40
r =
 0
.8
4;
 p
 <
 0
.0
1 
(n
 =
 50
 p
ai
re
d 
ob
s)
 C
O
M
FO
RT
 
vs
. V
A
S
r =
 0
.7
5;
 p
 <
 0.
01
O
S 
≤ 
16
A
S 
17
 - 2
9
U
S 
≥ 
30
CO
M
FO
RT
 
be
ha
vi
or
 
sc
al
e7
D
is
tr
es
s 
/ 
se
da
ti
on
78 (0
 t
o 
16
 y
rs
)
C
hi
ld
re
n 
w
it
h 
se
ve
re
 
m
en
ta
l r
et
ar
da
ti
on
,
C
hi
ld
re
n 
w
it
h 
se
ve
re
 
hy
po
to
ni
a,
 
Pa
ti
en
ts
 re
ce
iv
in
g 
ne
ur
om
us
cu
la
r b
lo
ck
ad
e
A
le
rt
ne
ss
,
C
al
m
ne
ss
/a
gi
ta
ti
on
,
Re
sp
ir
at
or
y 
re
sp
on
se
 
or
 c
ry
in
g,
Ph
ys
ic
al
 m
ov
em
en
t,
M
us
cl
e 
to
ne
,
Fa
ci
al
 te
ns
io
n
N
um
er
ic
al
It
em
: 1
 to
 5
To
ta
l: 
6 
to
 
30
K
ap
pa
 =
 0
.7
7 -
 1.
0 
(n
 =
 4
0 
pa
ir
ed
 o
bs
)
IC
C
 =
 0
.9
9
CO
M
FO
RT
 
be
ha
vi
or
 v
s.
 
N
IS
S
(K
ru
sk
al
-
W
al
lis
, 
p 
< 
0.
00
1)
O
S 
≤ 
10
A
S 
11 
- 2
2
U
S 
≥ 
23
St
at
e 
Be
ha
vi
or
al
 
Sc
al
e6
Se
da
ti
on
/ 
ag
it
at
io
n 
le
ve
l
91 (6
 w
ks
 t
o 
6 
yr
s)
Pa
ti
en
ts
 re
ce
iv
in
g
ne
ur
om
us
cu
la
r b
lo
ck
ad
e,
Po
st
op
er
at
iv
e 
pa
ti
en
ts
,
Pa
ti
en
ts
 a
ss
es
se
d 
to
 b
e 
in
 p
ai
n,
U
ns
ta
bl
e 
pa
ti
en
ts
,
Pa
ti
en
ts
 a
t r
is
k 
fo
r o
pi
oi
d 
w
it
hd
ra
w
al
Re
sp
ir
at
or
y 
dr
iv
e,
C
ou
gh
in
g,
Be
st
 re
sp
on
se
 to
 
st
im
ul
at
io
n,
A
tt
en
tiv
en
es
s t
o 
ca
re
 
pr
ov
id
er
,
To
le
ra
nc
e 
to
 c
ar
e,
C
on
so
la
bi
lit
y,
M
ov
em
en
t a
ft
er
 
co
ns
ol
ed
Bi
po
la
r 
nu
m
er
ic
It
em
: -
3 
to
 +
1
To
ta
l: 
-2
1 
to
 7
K
ap
pa
 =
 0
.4
4 
 ‑ 
0.
76
 
(n
 =
 19
8 
pa
ir
ed
 o
bs
)
IC
C
 =
 0
.7
9
SB
S 
vs
. N
RS
(F
 =
 75
.8
, 
p 
< 
0.
00
1)
 
N
ot
 d
on
e
PI
CU
 p
ed
ia
tr
ic
 in
te
ns
iv
e 
ca
re
 u
ni
t, 
VA
S 
vi
su
al
 a
na
lo
gu
e 
sc
al
e,
 N
IS
S,
 n
ur
se
 in
te
rp
re
ta
tio
n 
of
 s
ed
at
io
n 
sc
or
e,
 S
BS
 s
ta
te
 b
eh
av
io
ra
l s
ca
le
, N
RS
 n
um
er
ic
 r
at
in
g 
sc
al
e,
 K
ap
pa
 
lin
ea
rly
 w
ei
gh
te
d 
Co
he
n’
s k
ap
pa
, r
 p
ea
rs
on
 p
ro
du
ct
 co
rr
el
at
io
n 
co
effi
ci
en
t,
 yr
s y
ea
rs
, w
ks
 w
ee
ks
, o
bs
 o
bs
er
va
tio
ns
, O
S o
ve
rs
ed
at
io
n,
 A
S a
de
qu
at
e s
ed
at
io
n,
 U
S 
un
de
rs
ed
at
io
n,
 
IC
C
 in
tr
ac
la
ss
 c
or
re
la
ti
on
 c
oe
ffi
ci
en
t,
 v
s.
 v
er
su
s
General discussion
125
Sedation protocol
International sedation guidelines promote the use of standardized assessment of sedation 
levels, both in adults and children.8,9 Still, the level of evidence is relatively low due to 
the lack of appropriately conducted randomized controlled trials (RCTs). To improve 
effectiveness, assessment should be incorporated in a sedation protocol or algorithm. An 
additional advantage of this strategy is standardized treatment that does not depend on 
the caregiving nurse or doctor’s attitude towards sedation. 
In the past years we have seen growing attention to evidence-based practice in nursing 
(and especially in intensive care). Nurses appear to obtain knowledge from policy and 
procedure manuals rather than from (research) literature.10 It follows that protocols 
and care pathways must be evidence-based, relevant to local contexts and readily 
accessible to nurses. Several studies support the use of nurse-implemented protocols 
and guidelines of weaning sedatives or ventilation both in adult11‑16 and pediatric ICUs.17-20 
Some of these studies indeed report significant decreases in dosages of sedatives and 
duration of mechanical ventilation in adults11,16 and children18 after implementation of a 
nurse-implemented sedation protocol. 
Supported by the literature and the need felt in clinical practice, we developed our 
own sedation protocol. 
This sedation protocol shown in Chapter 3 provides decision trees for increasing 
or weaning of sedatives and analgesics in both hemodynamically stable and unstable 
patients. It standardizes sedation management and allows nurses themselves to adapt 
medication based on COMFORT behavior and NISS scores. 
Midazolam and morphine dosages increased significantly after implementation of 
this sedation protocol. The implications of these dosage changes are hard to define. Our 
studies did not consider the effects on duration of mechanical ventilation and length of 
ICU stay. Adult studies have shown that daily interruption of sedatives decreases duration 
of mechanical ventilation and length of ICU stay.21,22 Future RCTs are needed to study the 
effects of daily interruption in critically ill children. Nurses may be reluctant, however, 
to apply such a ‘drug holiday’, feeling that waking up ventilated critically ill children is 
inhumane. Good communication may solve this problem. 
Implementation of the sedation protocol also increased the proportion of ‘adequately 
sedated’ assessments according to the COMFORT behavior scale, i.e. from 63% to 75%. 
On the other hand, the proportion of assessments indicating ‘oversedated’ decreased 
from 36% to 23%. Eighty per cent of the nurses who completed a questionnaire on the 
sedation protocol considered it useful and clear. 
Although staff in general was satisfied with the sedation protocol, this was no 
guarantee of strict adherence. We found that in more than 50% of assessments indicating 
undersedation the infusion rate was not increased according to the protocol. We 
conclude, therefore, that adherence is far from perfect. There are several possible reasons 
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for violations of the treatment algorithm. An important question is: Why don’t nurses 
and physicians adhere to protocols and standardized care? Evidently, in some instances 
it may be unavoidable to deviate from the protocol, but caregivers may also prefer their 
own treatment plan, based on intuition and previous experiences. Furthermore, studies 
have shown that adherence to sedation protocols23,24 may be hampered by differences in 
values between protocol’s developers and its users, ignorance of aspects of a protocol, 
and nurses being uneasy with the responsibility for medication changes without specific 
doctor’s order.23‑26 
Another important role for nurses lies in the application of non-pharmacological 
interventions as complementary treatment. This strategy should be part of standard 
nursing care; we speculate these interventions may be so effective that sedatives dosing 
can be reduced. Generally, there is a choice of music therapy, distraction, aromatherapy, 
and massage therapy.9,27-30 Massage and music therapy have been found to decrease anxiety 
in critically ill adults.31-34 We feel distraction should be offered to children in collaboration 
with the play specialist. Nevertheless, non-pharmacological interventions are not often 
used in our ICU. This may be due to several factors, such as insufficient knowledge, lack 
of evidence, and attitude of nurses regarding the usefulness of complementary treatment. 
Recently, however, a randomized controlled trial was started in our ICU to compare 
aromatherapy and massage. This study stimulated the use of massage outside this trial 
as well. 
Another strategy nurses may apply is adaptation of the environment, like noise 
reduction. Noise is a major environmental factor to cause anxiety and sleep disturbance 
in critically ill patients.35,36 In a way, noise reduction could well be effective in decreasing 
anxiety.  It would be worthwhile, therefore, to reduce noise in the PICU as much as possible, 
so as to create a comfortably calm environment for child and parents. 
Bispectral index monitor
Although behavioral sedation scoring tools are valid and reliable, they do not allow 
continuous evaluation of level of sedation or agitation. The bispectral index (BIS) 
monitor continuously measures level of consciousness. This method has been extensively 
investigated in children older than 1 year. We studied the BIS monitor in younger infants, 
divided into two groups: postoperative sedation and natural sleep (without sedatives). 
In the postoperative sedation group we found a moderate overall correlation (rs = 0.50) 
between BIS monitor and COMFORT behavior scale. In the natural sleep group, this 
correlation for infants 6 to 12 months (rs = 0.72) was better than that for younger infants 
(rs = 0.62). This suggests that assessing pharmacological sedation with the BIS monitor 
may be less reliable in infants less than 1 year old. Possibly these children’s EEG pattern 
deviates too much from the adult pattern on which the BIS is based. This forms the most 
important limitation for the use of BIS monitor in infants.37-39 Until this major flaw has 
been amended and a specific BIS algorithm for this age group has been established, 
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the routine use of the BIS monitor for assessing sedation in children under one year is 
questionable. Rather than the absolute values, trends in BIS values are potentially more 
useful in daily clinical practice. 
Withdrawal symptoms
Benzodiazepine and opioid withdrawal syndrome remains a significant problem in the 
PICU, despite increased caregivers’ awareness and measures taken to prevent it. The 
reported incidence of withdrawal syndrome in pediatric ICU patients ranges from 35% 
to 57%.40,41 Better understanding of the occurrence of withdrawal symptoms and the 
risk factors involved is needed. To bridge the knowledge gap, we performed the series of 
studies presented in the second part of this thesis (Chapter 5 - 8). 
We started our ‘expedition’ with a literature review that revealed the broad spectrum 
of opioid and benzodiazepine withdrawal symptoms (Chapter 5). The review yielded 
24 such symptoms observable in children in a PICU. Symptoms such as agitation, 
anxiety, tremors, insomnia, fever, sweating, and tachycardia have been described for both 
benzodiazepines and opioids withdrawal. Symptoms such as seizure and hallucinations 
have only been observed as benzodiazepine withdrawal.
Generalization of the identified withdrawal symptoms is hampered by the fact that 
most are based on case series and case reports, and consequently on small numbers of 
patients. Furthermore, most studies considered only a few withdrawal symptoms and 
did not relate symptoms to times when medication was tapered off. Thus, representative 
incidence numbers of the full spectrum of withdrawal symptoms are lacking. Our next 
step, therefore, was a prospective study aimed at quantifying the withdrawal symptoms 
listed in this review, because earlier studies gave insufficient insight in the real incidence 
of withdrawal syndrome on the PICU.
Incidence and risk factors 
In Chapter 6, the 24‑items Sophia Benzodiazepine & Opioid Withdrawal Checklist 
(SBOWC) was used to assess the occurrence of withdrawal symptoms in practice. We created 
two subgroups of observations. First, a ‘weaning group’, observations obtained within 24 
hours after decrease and/or discontinuation of midazolam and/or opioids. Second, an 
‘unsuccessful weaning’ group. These observations were obtained before midazolam and/
or opioids were increased in order to counteract possible withdrawal related symptoms. A 
particular set of symptoms stood out clearly in a so-called ‘unsuccessful weaning’ group. 
These symptoms were: agitation, increased muscle tension, anxiety, grimacing, sleeping 
less than 1 hour, poor feeding and tachypnea. Although symptoms such as tremors, 
hallucinations and seizures were rare, they may still have a high positive predictive value.
We found statistically significant correlations between duration of use and total dose 
of midazolam administration on the one hand, and maximum SBOWC sum score on the 
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other hand (respectively 0.52 and 0.51). The correlation between total dose of opioids and 
maximum sum score (rs = 0.39) was moderate. We conclude that both longer duration of 
administration and higher total doses of midazolam and opioids are clearly related with 
the occurrence of withdrawal symptoms, and may therefore be considered risk factors. 
These findings are in line with other studies.40-43 We suggest that tapering off (weaning) 
too rapidly increases the risk of withdrawal symptoms. Thus, strategies to reduce the 
incidence of withdrawal symptoms should begin by making efforts to reduce doses of 
benzodiazepines and/or opioids. Based on a few prospective studies several authors 
recommend a daily tapering rate of 10 ‑ 20% for children on benzodiazepines and/or 
opioids for more than 5 to 7 days.43‑46  This strategy, however, did not prevent withdrawal 
symptoms in these studies. There is a great need for effective weaning strategies in clinical 
practice, which can be used in a PICU, general hospital or in particular circumstances at 
home. For home weaning we proposed a strategy in Chapter 7, based on our experience. 
Withdrawal symptoms scoring tool
For objective assessment of withdrawal symptoms, nurses cannot do without a valid and 
sensitive tool. Our literature review nevertheless revealed that a good assessment tool for 
clinical use in children is lacking. The Opioid Benzodiazepine Withdrawal Scale (OBWS) 
is the only tool with prospective validation, but regrettably shows low sensitivity.43 Our 
next step, therefore, was constructing a new scale, the Sophia Observation withdrawal 
Symptoms-scale (SOS). It is based on the underlying empirical structure of co-occurrences 
of all previously identified 24 withdrawal symptoms. In addition, experts (physicians and 
PICU nurses) were asked to indicate relevant and essential symptoms. The final construct 
contained 15 symptoms. The co-occurrences of these symptoms could be adequately 
represented in a three-dimensional solution. Nevertheless, the heterogeneity suggested 
that the symptoms did not constitute homogeneous clusters within the three-dimensional 
solution, indicating that withdrawal symptoms vary from patient to patient in number, 
severity and presentation. Many PICU patients, however, show relatively subtle clinical 
symptoms that can easily be confused with responses to other factors in the PICU. Symptoms 
such as agitation, anxiety, insomnia, irritability, fever, tachycardia, hypertension, and 
sweating are also expressions in response to inadequate sedation or pain management, 
ventilator distress, infection, noisy environment, paradoxical reactions, or delirium.36,47‑50 
These key confounders may mask withdrawal symptoms. We maintain that the diagnosis 
of withdrawal symptoms remains one of exclusion and must be time-related to decrease 
or cessation of benzodiazepines and/or opioids. 
After data collection for the study in Chapter 6, we continued to collect SOS scores in 
daily practice.  The aim was to determine a cutoff for high probability of withdrawal as well 
as the tool’s sensitivity to change. Between July 2006 and November 2007, 440 SOS scores 
in 16 children with a median age of 6 months (range 0  to 74) were collected. SOS scores of 
4 (75th percentile) or higher were taken to reflect a high probability of withdrawal. 
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Sensitivity to change was confirmed in 26 paired observations before and after 
administration of extra sedation (e.g. midazolam, morphine, clonidine, alimemazine) and 
showed that: the median SOS score significantly decreased from 6 to 2 (Mann‑Whitney 
test, Z = -5.79, p < 0.0001). In future research, we will explore interrater reliability more 
extensively. To this aim, we will collect videotaped material of patients with varying levels 
of withdrawal. This material will be observed and scored with the SOS by at least eight 
experienced PICU nurses. Also, we will collect more data to test sensitivity to change. 
Recently, a new withdrawal assessment tool has been developed and tested in pediatric 
ICU patients, the Withdrawal Assessment Tool version-1 (WAT-1).51 Table 2 presents 
characteristics of this tool, side by side with those of the SOS. Reliability and validity 
of both instruments look promising. Validation is a never-ending process and it will be 
worthwhile to compare the two instruments in a multicenter study. 
Transition of care - weaning at home
In selected cases, children do no longer need medical treatment for their primary disease, 
but remain in hospital, or even in the ICU, for weaning of sedatives or opioids. We assumed 
that some of these children could be discharged earlier, to continue stepwise weaning at 
home, albeit supervised by a pediatric intensivist. 
We studied the feasibility of this approach in a selective patient group, infants with 
congenital diaphragmatic hernia treated with extra corporeal membrane oxygenation. 
They were at risk for development of withdrawal symptoms. Final weaning at home with 
the aid of weekly telephone consultations with a pediatric intensivist proved satisfying for 
parents. Nevertheless, some of these children still showed withdrawal symptoms. For the 
five studied infants home weaning reduced hospital stay by a median of 107 days, which 
is beneficial for child and parents and reduces costs of hospitalization. We feel it would 
help parents to apply the SOS as a helpful checklist. Then, if symptoms are confirmed, the 
proposed weaning schedule could be adjusted. 
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Table 2 Characteristics of the SOS and the WAT-1
SOS - Sophia Observation 
withdrawal Symptoms-scale 
WAT-1 Withdrawal Assessment 
Tool - version 151
Scale symptoms Tachycardia Loose /watery stools
Tachypnea Vomiting/retching/gagging
Fever (≥ 38.5°C) Temperature > 37.8°C
Sweating State*
Agitation Tremor
Anxiety Sweating
Tremors Uncoordinated/repetitive movement
Increased muscle tension Yawning of sneezing
Inconsolable crying Startle to touch
Grimacing Time to gain calm state (SBS ≤ 0)
Sleeplessness 
Motor disturbance:
Slight muscle jerks/twitching or
Uncontrolled, robust movements
•
•
Hallucinations
Vomiting
Diarrhea
Number of items 15 11
Total score 0 - 15 0 - 12
Time to assess 2 minutes 7 minutes 
How information 
obtained? 
Patient record, observation (most 
extreme moment during past 4 hours)
Patient record, observation during: 
pre-stimulus, stimulus, post-
stimulus
Instructions provided? Yes Yes
Psychometric evaluation
Number of patients 79 83
Age patients 3.4 months (0 ‑ 16 years)† 35 months (7 months  - 10 years)‡
Number of observations 932 1040
Number of centers 
included
1 2
Reliability
Internal consistency MDS, 3 dimensions PRINCALS, 4 factors
Interrater N=23 paired observations
ICC = 0.97 (95% CI 0.92 to 0.99)
Cohen’s kappa = 0.73 - 1.0 (items)
N=30 paired observations
ICC = 0.98
Cohen’s kappa = 0.80 
Validity
Content 85 experts ND
Construct + ∞ sen.= 0.87, spec. = 0.88
Sensitivity to change + ND
Cutoff point SOS ≥ 4 WAT‑1 score ≥ 3
Advantages Development based on empirical 
structure of co-occurrences and expert 
opinions
Multi centre 
Disadvantages Single centre Stimulation (painful) required
*(asleep/awake/calm or awake/distressed), SBS state behavioral scale6, sen. sensitivity, spec. specificity, ND 
not done, † median (range), ‡ median (IQR), MDS multidimensional scaling, PRINCALS principle components 
analysis, ∞ significant correlations between total doses of midazolam /opioids and maximum sum score of 
withdrawal symptoms52
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Future research perspectives
The studies in this thesis are part of a larger series of pain and sedation studies from our 
research group since 1993. On the whole, they have resulted in pain and sedation tools 
for different groups of patients. In addition, pharmacological studies have improved our 
knowledge on pharmacokinetics and pharmacodynamics in the developing human being. 
We hope this thesis will be a source of inspiration for future studies. Several topics of 
interest present themselves.
Interrupting sedation by means of daily ‘wake-ups’, so-called drug holidays. These 
were found to shorten duration of sedation and ventilation in adult intensive care.22 
RCTs are needed to assess these effects in critically ill children. 
As discussed, several non-pharmacological interventions are recommended 
for sedation in children. Prospective studies should determine effects of these 
interventions on pain, distress, and sedatives administration. 
The use of methadone and clonidine as a means to counteract withdrawal symptoms 
has increased over the last few years - yet without solid data on pharmacokinetics, 
efficacy and side effects. This warrants further study.
We suggested that the SOS is a feasible scoring tool for withdrawal symptoms. 
Psychometric properties such as validity and reliability need to be established in 
prospective studies. 
Implementation of the SOS in all PICUs in the Netherlands could help increase our 
knowledge through multicenter studies. 
Epilogue
Providing comfort and minimizing anxiety in critically ill children is a very important part 
of our daily activities as IC nurses. In this thesis we point at possible means to accomplish 
this in clinical practice, namely assessment tools for sedation and withdrawal syndrome. 
Judicious use of these tools may indeed prevent inadequate sedation and recognize 
withdrawal syndrome in time. 
Fraser and Riker53 have remarked, ‘it may be time to add the evaluation of sedation, 
agitation and delirium to that of pain assessment, making all aspects of patients’ comfort 
to the fifth vital sign for the critically ill’.  We fully agree with this statement. Assessments 
of patients’ comfort should be done before and after a (non-)pharmacological intervention 
that affects level of comfort. We as IC nurses take care of critically ill children and partly 
replace the loving care of the parents. We succeed if they say: we’re happy to see our child 
so ‘comfortably calm’.
•
•
•
•
•
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Summary 
Critically ill children admitted to an intensive care unit (ICU) are bound to experience 
some degree of discomfort, distress and pain, more than in other settings in a children’s 
hospital. Inserting intravenous lines, catheters and tubes is a major source of these adverse 
effects. Other sources are: mechanical ventilation, suctioning of the ventilation tube, 
removing adhesive plasters and electrodes, as well as manipulating tubes and catheters. 
In addition, the child may feel threatened by the ICU environment, not being able to 
communicate, burdened by lights, sounds, noise of alarms going off, and unpredictable 
events. 
In order to achieve that children will experience ICU stay less consciously they 
will regularly receive sedatives, such as midazolam, and analgesics, such as morphine, 
fentanyl). 
One of the nurse’s responsibilities is observing the degree of discomfort and the effect 
of the sedatives and analgesics used. Adequate sedation is very important. Scoring tools 
may help to objectivize evaluation. This thesis explores how to best determine depth of 
sedation in children in an ICU. To this aim we evaluated the application of a scoring tool 
that assesses sedation depth from the child’s behavior, heart rate and blood pressure. In 
addition we explored the feasibility of developing a standard sedation guideline on the 
basis of an scoring tool. Finally we evaluated the usefulness of a brain function monitor 
for determining depth of sedation in young children. 
Long-term administration of sedatives and analgesics in critically ill children may lead 
to various complications. For example, too rapid tapering or abrupt discontinuation of 
this medication may result in withdrawal symptoms. We therefore studied frequencies of 
occurrence of withdrawal symptoms in critically ill children. On the basis of the findings 
we then developed a tool with which nurses can assess withdrawal symptoms. 
Sedation of critically ill children
In our studies, nurses assessed levels of sedation of critically ill children with the use of 
the COMFORT scale. This instrument was opted for because it is a multi-dimensional 
instrument including both behavioral and physiological stress indicators. The COMFORT 
scale, for that matter, was originally developed for this purpose. In clinical practice, 
however, the physiological indicators (heart rate and blood pressure) are influenced by 
many other factors as well, such as: severity of illness and use of drugs that raise blood 
pressure. 
In Chapter 2 we evaluated the psychometric properties of the COMFORT scale as well as 
the relation between behavioral and physiological indicators. We found that nurses were 
able to reliably observe level of sedation. Interrater reliability appeared to be satisfactory 
to good for all items of the COMFORT scale. 
In total 843 COMFORT scores were obtained for 78 children aged from 0 to 16 years. 
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The physiological stress indicators, i.e. ‘Heart rate’ and ‘Mean arterial blood pressure’ 
showed little variation between measurements. On the other hand we found low statistical 
correlation with the behavioral items of the COMFORT scale. These items are: ‘Alertness’, 
‘Calmness/Agitation’, ‘Respiratory response’ or ‘Crying’, ‘Physical movement’, ‘Facial 
tension’, and ‘Muscle tone’. We concluded that on the basis of the behavioral items, which 
form the COMFORT behavior scale, nurses are capable of assessing level of sedation in 
critically ill children in a reliable and valid manner. 
As a next step we defined new cutoff points for the COMFORT behavior scale. Score 
ranges 6 to 10 and 23 to 30 are associated with a high degree of certainty that a child is 
‘oversedated’ or ‘undersedated’, respectively. The intervening score range 11 to 22 forms a 
grey area that requires the nurse’s clinical expertise expressed in the Nurse’s Interpretation 
of Sedation Score (NISS). 
Chapter 3 describes the implementation of a sedation protocol in our pediatric ICU. 
The aim of a sedation protocol is twofold: on the one side setting uniform policy around 
sedation, and on the other side facilitating nurses to increase or decrease dosing of 
sedatives on the basis of the COMFORT behavior scale and the NISS. The ultimate goal is 
achieving adequate sedation of children in intensive care. 
The first step was implementing the COMFORT behavior scale as standard assessment 
tool for sedation. Next we developed a sedation protocol in the shape of decision-trees 
for increasing and decreasing dosing of sedatives and/ or analgesics, based on the cutoff 
points of the COMFORT behavior scale and the NISS. After implementation of the sedation 
protocol the use of sedatives and the application of the protocol was evaluated. Nurses’ 
routine assessment of sedation depth in critically ill children in intensive care appeared 
to be feasible. The first follow-up measurement showed that after implementation mean 
doses of midazolam and morphine had significantly increased. Correspondingly, the 
proportion of observations with the indication ‘adequately sedated’ rose from 63 to 75%. 
In almost half of the observations in which the patient was found undersedated on the 
basis of the cutoff points, doses of sedatives were increased on the guidance of the ‘increase 
decision-tree’. In very few observations medication was tapered off on the guidance of the 
‘decrease decision-tree’. In spite of the fact that the steps in the sedation protocol are not 
always followed correctly, the large majority of the nurses assert that the sedation protocol 
(decision-trees) is clear and well applicable in practice. 
 
It is of importance that nurses regularly assess level of sedation in children in intensive 
care. This should prevent complications or too deep or inadequate sedation. There is 
no gold standard, however, for the assessment of sedation in very young children or in 
children who cannot communicate verbally. Self-report is the gold standard for older 
children and adults. In our target group behavioral observation instruments are the 
only instruments so far. The COMFORT behavior scale is one of those. A relatively new 
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method to measure sedation depth is the brain function monitor. The bispectral index 
(BIS) monitor is a brain function monitor that can reflect depth of narcosis and sedation. 
The technique of the brain function monitor is based on the principle that the wave 
patterns of an electroencephalogram (EEG) change with different level of consciousness. 
If a person is deeply sedated, the frequency decreases and the amplitude increases. The 
monitor generates a number on a continuous scale of 0 - 100, with 0 indicating cortical 
electrical silence. The BIS has been extensively evaluated in adults and children during 
narcosis and during ICU stay. It proved valuable to this aim. Its use in children younger 
than one year staying in the IC is still underdocumented. In Chapter 4 we report a study 
on assessment of state of consciousness in two groups of children younger than one 
year. Assessment was both by the BIS and the COMFORT behavior scale. One group 
of 39 children was studied during postoperative sedation. Correlation between the BIS 
and the COMFORT behavior scale proved moderate. Further more it appeared that 
sedation level measured with the BIS corresponds best with the item ‘Alertness’ of the 
COMFORT behavior scale. This is not surprising, seeing that this item serves to assess 
state of consciousness. In the second group of 32 children in medium care we assessed 
state of consciousness during natural sleep state. BIS values were found to be less accurate 
in determining state of consciousness, especially in the younger children aged from 
0 to 6 months. As an illustration, when children were deeply asleep as assessed with the 
COMFORT behavior scale, the BIS monitor generated values indicative of an alert and 
awake child. We encountered the reverse of this phenomenon as well. From this study 
we concluded that in view of the typical EEG pattern of children younger than one year 
- deviating from that of older children and adults - the BIS is not reliable enough to serve 
as a gold standard for assessing level of sedation. 
Withdrawal in children in intensive care
Chapter 5 provides an overview of the English-language literature on withdrawal 
symptoms in children in intensive care and available instruments to ascertain this 
phenomenon in children aged from 0 to 16 years. An emphasis was placed on studies 
that describe symptoms of withdrawal as a consequence of long-term administration of 
benzodiazepines and/ or opiates. 
Long-term use of benzodiazepines and/or opiates may result in physical dependence 
and withdrawal symptoms. Withdrawal occurs when drugs (sedatives/analgesics) are 
tapered off too rapidly in children who have developed physical dependence. Symptoms of 
benzodiazepines- and opiates withdrawal can broadly be distinguished into three groups: 
overstimulation of the central nervous system (CNS) and autonomous disregulation. A 
third group is gastro-intestinal symptoms, which have only been described in opiates 
withdrawal. 
Two assessment tools have been designed to assess withdrawal symptoms in children: 
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Sedation Withdrawal Score (SWS) and the Opioid Benzodiazepine Withdrawal Scale 
(OBWS). We came to the conclusion that neither is sufficiently valid and reliable for use 
in the pediatric ICU. 
The literature search yielded 24 possible symptoms of withdrawal in the above 
mentioned three main categories. As a valid tool to assess frequencies of occurrence 
of withdrawal was lacking, we compiled a checklist including these 24 symptoms, the 
Sophia Benzodiazepine & Opioid Withdrawal Checklist (SBOWC). On the guidance 
of the SBOWC we performed 2188 observations in 79 children (Chapter 6). These 
children had been receiving midazolam, morphine or fentanyl for five days or longer. Of 
all observations, 932 had been performed within 24 hours after medication had been 
tapered off. CNS overstimulation symptoms anxiety, agitation, grimacing, disturbed sleep 
pattern, increased muscle tension, and movement disorder were observed in over 10% of 
observations. Of gastro-intestinal symptoms, diarrhea and food retention occurred most 
frequently. Tachypnea, fever, sweating and hypertension as symptoms of autonomous 
disregulation were observed in more than 13% of the observations. Furthermore, we 
established correlations between total amount of midazolam, duration of midazolam use 
and number of withdrawal symptoms (maximum sum score) per patient. This allowed us 
to conclude that longer duration of use and high dosing are risk factors for development 
of withdrawal symptoms in critically ill children. This study provided a comprehensive 
overview of frequencies of occurrence of all 24 different withdrawal symptoms after 
tapering off or cessation of benzodiazepines and/or opiates in children. It was concluded, 
too, that the SBOWC required further validation in order to develop it into a clinically 
useful tool. 
For this reason we performed a psychometric validation study on the basis of the 
SBOWC. Apart from psychometric evaluation, we aimed at reducing the number of 
symptoms included in the checklist, leaving only the essential ones in an assessment 
tool for withdrawal symptoms. The construction of the Sophia Observation withdrawal 
Symptoms-scale (SOS) is described in Chapter 7. The underlying clinical-empirical 
structure of the interrelationship of the 24 withdrawal symptoms was explored with a 
statistical method called multidimensional scaling (MDS). Input parameters were the 
observations made after weaning of medication in the preceding study (Chapter 6). 
Withdrawal symptoms such as ‘agitation’, ‘anxiety’, sleeplessness’, ‘movement disorder’ 
and ‘increased muscle tension’ showed the highest interrelationships. Nevertheless, the 
MDS analyses yielded insufficient evidence for reduction of number of symptoms. Some 
symptoms, such as ‘tremors’ and ‘hallucinations’, are very specific to withdrawal, but 
occurred infrequently. We therefore asked a panel of experts, both pediatric intensive 
care nurses and pediatric intensivists, to rate the relevance of each of the 24 withdrawal 
symptoms. By combining the results from this survey with the findings of the MDS 
analysis we were able to reduce the number of symptoms relevant to a withdrawal scale 
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to 15. This stepwise approach enabled us to construe the SOS in a meticulous manner. 
Further reduction of the number of withdrawal symptoms would seem inadvisable, as we 
know from experience that withdrawal in critically ill children has diverse manifestations. 
Further studies are required to validate the SOS and to define cutoff points to be included 
in a treatment algorithm that provides for adequate treatment of children showing 
withdrawal symptoms.
Research indicates that specific types of patients have higher risk of developing 
withdrawal symptoms. Higher risk is mainly associated with high dosing and long-
term administration of sedatives and analgesics administered to provide comfort. For 
example, newborns with congenital diaphragmatic hernia who undergo extra corporeal 
membrane oxygenation are at higher risk. Since 2003 these children may be eligible for 
earlier discharge from hospital, and continue gradual drug weaning at home under the 
supervision of a consultant pediatric intensivist. In weekly telephone calls the parents 
of these children report possible withdrawal symptoms, where upon recommendations 
on dose decreases are given. Chapter 8 reports the results of a first evaluation study 
among five children weaned at home. The strategy of final weaning with the aid of weekly 
telephone consultations with a consultant pediatric intensivist was feasible and satisfying 
for the parents involved. Weaning at home provides an opportunity to reduce length of 
hospital stay. In the future it would be advisable to ask parents to use the SOS in the home 
situation. 
In Chapter 9 the findings from the studies reported in this thesis are discussed with a 
view on future perspectives. 
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Samenvatting 
Het noodgedwongen verblijf van ernstig zieke kinderen op een intensive care (IC) afdeling 
is, meer nog dan in andere settings binnen een kinderziekenhuis, een bron van ongemak, 
onrust en pijn. Ze staan bloot aan een reeks pijnlijke en stressvolle prikkels, zoals het 
inbrengen van infusen, katheters en sondes, de beademing, het wegzuigen van slijm uit 
de beademingsbuis, en het verwijderen van pleisters en elektrodes. Daarbij kunnen ze 
onrustig worden door de hectiek van de kinder-IC   met alle licht, lawaai en onvoorspelbare 
gebeurtenissen. Daarbij zijn ze vaak ook nog in een positie waarin ze dit alles niet kunnen 
communiceren.
Om kinderen het verblijf op een IC minder bewust te laten ervaren krijgen ze 
regelmatig kalmerende middelen (sedativa, zoals midazolam) en pijnstillers (analgetica, 
zoals morfine, fentanyl) toegediend. Adequate sedatie is heel belangrijk. Een van de 
verantwoordelijkheden van de verpleegkundigen is dan ook het observeren van de mate 
van ongemak en het effect van de gebruikte sedativa en analgetica. Om dit te objectiveren 
kunnen speciale observatie-instrumenten worden gebruikt. In dit proefschrift hebben we 
onderzocht hoe de diepte van sedatie bij kinderen op een IC het best kan worden bepaald. 
Voor dit doel is de toepassing geëvalueerd van een observatie-instrument dat de mate 
van sedatie bepaalt aan de hand van gedrag, hartslag en bloeddruk van het kind. Tevens 
hebben we onderzocht of het mogelijk is om op basis van dit observatie-instrument een 
sedatierichtlijn te ontwikkelen. Tenslotte is gekeken of een hersenfunctiemonitor (BIS) 
bruikbaar is voor het bepalen van de diepte van sedatie bij jonge kinderen. 
Langdurige toediening van sedativa en analgetica kan leiden tot allerlei 
complicaties. Zo kan te snel afbouwen of abrupt stoppen van deze medicatie leiden 
tot ontwenningsverschijnselen. We hebben daarom onderzocht hoe vaak dit soort 
ontwenningsverschijnselen voorkomt bij ernstig zieke kinderen op de IC. Daarnaast is een 
meetinstrument ontwikkeld waarmee verpleegkundigen de ontwenningsverschijnselen 
kunnen scoren. 
Sedatie van ernstig zieke kinderen
Verpleegkundigen kunnen de diepte van sedatie van ernstig zieke kinderen bepalen met 
de COMFORT schaal. Er is voor dit instrument gekozen omdat het een multidimensioneel 
instrument is met zowel gedrag- als fysiologische stressindicatoren. De gedragsitems 
zijn: ‘alertheid’, ‘kalmte’, ‘reactie op beademing’ of ‘huilen’, ‘lichaamsbeweging’, 
‘gelaatsspanning’ en ‘spierspanning’. Als fysiologisch indicatoren worden hartslag en 
bloeddruk gemeten. De COMFORT schaal is oorspronkelijk voor dit doel ontwikkeld. 
Echter in de klinische praktijk worden hartslag en bloeddruk ook beïnvloed door 
vele andere factoren, zoals: mate van ziek zijn en gebruik van bloeddrukverhogende 
medicijnen. 
In Hoofdstuk 2 hebben we de psychometrische eigenschappen van de COMFORT 
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schaal geëvalueerd en de relatie tussen gedrag- en fysiologische indicatoren. We vonden 
dat verpleegkundigen op een betrouwbare manier het sedatieniveau konden observeren. 
De interbeoordelaarsbetrouwbaarheid bleek voldoende tot goed te zijn voor alle items 
van de COMFORT schaal. 
Van 78 kinderen, in de leeftijd van 0 tot 16 jaar, werden in totaal 843 COMFORT 
scores verzameld voor dit onderzoek. De fysiologische stressindicatoren, ‘hartslag’ en 
‘gemiddelde arteriële bloeddruk’ vertoonden weinig variatie gedurende de metingen. 
Aan de andere kant vonden we geringe statistische samenhang van deze indicatoren 
met de gedragsitems van de COMFORT schaal. We kwamen tot de conclusie dat met een 
schaal die alleen de gedragsitems bevat, de zogenaamde COMFORT gedragschaal, de 
verpleegkundige betrouwbaar en valide het niveau van sedatie bij ernstige zieke kinderen 
kan bepalen. 
Vervolgens hebben we nieuwe beslispunten gedefinieerd voor de COMFORT 
gedragschaal. De mogelijke score loopt uiteen van 6 tot 30. Bij scores van 6 tot 10 en 
23 tot  30 kan met een hoge mate van zekerheid worden gesteld dat een kind respectievelijk 
‘overgesedeerd’ dan wel ‘ondergesedeerd’ is. Verder is er een grijs gebied voor scores van 
11 tot 22. Om in dit gebied te kunnen vast stellen of een kind adequaat gesedeerd is, is 
de klinische expertise van de verpleegkundige nodig, uitgedrukt in de Verpleegkundige 
Interpretatie Sedatie Score (VISS). 
Hoofdstuk 3 beschrijft de implementatie van een sedatieprotocol op onze kinder-IC. 
Het primaire doel van dit sedatieprotocol is tweeledig. Enerzijds om te komen tot een 
uniform beleid rondom sedatie, en anderzijds om de verpleegkundigen de mogelijkheid 
te geven op basis van de COMFORT gedragschaal en de VISS sedatie op te hogen dan wel 
te verlagen. Vanzelfsprekend is het uiteindelijke doel: er voor te zorgen dat kinderen op 
een IC adequaat gesedeerd zijn. 
Allereerst is de COMFORT gedragschaal als een standaard meetinstrument voor 
sedatie geïmplementeerd. Vervolgens hebben we een sedatieprotocol ontwikkeld, 
bestaande uit beslisbomen voor verhogen en verlagen van sedativa en/of analgetica, 
gebaseerd op de beslispunten van de COMFORT gedragschaal en de VISS. Na de 
implementatie van het sedatieprotocol is het gebruik van sedativa en de toepassing van 
het protocol geëvalueerd. Uit de eerste nameting bleek dat de kinderen nu gemiddeld 
significant hogere doseringen midazolam en morfine kregen toegediend. Het percentage 
metingen met de kwalificatie ‘adequaat gesedeerd’ steeg van 63 naar 75%. In bijna de helft 
van de metingen, waarbij de patiënt volgens de beslispunten ondergesedeerd was, werden 
sedativa volgens de ‘beslisboom-ophogen’ verhoogd. In een zeer gering percentage werd 
volgens de ‘beslisbomen-verlagen’ medicatie afgebouwd. Ondanks dat de stappen in het 
sedatieprotocol niet altijd correct worden gevolgd, geeft een overgrote meerderheid van de 
verpleegkundigen aan dat het sedatieprotocol begrijpelijk en toepasbaar is in de praktijk. 
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De verpleegkundigen dienen de mate van sedatie bij kinderen op een IC regelmatig te 
bepalen. Dit om complicaties van te diepe of inadequate sedatie tegen te gaan. Voor kleine 
kinderen of kinderen die verbaal niet kunnen communiceren is dit echter moeilijk. Waar 
voor volwassen zelfrapportage als de gouden standaard wordt gezien, vormden bij onze 
doelgroep observatie-instrumenten voor het gedrag tot voor kort de enige mogelijkheid. 
De COMFORT gedragschaal is er daar één van. Er is nu echter een betrekkelijk nieuwe 
manier, het gebruik van de Bispectral index (BIS) hersenfunctiemonitor. De techniek 
van de hersenfunctiemonitor is gebaseerd op het principe dat de golven van een elektro-
encefalogram (EEG) veranderen bij een verschillend niveau van bewustzijn. Als een persoon 
diep gesedeerd is neemt de frequentie af en de amplitude toe. De hersenactiviteit wordt 
omgezet in een numerieke waarde van 0 tot 100. Bij 0 is er een volledige onderdrukking 
van het EEG. De BIS is uitgebreid onderzocht en waardevol gebleken bij volwassenen 
en kinderen tijdens narcose en op de IC. Het gebruik van de BIS monitor bij kinderen 
jonger dan één jaar op de IC is nog onvoldoende onderzocht. In Hoofdstuk 4 beschrijven 
we een onderzoek naar de waarde van de BIS monitor voor het meten van de diepte van 
sedatie bij kinderen jonger dan één jaar. Voor dit doel keken we naar de relatie tussen 
de BIS-waarden en de COMFORT gedragschaal scores. Dit werd voor twee verschillende 
groepen gedaan. De eerste bestond uit 39 kinderen die voor postoperatieve sedatie op 
onze kinder-IC lagen. Bij deze groep vonden we een matige samenhang tussen de BIS 
monitor en de COMFORT gedragschaal. Verder bleek dat het sedatieniveau gemeten met 
de BIS het beste overeenkomt met het item ‘alertheid’ van de COMFORT gedragschaal. 
Dit is ook begrijpelijk omdat ‘alertheid’ refereert aan het bewustzijn. De tweede groep 
bestond uit 32 gezonde kinderen. Bij deze kinderen werd de bewustzijnstoestand tijdens 
slapen en wakker zijn gemeten. Vooral bij de kinderen van 0 tot 6 maanden was het 
bewustzijnsniveau met de BIS monitor minder goed te bepalen. Als ze diep in slaap waren 
volgens de COMFORT gedragschaal werden met de BIS monitor waarden gemeten die 
horen bij een staat van alertheid en wakker zijn. Het omgekeerde van dit fenomeen zagen 
we ook. De belangrijkste conclusie was derhalve dat het EEG patroon van kinderen jonger 
dan 1 jaar zo afwijkt van dat van oudere kinderen en volwassen dat voor hen de BIS monitor 
onvoldoende betrouwbaar voor het bepalen van de mate van sedatie. 
Ontwenning bij kinderen op IC
Hoofdstuk 5 geeft een overzicht van de Engelstalige literatuur op het gebied van 
ontwenningsverschijnselen bij kinderen op een intensive care en de beschikbare 
instrumenten voor verpleegkundigen om dit fenomeen bij kinderen vast te stellen. De 
nadruk lag op artikelen die de symptomen beschrijven van ontwenning als gevolg van 
langdurige toediening van benzodiazepinen en/of opiaten. Voor de meetinstrumenten 
werd gekeken of ze geschikt zijn voor kinderen in de leeftijd van 0 tot 16 jaar. 
Langdurige toediening van benzodiazepinen en/of opiaten kan lichamelijke 
afhankelijkheid en ontwenningsverschijnselen veroorzaken. Ontwenning (afkicken) 
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treedt op wanneer deze medicijnen te snel worden afgebouwd bij kinderen met lichamelijke 
afhankelijkheid. De symptomen van benzodiazepinen- en opiatenontwenning zijn te 
verdelen in drie groepen: overprikkeling van het centraal zenuwstelsel en autonome 
disregulatie. Een derde groep bestaat uit gastro-intestinale symptomen, maar die zijn 
alleen bij opiatenontwenning beschreven. 
Er bestaan twee meetinstrument om ontwenningsverschijnselen op de kinderleeftijd 
te bepalen: Sedation Withdrawal Score (SWS) en de Opioid Benzodiazepine Withdrawal 
Scale (OBWS). We hebben vastgesteld dat beide meetinstrumenten onvoldoende valide 
en betrouwbaar zijn voor gebruik op de kinder-IC. 
Het literatuuronderzoek leverde 24 verschillende symptomen van ontwenning op. 
Omdat er geen valide meetinstrument voorhanden was om de frequentie van voorkomen 
van ontwenningsverschijnselen te onderzoeken, hebben we met deze 24 symptomen een 
checklist gecreëerd, en hiermee 2188 observaties uitgevoerd bij 79 kinderen (Hoofdstuk 6). 
Deze kinderen kregen al minimaal vijf dagen midazolam, morfine of fentanyl toegediend 
voor hun comfort of pijnstilling. Van deze observaties waren er 932 uitgevoerd binnen 24 
uur na afbouw van genoemde medicatie. Binnen de hoofdgroep ‘overprikkeling centraal 
zenuwstelsel’ werden angst, agitatie, grimassen, verstoord slaappatroon, toegenomen 
spierspanning en motorische onrust in meer dan 10% van de observaties waargenomen. 
Als gastro-intestinale symptomen kwamen diarree en voedingsretentie het meest voor. 
Tachypnoe, koorts, zweten en hypertensie werden in meer dan 13%  van de observaties 
waargenomen als uiting van autonome disregulatie. Verder bleek er verband te zijn 
tussen de totale hoeveelheid midazolam, aantal dagen midazolam gekregen en het aantal 
ontwenningsverschijnselen per patiënt. Daarmee kunnen we stellen dat langere duur 
van toediening en een hogere totale dosis midazolam of opiaten risico’s vormen voor 
het optreden van ontwenningverschijnselen bij ernstig zieke kinderen. Ons onderzoek 
geeft een volledig overzicht van de frequentie van voorkomen van elk van de 24 mogelijke 
ontwenningsverschijnselen na afbouwen en/of stoppen van benzodiazepinen en/of 
opiaten bij kinderen. Om te komen tot een valide en betrouwbaar instrument waarmee 
verpleegkundigen ontwenningsverschijnselen kunnen vast stellen bij ernstig zieke 
kinderen is nader onderzoek gedaan naar de gebruikte checklist. De centrale vraag 
hierbij was: hoe kunnen we een goed onderbouwd instrument ontwikkelen en kan het 
aantal symptomen worden teruggebracht tot de belangrijkste, die werkelijk nodig zijn 
voor een meetinstrument ontwenningsverschijnselen. De constructie van de Sophia 
Ontwenningsverschijnselen Scorelijst (SOS) wordt beschreven in Hoofdstuk 7. Met 
behulp van een statistische procedure, multi-dimensionale schaaltechnieken (MDS), 
is gekeken naar de onderlinge samenhang van de 24 symptomen. Hiervoor zijn de 
observaties na afbouw van medicatie uit het vorige onderzoek (hoofdstuk 6) gebruikt. 
We vonden dat ontwenningsverschijnselen zoals ‘agitatie’, ‘angst’, slapeloosheid’, 
‘motorisch onrust’ en ‘toegenomen spierspanning’ de grootste onderling samenhang 
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vertoonden. Sommige symptomen zoals ‘tremoren’ of ‘hallucinaties’ zijn zeer specifiek 
voor ontwenning, maar kwamen weinig voor. Daarnaast hebben we aan kinder-intensive 
care verpleegkundigen en kinder-intensivisten gevraagd het belang van elk van de 24 
afzonderlijke ontwenningsverschijnselen aan te geven. Door deze resultaten te combineren 
met de resultaten van de MDS procedure konden we het aantal relevante symptomen 
terugbrengen tot 15. Vervolgonderzoek is nodig om de SOS te valideren en beslispunten 
te definiëren zodat kinderen met ontwenningsverschijnselen op een IC ook adequaat 
behandeld kunnen worden.
Uit eerder onderzoek is bekend dat bepaalde groepen patiënten een verhoogd risico 
hebben op het ontwikkelen van ontwenningsverschijnselen. Dit wordt voornamelijk 
veroorzaakt door hoge doseringen en langdurige toediening van sedativa en analgetica 
die nodig zijn om er voor te zorgen dat ernstig zieke kinderen comfortabel zijn. Een 
voorbeeld van een dergelijke risicogroep zijn pasgeborenen met een aangeboren 
afwijking van het middenrif (congenitale hernia diafragmatica) die een ECMO (extra 
corporale membraan oxygenatie) behandeling ondergaan. Tijdens het afbouwen van de 
sedativa en analgetica bij deze kinderen kunnen ontwenningsverschijnselen optreden. 
Enige jaren geleden is besloten om sommige van deze kinderen eerder te ontslaan uit het 
ziekenhuis en dan thuis de medicijnen langzaam af te bouwen. Over een periode van 2 
jaar (2003 - 2005) kwamen hiervoor vijf kinderen in aanmerking. Dit afbouwen gebeurde 
onder begeleiding van een arts van de intensive care. De ouders van deze kinderen hadden 
wekelijks telefonisch contact met de arts om de ernst van de ontwenningsverschijnselen 
te bespreken alsmede de mogelijkheid om de dosering te verlagen. In Hoofdstuk 8 worden 
de resultaten van dit evaluatieonderzoek besproken. Het blijkt goed mogelijk te zijn om 
onder begeleiding van een arts in de thuissituatie medicatie af te bouwen bij kinderen met 
ontwenningsverschijnselen. Hierdoor kunnen kinderen eerder uit het ziekenhuis worden 
ontslagen wat leidt tot een verkorting van de opnameduur op een kinder-IC. Het verdient 
nadere overweging om ook ouders in de thuissituatie de SOS te laten gebruiken. 
In Hoofdstuk 9 worden de resultaten van dit onderzoek in toekomstperspectief 
besproken. 
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De leden van de kleine commissie, prof.dr. J.A. van den Anker en prof.dr. J. Klein wil ik 
bedanken voor de snelle beoordeling van het proefschrift. Also I would like to thank 
professor L.S. Franck. I’m pleased you agreed to be a member of the thesis committee, 
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